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Development
Abstract
Malaria is an infectious disease caused by a protozoan parasite of the genus
Plasmodium, which is transferred by female Anophelesmosquitos. WHO
estimates that in 2012 there were 207 million cases of malaria, of which 627,000
were fatal. People living in malaria-endemic areas, gradually acquire immunity
with multiple infections. Placental malaria (PM) is caused by P. falciparum
sequestering in the placenta of pregnant women due to the presence of novel
receptors in the placenta. An estimated 200,000 infants die a year as a result of
PM. In 2004 the specific protein responsible for the pathogenesis of PMwas
identified as the P. falciparum Erythrocyte Membrane Protein 1 (PfEMP1)
variant VAR2CSA. VAR2CSA is the leading candidate for a vaccine against PM.
The thesis is divided into 4 parts, where part I provide the reader with an
introduction and background for the subjects covered in the thesis. Part II
presents the first paper: ”SigniSite: Identification of residue-level genotype-phenotype
correlations in protein multiple sequence alignments”. SigniSite is based on a
non-parametric statistical evaluation of the positional distribution of amino acid
residues in a multiple sequence alignment (MSA), thereby quantifying residue
association toMSA phenotype. SigniSitewas found to outperform comparable
state-of-the-art methods. Furthermore part II addresses the issue of controlling
type I and type II error probabilities in multiple testing scenarios and lastly the
ix
Dissertation advisor: Prof. Ole Lund Leon Eyrich Jessen
analysis of the MHCI:peptide binding interaction by application of the SigniSite
method. Part III presents the second paper: ”Insight into Antigenic Diversity of
VAR2CSA-DBL5ε Domain fromMultiple Plasmodium falciparum Placental
Isolates”. The data consisted of 70 VAR2CSA-DBL5ε sequences each with
associated phenotypes. Immunity towards PM is gradually acquired, therefore if
a given sequence motif can be phenotype-correlated then the motif may be
involved in VAR2CSA immunogenecity. Motifs defining VAR2CSA
immunogenecity are naturally interesting in vaccine development context. The
motif ’TFKNI’ was found to be correlated with the birth weight of the child. Part
IV presents the development of two methods for analysis of high-throughput
data from a novelHigh Density Peptide Microarray (HDPMa) chip technology.
Subsequently the HDPMa chip is applied for the discovery of linear B-cell
VAR2CSA epitopes. Peptides ’GMDEFKNTFKNIKE’ and
’SCGSARTMKRGYKNDNYELCKYC’ were identified as linear B-cell epitopes. The latter
subsequently experimentally found to be highly immunogenic, but not capable of
blocking VAR2CSA:receptor interaction. In summary, the work described in this
thesis centres around the development and application of bioinformatics tools
for in silico analysis of VAR2CSA, with an emphasis on statistical methodology. It
is the hope of the author that the tools, developed, presented and applied in this
thesis, may serve as an oﬀset for further research and development in the field of
placental malaria vaccine development.
x
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Resume
Malaria er en infektionssygdom, forårsaget af en protozoisk parasit af slægten
Plasmodium. Parasitten overføres af hunmyg af arten Anopheles. WHO estimerer
at der var 207 millioner tilfælde af malaria i 2012, hvoraf 627.000 var fatale.
Mennesker, som bor i malariaendemiske områder, erhverver gradvist immunitet,
med stigende antal infektioner. Placental malaria (PM) forårsages af P.
falciparum, som afsondres i moderkagen hos gravide kvinder. Dette skyldes
tilstedeværelsen af nye receptorer i moderkagen. Det estimeres at der hvert år dør
200.000 spædbørn af PM. I 2004 blev det specifikke protein, som er ansvarlig for
patogenesen af PM, identificeret som P. falciparum Erythrocyt Membran Protein
1 (PfEMP1) varianten VAR2CSA. VAR2CSA er den førende kandidat til en
vaccine mod PM. Denne ph.d. afhandling er inddelt i 4 hoveddele, hvor del I
forsyner læseren med en introduktion til og baggrund for emnerne, indeholdt i
afhandlingen. Del II præsenterer den første artikel: ”SigniSite: Identifikation af
aminosyrerest-niveau genotype-fænotype korrelationer i multiple sekvens alignment af
proteiner”. SigniSite er baseret på en ikke-parametrisk statistisk evaluering af den
positionelle aminosyrerestfordeling i et multipelt sekvensalignment (MSA),
hvorved aminosyrens associering medMSA fænotypen kvantificeres. Vi fandt at
SigniSite var i stand til at performe bedre end den nyeste sammenlignelige
metode. Ydermere adresserer del II udfordringen med at kontrollere
xi
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sandsynligheden for fejl af type I og type II i multiple testscenarier. Sluttelig
anvendes SigniSite til at analysere MHCI:peptide bindingsinteraktionerne. Del
III præsenterer den anden artikel: ”Indsigt i den antigeniske diversitet af
VAR2CSA-DBLε domænet fra multiple Plasmodium falciparum placentale isolater”.
Dataene bestod af 70 VAR2CSA-DBL5ε sekvenser, hver især associeret med et
sæt af fænotyper. Immunitet mod PM erhverves gradvist, hvorfor såfremt et givet
sekvensmotiv kan fænotype korreleres, så er dette motiv muligvis involveret i
VAR2CSA immunogenicitet. Motiver, som definerer VAR2CSA
immunogenecitet er naturligvis interessant i kontekst med vaccineudvikling.
Motivet ’TFKNI’ korrelerede med barnets fødselsvægt. Del IV præsenterer
udviklingen og anvendelsen af to metoder til analyse af høj-produktionsdata fra
en nyHøj Densitets Peptid Mikroarray (HDPMa) chip teknologi. HDPMa
chippen blev efterfølgende anvendt til opsporing af lineære b-celle epitoper.
Peptiderne ’GMDEFKNTFKNIKE’ og ’SCGSARTMKRGYKNDNYELCKYC’ blev identificeret
som lineære b-celle epitoper. Den sidste af de to, blev efterfølgende
eksperimentelt fundet til at være høj-immunogent, men ikke i stand til at blokere
VAR2CSA:receptor interaktionen. I sammendrag, centrerer arbejdet, som
beskrives i denne ph.d. afhandling sig om udviklingen og anvendelsen af
bioinformatiske værktøjer til in silico analyse af VAR2CSA, med særlig vægt på
statistisk metodologi. Det er forfatterens håb at værktøjerne udviklet og anvendt i
denne ph.d. afhandling, kan tjene som udgangspunkt for, eller blot bidrage til,
videre forskning og udvikling i feltet for placental malaria vaccineudvikling.
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Part I
Introduction andBackground
1
Life begins at the end of your comfort zone.
Neale Donald Walsch
1
Introduction
March 1st 2010 I handed in my thesis for the degree of master of science in
engineering. Here I sit once again, trying to persuade LATEX to yield the expected
output, finding the proper references to build the introduction, which is to serve
as the foundation for the entire thesis. In the midst of all this, I realise one
important thing. Except for meetings and conferences - For the past 4 years I
have been sitting at the same desk day after day, analysing, thinking, deliberately
challenging myself and constantly ending up in situations, where I had no clue
about the answer or how to get there or even how to begin. Physically I have not
moved for the past 4 years, but I now have a much more profound understanding
of the quote in the upper left corner of this page and have thusly arrived at my
personal mantra: I’ll figure it out - I always do!
2
1.1 PhD ProjectOverview
1.1.1 PhD Partners
This PhD project was initiated as a collaboration between the Center for
Biological Sequence Analysis (CBS), Department of Systems Biology, Technical
University of Denmark (DTU) and the Centre for Medical Parasitology (CMP),
Department of International Health, Immunology andMicrobiology, University
of Copenhagen (KU) and the PepChipOmics project, 7th Framework
Programme for Research and Technological Development (FP7) of the EU,
HEALTH-2007-1.1-4.
1.1.2 The CMP VAR2CSA Team
The VAR2CSA research team at CMP, lead by Professor Salanti, is world leading
in the search for a placental malaria vaccine. In 2004 they identified the PfEMP1
variant VAR2CSA as the protein responsible for placental malaria [129], in 2010
they managed to recombinantly produce full-length VAR2CSA [83] and in 2012
the team received substantial financial support for preclinical development of a
VAR2CSA-based vaccine from the EU Eurostars program.
1.1.3 PhD Project Objective
The objective of this PhD programme was: ”The development and application of
computational tools aiming at obtaining a better understanding of how VAR2CSA
sequence variation aﬀects immunogenicity and capability to induce parasite adhesion
blocking antibodies. The ultimate goal being able to produce a vaccine, which can be
used to protect pregnant women against Placental Malaria.”
1.1.4 Additional projects not included in this PhD thesis
1. Development and Application of VAR2CSADiversity Covering Sequence
Generator aiming at creating a set of diversity covering sequences for
3
inducing broad immune response towards VAR2CSA.
2. Analysis of sequence data fromMalaria Protein domain DBL3X. External
collaborators: Centre for Medical Parasitology, University of Copenhagen,
Denmark.
3. Prediction of HIV-1 protease inhibitor drug resistance. External
collaborators: Department of Biology, Biomolecular Sciences, University
of Copenhagen, Denmark.
4. NGS: Next Generation Sequencing - Full genome sequencing and
assembly of Plasmodium falciparum genomes, aiming at elucidating
genomic stability. External collaborators: Center for Genomic
Epidemiology, Technical University of Denmark, Denmark.
1.2 Immunology
1.2.1 Introduction to the human immune system
To put in an popular tongue, there is a constant arms race going on inside every
human being. Pathogens constantly invade our body seeking nutrition aiming at
multiplying in order to preserve their genetic material. As a counter measure, the
immune system is constantly monitoring the health of every cell in out body
along with the composition of extracellular fluids and tissues. Themechanisms
by which the body is monitoring itself are highly eﬃcient. In fact so eﬃcient, that
it has been proposed to mimic the system when monitoring IT infrastructure
[34]. Which is an interesting extrapolation if you are a computational biologist,
with a background in engineering.
The innate and the adaptive immune systems make up the human immune
system [30, 31]. Traditionally has been viewed as two distinct mechanisms, new
research however suggests that innate and adaptive immunity to a much higher
degree are intertwined [92, 93]. In the following, the traditional view will be
described, it should however be noted that there still is much to learn about the
4
Innate immunity augments the protection offered by anatomic
and physiologic barriers.2 The innate immune system relies on a
limited repertoire of receptors to detect invading pathogens but
compensates for this limited number of invariant receptors by tar-
geting conserved microbial components that are shared by large
groups of pathogens. Speed is a defining characteristic of the in-
nate immune system: within minutes of pathogen exposure, the
innate immune system starts generating a protective inflamma-
tory response. Moreover, innate immunity plays a central role
in activating the subsequent adaptive immune response.
T and B lymphocytes are the main self-defensive weapons of
the adaptive immune system, so-named because this system is
shaped by antigen exposure. In contrast to the limited number of
pathogen receptors used by the innate immune system, the
adaptive immune system boasts an extremely diverse, randomly
generated repertoire of receptors. The benefit of this receptor
diversity is that the adaptive immune system can recognize
virtually any antigen, but there is a price for this diversity.
First is the risk of autoimmune disease. Receptors specific for
self-proteins (eg, insulin and myelin) are created by means of the
random process of gene rearrangement that generates receptors
expressed by T and B cells. Consequently, elaborate tolerance
mechanisms have evolved to eliminate or regulate self-reactive
cells.
Second is the time delay required to generate a protective
adaptive immune response after the first exposure to a pathogen.
Adaptive immunity relies on a clonal system,with eachTandB cell
expressing its own unique receptor, and after the initial encounter
with a pathogen, it takes up to 5 days for clonal expansion of these
rare antigen-specific T and B cells to occur before the adaptive
immune response is sufficiently robust to clear the pathogen.
ELEMENTS OF THE INNATE IMMUNE SYSTEM
In contrast to the adaptive immune system, which depends on T
and B lymphocytes, innate immune protection is a task performed
by cells of both hematopoietic and nonhematopoietic origin (Fig
1 and Table I). Hematopoietic cells involved in innate immune re-
sponses include macrophages, dendritic cells, mast cells, neutro-
phils, eosinophils, natural killer (NK) cells, and NK T cells. In
addition to hematopoietic cells, innate immune responsiveness
is a property of the skin and the epithelial cells lining the respira-
tory, gastrointestinal, and genitourinary tracts.
To augment these cellular defenses, innate immunity also has a
humoral component that includes well-characterized compo-
nents, such as complement proteins, LPS binding protein,
C-reactive protein and other pentraxins, collectins, and antimi-
crobial peptides, including defensins. Circulating innate immune
proteins are involved in both sensing of microbes and effector
mechanisms to facilitate clearance of the infection. For example,
mannose-binding lectin, a member of the collectin family of
receptors, binds mannose-containing carbohydrates on microbes,
triggering activation of the complement cascade, which enhances
clearance of the pathogen.
HOST DEFENSE IS ACHIEVED THROUGH
INTEGRATION OF INNATE AND ADAPTIVE
IMMUNITY
Innate immunity, an evolutionarily ancient component of host
defense, is present in all multicellular organisms, whereas adap-
tive immunity evolved much later and is only found in jawed fish
and all ‘‘higher’’ vertebrates.3 During evolution, adaptive immu-
nity developed in the context of a functioning innate immune
FIG 1. Integrated human immune system. The human microbial defense system can be simplistically
viewed as consisting of 3 levels: (1) anatomic and physiologic barriers; (2) innate immunity; and (3) adaptive
immunity. In common with many classification systems, some elements are difficult to categorize. For
example, NK T cells and dendritic cells could be classified as being on the cusp of innate and adaptive
immunity rather than being firmly in one camp.
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Figure 1.2.1: Simplistic 3-level view of the human immune system. Initially microbial infection
is prevented by physical nd chemi al barriers, uch the skin and the low stomach pH.
Should these fail, the immune system can mount a swift, but non-speciﬁc response via innate
immunity. Adaptive immunity is responsible for long term immunity following an infection [147].
immune system and that the knowledge about it is highly dynamic. E.g. recently
a new population of immune cells known as Innate lymphoid cells (ILCs) have
been discovered [153]. These ILCs cannot be classified using the traditional
system, due to lack of specific surface markers [141].
Si plified, the i mune system consists of 3 levels: i. Physicoch mical
barriers, ii. The innate and the iii. adaptive immunesystem (se figure 1.2.1).
The innate immune system, also kn wn as the no -sp c fic immu e system,
provides an immediate response to infection, but does no give rise to long term
immu ity [147]. Innate eﬀectors include e. . anti-micr bial peptides (AMPs)
[55, 134], which are pres nt n our skin and intestinal tract [53] protecting
against invasion of opportunistic pathogens [65], such as e.g. Staphylococci, which
are abundant [113]. I. . non-specific ﬀectors targeting common pathogenic
structures. Th innate immu e system is considered a cient and shared cross a
wid variety of species [35]. Th aptive immune system on the other hand is
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unique to vertebrates and is responsible for long term immunity [22]. The
adaptive immune system is capable of recognising and clearing highly specific
non-self structures, but initial response is slow [22]. If a previously recognised
non-self structure is encountered, the response will however be massive and swift
[104]. This strong and specific response elicited when encountering a previously
’seen’ pathogen structure is the reason that he activation of the adaptive immune
system is a paramount step in vaccine development. Long term immunity can be
achieved via two types of responses: Cell-mediated and humoral.
1.2.2 Cell mediated immunity
Somemicrobes such as vira or certain types of parasites, will invade human cells
in order to use the cell as a factory for proliferation. These intra-cellular
pathogens are not directly visible to the human immune system, but rather
indirectly via antigen presentation using theMajor Histocompability Complex
(MHC) class I partway [158] (See figure 1.2.2).
On the surface of every nucleated cells in the human body, sits the MHC class
1 molecule. The purpose of theMHC class 1 is to reflect the inner protein
composition, by presenting samples of the current protein pool inside the cell.
Inside every living cell, there is a constant production and degradation of
proteins (protein turnover). Various proteins are constantly synthesised and
released into the cytoplasm [99]. These cytoplasmic proteins are constantly
being degraded by the proteasome into free amino acids and smaller chains of
amino acid residues referred to as peptides [94]. The free amino acids are
recycled for new protein synthesis, whereas the peptides enter the endoplasmic
reticulum through a system known as ’the transporter associated with antigen
processing’ (TAP). Once inside the endoplasmic reticulum, helper proteins
called chaperones assist the pairing of peptides, typically 9-mers, andMHC class
1 molecules. The formedMHCI:peptide complex is transported through the
Golgi Apparatus to the surface of the cell, where it is made visible to the immune
system. [158]
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Autophagy
Any process involving delivery 
of a portion of the cytoplasm  
to lysosomes that does not 
involve direct transport through 
the endocytic or vacuolar 
protein-sorting pathways.
DRiPs
(Defective ribosomal products). 
Misfolded proteins that result 
from defective transcription or 
translation.
Cytotoxic T lymphocytes
(CTLs). T cells that express the 
glycoprotein CD8 at the cell 
surface and that are capable of 
killing cells after recognizing 
peptides presented by MHC 
class I molecules.
Pulse-chase experiments
A method to examine a cellular 
process that occurs over time 
by following a molecule of 
interest, which is labelled at 
time-point zero.
Mammalian target of 
rapamycin
(mTOR). A conserved serine/
threonine protein kinase that 
regulates cell growth and 
metabolism, as well as cytokine 
and growth factor expression, 
in response to environmental 
cues. mTOR receives 
stimulatory signals from RAS 
and phosphoinositide 3-kinase 
downstream of growth factors 
and nutrients (such as amino 
acids, glucose and oxygen).
microRNAs
Small RNA molecules that 
regulate the expression of 
genes by binding to the 
3ʹ-untranslated regions of 
specific mRNAs.
26S proteasome
A giant multicatalytic protease 
that resides in the cytosol and 
the nucleus. The 20S core, 
which contains three distinct 
catalytic subunits, can be 
appended at either end by a 
19S cap or an 11S cap. The 
binding of two 19S caps to  
the 20S core forms the 26S 
proteasome, which degrades 
polyubiquitylated proteins.
Thymic epithelial cells
(TECs). Cortical TECs promote 
the survival of thymocytes that 
possess T cell receptors  
that can bind to self MHC 
molecules. Medullary TECs 
induce apoptosis in thymocytes 
specific for self antigens.
greatly, ranging from minutes to days, and therefore it 
would be expected that the time between the synthe-
sis of a protein and the presentation of its peptides by 
MHC class I molecules should be similar to the half-life 
of the protein. Such a notion, however, conflicts with 
observations that viral antigens are presented by MHC 
class I molecules much quicker than their natural half-
lives would allow. This contradiction was solved by the 
observation that a large fraction of proteins (varying 
from 30% to 70% of all proteins made) is immediately 
degraded after synthesis before forming functional 
proteins7,8. These so-called DRiPs (defective ribosomal 
products) are the result of defective transcription or 
translation9, alternative reading frame usage, failed 
assembly into larger protein complexes, the incor-
poration of wrong amino acids owing to mistakes 
by aminoacyl-tRNA synthetases or altered ubiquitin 
modifications9–13. DRiPs are immediately degraded 
to prevent the formation of protein aggregates, which 
would affect cell viability. Because of this translation-
coupled degradation pathway, the translation of viral 
products is also directly coupled to MHC class I antigen 
presentation. DRiPs thus explain why influenza virus is 
recognized by T cells ~1.5 hours post-infection, rather 
than 8 hours later, when the first stable viral proteins 
are degraded in infected cells14.
The study of MHC class I antigen presentation has 
revealed another surprise, namely the presentation of 
peptides that are not encoded in the genome. Proteases 
usually cleave off protein fragments, but they can also 
ligate two peptides, as in the case of protein splicing 
by the 20S core of the proteasome15,16. The resulting 
ligated peptides cannot be predicted on the basis of the 
genomic sequence and include neo-antigens that can 
be detected by tumour-specific cytotoxic T lymphocytes 
(CTLs)17.
Pulse-chase experiments have indicated that a sub-
stantial fraction of MHC class I molecules never binds 
proper peptides18 and that these MHC molecules are 
ultimately degraded by the ER-associated protein degra-
dation (ERAD) system5. The concentration of peptides 
(which is related to the rate of protein synthesis) is thus 
rate limiting in the MHC class I antigen presentation 
response. The synthesis of proteins may be affected 
by various stimuli, such as interferon-γ (IFNγ), ion-
izing radiation (via mammalian target of rapamycin 
(mTOR) activation)19 and the expression of particular 
microRNAs20–22. Under these conditions, a defined set 
of proteins is selectively produced at higher levels, and 
this results in alterations in the peptidome presented by 
MHC class I molecules. The presentation of new pep-
tides may alter MHC class I antigen presentation and 
CD8+ T cell responses, as illustrated by the enhanced 
antitumour responses by CD8+ T cells in response to 
ionizing radiation19,23.
In summary, the MHC class I peptidome includes a 
substantial fraction of DRiPs, which are derived from 
proteins that have never been functional, and the lev-
els of DRiPs are controlled by external factors that can 
affect translation. In addition, imperfections in trans-
lation mechanisms together with peptide ligation can 
generate new peptide fragments that are not encoded 
in the genome but are still immunogenic. Therefore, 
studies on the MHC class I-associated peptidome have 
expanded our knowledge about the peptide repertoire24 
and have also uncovered cell biological processes that 
were previously unknown.
The proteasome. The 26S proteasome is composed of 
a 20S core barrel that has protease activity25 and two 
19S caps. It generates the bulk of peptides for MHC 
class I molecules and defines the carboxyl terminus of 
these peptides26. The resulting peptides then only need 
amino-terminal trimming. Two ‘alternative’ proteas-
omes have been described: the immunoproteasome, 
which is expressed by many immune cells; and the 
thymus-specific proteasome, which is expressed in 
thymic epithelial cells (TECs)27. Immune cell- or thymus-
specific variants of the proteolytic subunits are incorpo-
rated into the 20S barrel, and this alters the degradation 
pattern of the proteasome28,29. Immunoproteasomes 
were thought to improve MHC class I antigen presen-
tation by selectively generating particular (immuno-
genic) peptides. Obviously, (immuno)proteasomes 
have to generate fragments for all of the different MHC 
class I alleles, which bind to different peptide sequences. 
Figure 1 | The basic MHC class I antigen presentation 
pathway. The presentation of intracellular antigenic 
peptides by MHC class I molecules is the result of a series of 
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conditions, as only a few endosomal peptides have been 
extracted from MHC class I molecules, but it may be 
more prevalent under conditions of cross-presentation.
The process of MHC class I antigen presentation has 
been resolved to a unique level of detail (FIG. 2). Many 
recent findings on the type of peptides that are pre-
sented and the function of various components of this 
system have deepened our insight into this process. The 
specificity of many steps has been resolved, most promi-
nently that of peptide binding to MHC class I molecules. 
However, although the collective knowledge of the differ-
ent steps in MHC class I antigen presentation allows us 
to determine which peptides are excluded from binding 
to MHC class I molecules, we cannot predict the actual 
peptides that are presented. How immunodominant 
peptides are generated and whether and how they differ 
from normal peptides is also not known with certainty. 
This indicates that gaps in our understanding have to 
be filled in order to move from descriptive to predictive 
biochemistry of MHC class I antigen presentation.
MHC class II versus MHC class I molecules
One reason to discuss MHC class I and MHC class II 
molecules in a single review is that they overlap in a 
number of characteristics. Both classes have high levels 
of polymorphism; a similar three-dimensional struc-
ture (owing to the fact that they originate from one 
common founder gene by simple gene duplication); a 
genetic location within one locus; and a similar function 
in presenting peptides to the immune system. However, 
these molecules have different tissue distributions and 
differ in the types of antigenic peptides that they present 
owing to their use of different cell biological pathways. 
Here, we discuss how the MHC class II antigen presen-
tation pathway differs from the MHC class I pathway 
and thus presents protein fragments that are generated 
at different cellular locations.
Like the MHC class I heavy chain, MHC class II 
molecules are encoded by three polymorphic genes 
(HLA-DR, HLA-DQ and HLA-DP in humans) that bind 
to different peptides. Many MHC class II alleles are the 
strongest genetic markers for several autoimmune dis-
eases, possibly owing to the peptides that they present75. 
Although the different variants appear to associate dif-
ferently with the chaperone HLA-DM (see below)76, the 
effects of MHC class II polymorphism on the functions 
of MHC class II molecules are poorly studied when 
compared with MHC class I. The MHC class II pathway 
described below is mainly based on studies of HLA-DR 
and mouse MHC class II (I-A and I-E); the pathway may 
differ in details for other MHC class II molecules.
The basics of MHC class II antigen presentation. Whereas 
MHC class I molecules are ubiquitously expressed, MHC 
class II molecules are primarily expressed by professional 
APCs, such as DCs, macrophages and B cells. It has been 
concluded from the work of many groups that the trans-
membrane α- and β-chains of MHC class II are assem-
bled in the ER and associate with the invariant chain (Ii). 
The resulting Ii–MHC class II complex is transported 
to a late endosomal compartment termed the MHC 
class II compartment (MIIC). Here, Ii is digested, leav-
ing a residual class II-associated Ii peptide (CLIP) in the 
peptide-binding groove of the MHC class II heterodimer. 
In the MIIC, MHC class II molecules require HLA-DM 
(H2-DM in mice) to facilitate the exchange of the CLIP 
fragment for a specific peptide derived from a protein 
degraded in the endosomal pathway. MHC class II mol-
ecules are then transported to the plasma membrane 
to present their peptide cargo to CD4+ T cells (FIG. 3). 
In B cells, a modifier of HLA-DM is expressed called 
HLA-DO (H2-O in mice), and this protein associates 
with HLA-DM and restricts HLA-DM activity to more 
acidic compartments, thus modulating peptide binding 
to MHC class II molecules77.
Cross-presentation aside, MHC class I molecules 
present peptides of cytosolic origin, whereas MHC 
class II molecules bind to peptides that are derived 
from proteins degraded in the endocytic pathway. Their 
combined specificities cover antigens from almost all 
cellular compartments. However, essential differences 
in the pathways complicate this basic paradigm. In 
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Figure 1.2.2: Antigen presentation through the MHC class I and II pathways [109]. Details in
text.
TheCD8+ cytotoxic t-cells (CTLs) are constantly monitoring the health of
each cell, by coupling of the t-cell receptor (TCR) to the presented
MHCI:p ptid complex [114]. Each CTL recognises one specific target. If a
MHCI:peptide complex is recognised, the CTL will adhere through the
MHCI:peptide:TCR interaction. The interaction is further stabilised by the CD8
co-receptor (hence CD8+). This is the first signal in a tightly controlled two step
activation [20]. The second signal comes from the stimulation of the CD28
receptor on the CTL by either the CD80 or the CD86molecules on the infected
cell [36]. The exact mechanism of t-cell activation has yet to be eluded [14]. The
result of this two-step activation of the CTL, is clonal expansion, resulting in a
dramatic increase in CTLs specific for the pathogen derived peptide, presented
on the surface of the infected cell. Each of these CTLs are activated and capable
of inducing programmed cell death (apoptosis). Figure 1.2.2 illustrates the
process.
During apoptosis, the cell undergo a series of changes resulting in the
complete, yet controlled disintegratio of the cell into small packages, which will
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be taken up by macrophages. Themacrophages serve as bins for the immune
system, devouring anything tagged for destruction. It is obviously paramount
that this system is tightly controlled.
1.2.3 Humoral immunity
B-cells, a specific type of immune cell, is found throughout the human body.
Immobilised on the surface of the b-cell, sits up to 120,000 b-cell receptors
(BCRs) [156]. The specificity of each BCR is extremely high and the repertoire
of unique BCRs is potentially up to 1011 [60] in each human. As with the TCR,
BCRs will recognise non-self structures with a very high specificity, e.g. a surface
protein of a bacterium. Once a b-cell encounters and binds such a non-self
structure, the BCR:antigen binding trickers a signal cascade leading to the uptake
and subsequent degradation of the antigen. It has been shown, that the B-cells
are capable of extracting pathogen antigens tightly anchored in a
non?internalisable surface [12]. This way, the B-cell is capable of ’stealing’ the
antigen from the surface of e.g. a bacterium and process it as follows: The BCR
bound structure is transported to the Golgi apparatus, where it is coupled with a
major histocompability complex class II (MHCII) molecule [13]. The
MHCII:peptide complex is then transported to the surface, where it is presented.
The B-cell have thus become an antigen presenting cell (APC). MHCII:peptide
complex can be recognised by the TCR of a T-helper cell (CD4+) [116] (See
figure 1.2.2). The Th trickers full activation of the b-cell. The b-cell will
proliferate and divide into eﬀector b-cells and memory b-cells. Some of the
eﬀector b-cells will become plasma b-cells capable of releasing vast amounts of
soluble BCRs. Soluble BCRs are commonly known as antibodies. [116]. Each
released antibody has the same specificity as the BCR which initially recognised
the pathogen structure, the antibodies will following release, target these
pathogen structures and tag them for pick up by macrophages. This process is
known as opsonisation. Furthermore the antibody tag of the pathogen can lead
to inhibition of pathogen surface antigens, which are essential for pathogenesis.
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Figure 1.2.3: Simplistic model of an antibody and antibody-antigen interaction. Antibody
model adapted from [15].
1.2.4 Antibodies, epitopes and paratopes
A key component of the humoral response from the adaptive immune system is
the antibodies [147]. Antibodies are proteins capable of highly specific
interaction with other molecules. An antibody consists of two light chains and
two heavy chains, held together by sulfide bridges. Both the light and heavy chain
have a constant and a variable part. The variable part determines the specificity of
the antibody and the antigen binding part is located distal from the hinge region
connecting the two heavy chains [15] (See figure 1.2.3).
Five type of human antibodies exist: immunoglobulin (Ig)G, IgA, IgM, IgE
and IgD [108]. Antigen-binding non-immobilised antibodies in the bloodstream
of the IgG type are important for protection against pathogen infections [136],
whereas antigen-binding immobilised antibodies, found on the surface of b-cells,
are of the IgD and IgM types [108].
The amino acid residues on the antigen binding sites, which interact directly
with the antigen, constitute the paratope. The amino acid residues on antigen,
which interact directly with the paratope, constitute the epitope [151].
Monoclonal antibodies target the same epitope on the same antigen, whereas
polyclonal antibodies target diﬀerent epitopes on the same antigen.
Epitopes can be either continuous (linear) or discontinuous (conformational)
[151]. A linear epitope, consists of a continuous stretch of amino acid residues,
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Figure 1.2.4: Primary and secondary immune response. The primary response takes time
to develop. Upon second challenge with the same antigen, the secondary response is much
stronger and faster. Adapted from [84].
e.g. a protruding loop. Conformational epitopes, on the other hand, are made up
of amino acid residues brought together by the tertiary structure of the protein.
Themajority of epitopes are discontinuous [138]. But the vast majority harbours
a linear determinant (>5 residues) [66, 87].
The identification of which structures are responsible for the elicited immune
response represents the initial and crucial step of vaccine development.
1.2.5 Vaccine strategies and development
Briefly on vaccines
A vaccine consists of a biologically active structure, capable of activating the
immune system in such a way, that a future exposure to the actual pathogen will
lead to a swift clearance, but without any of the symptoms of infection. Fig. 1.2.4
illustrates the primary and secondary immune response, when encountering the
same antigen twice. The first response takes time to develop and at peak is not as
strong as the secondary response. Furthermore upon second encounter, the
10
response is swift.
The purpose of a vaccine is to induce the primary response in a harmless way,
such that upon infection with the pathogen, from which the vaccine has been
derived, the response will be quick and the pathogen will be cleared.
On the Origin of Vaccines
Vaccines represent one of mankind major health related scientific breakthrough
and have virtually eliminated a wide range of otherwise potentially fatal
childhood diseases [120]. Vaccines are routinely administered in the developed
world. In the US approximately 80 - 90% of all infants are vaccinated against
diphtheria, pertussis, tetanus, measles, mumps, rubella, polio, Haemophilus
influenzae type b, hepatitis B, varicella, pneumococcus and hepatitis A [149].
Edward Jenner (1749-1823), an English physician, made the discovery laying
the foundation for the later smallpox vaccine and the subsequent eradication of
smallpox [18, 143]. Jenner inoculated a boy with cowpox and subsequently
exposed the boy for smallpox, the result of which was that the boy was protected
[123]. The word vaccine originates from the latin ’vacca’ meaning ’cow’ [8].
Figure 1.2.5 depicts Jenner as he is vaccinating a baby [139]. Continuing Jenner’s
work, Louis Pasteur (1822-1895), Paul Ehrlich (1854-1915) and Emil Behring
(1854-1917) became known as ’The fathers of immunology and vaccinology’
[81]. The variola virus, the cause of smallpox, was completely eradicated in 1977
[139].
Vaccine Strategy
An eﬃcient vaccine must activate an immune response, as good as possible
compared to that, which would be elicited by an actual infection, without
inducing disease symptoms. A major challenge in vaccine development is
therefore that the eﬃciency of the vaccine is proportional to the
immunogenecity, but as the immunogenecity increases, so does safety and
11
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anthrax in the United States. If fanatics were
prepared to commit suicide and mass murder
by flying aeroplanes into densely populated
buildings, would such individuals hesitate to
use biological weapons, such as smallpox, if
these were available? In view of this threat,
several countries have started to manufacture
smallpox vaccine to replenish their depleted
and ageing stocks24. Furthermore, intense
debate about the potential consequences of
the use of smallpox for biowarfare has pene-
trated to the highest levels of governments
around the world.
The feared scenario of re-emergence
There are various reasons for the escalated
fears about the potential for smallpox re-
emergence (BOX 2). Twenty-five years since the
last natural case of smallpox, most of the
world’s population has never been immunized
against smallpox . To provide continuous pro-
tection against smallpox, it was recommended
that individuals in endemic areas should be
vaccinated every three years. So, it is probable
that those who were vaccinated more than two
decades ago would no longer be protected
against infection, although the disease might
be controlled in some of the former vacinees25.
In 1978 in Birmingham, United Kingdom, a
person who contracted smallpox because of a
laboratory accident died of the disease despite
having been vaccinated 12 years before.
If a deliberate and unannounced release of
variola virus were to occur in a public place,
there would be no knowledge of this event for
about 9–11 days, until the first symptoms
appeared in infected persons2,26. By this time,
those individuals who were infected would
probably have disseminated widely through-
out the world and would, subsequently,
become contagious once lesions appeared in
the oropharynx. This crisis would present
health officials globally with the daunting,
perhaps impossible, task of tracking all of the
unseen in the human population for many
years before the first cases of AIDS were
identified in the United States in 1981; con-
sequently, the HIV epidemic was already out
of control before anyone knew that it
existed. Fourth, the smallpox vaccine was
effective against all strains of variola virus
and these strains were unable to undergo
antigenic variation to escape existing immu-
nity (because the poxvirus DNA polymerase
has high replication fidelity), in contrast
with HIV and influenza virus. Finally, the
vaccine was cheap, plentiful, potent, stable
without refrigeration, effective, and easy to
manufacture and administer.
After the eradication of smallpox was cer-
tified in 1980, there were many who saw the
destruction of the remaining stocks of vari-
ola virus as the logical completion of the
eradication campaign6,7,9. Advocates of this
policy stated that this would eliminate the
risk of accidental release of the virus and pre-
vent the repetition of a tragic laboratory acci-
dent in Birmingham, United Kingdom in
1978 (REF. 21). Towards this goal, under the
direction of the WHO, all known stocks of
variola virus throughout the world were cen-
tralized in two maximum-security laborato-
ries in Russia and the United States, which,
today, are the only official places where
declared variola virus stocks are maintained.
Variola virus has been scheduled for destruc-
tion several times in the past two decades,
but each time, the destruction has been post-
poned to allow further research with the live
virus22. Such research projects are all consid-
ered carefully and monitored strictly by the
WHO23.
The terrible events of 11 September, 2001
raised the political and public awareness of
the global threat of terrorism. Shortly there-
after, the fears of bioterrorism, in particular,
were exacerbated by the deliberate release of
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Figure 1 | Smallpox vaccination. Historical engraving of Edward Jenner (1749–1823) vaccinating a baby
against smallpox. In 1796, Jenner coined the term ‘vaccination’ to describe his use of cowpox inoculation
to obtain immunity to smallpox. Jenner experimented on an 8-year-old boy (James Phipps) by inoculating
him with fluid obtained from a blister on the hand of a milk-maid (Sarah Nelmes) who had cowpox. He later
inoculated the boy with smallpox. The boy survived and did not contract smallpox. Vaccination against
smallpox soon became widespread. © 2002 Science Photo Library.
Box 2 | Variola virus, smallpox and bioterrorism 
Is the re-emergence of variola virus a cause for concern?
• Mortality rates vary from 40% for variola major virus to 1–2% for the less virulent variola
minor virus.
• Smallpox is prevented by previous vaccination with vaccinia virus, which is a related virus of
the same genus.
• Vaccination also has some benefit up to four days after infection.
• There are no licensed drugs to treat smallpox.
• Much of the world’s population has either never been immunized or has not been immunized
for more than 20 years.
• The available vaccine is old and in limited supply.
• A covert release in a public place would cause infections that would not be apparent until at
least 9–11 days later.
Figure 1.2.5: Engraving
depicting Edw rd Jen-
ner (1749-1823), while
he vaccinates a baby
ag inst smallpox. Jenner
is considered the father
of vaccinations, as he
reali ed that human im-
munisation with cowpox,
pr vided protection from
smallpox [139]. ©2002
Science Photo Library.
tolerance issues [8]. One approach for imicking the immune respons from an
actual infection is by using a live attenuated vaccine. A live atte uated vaccine is
produced by re eated cultivation of the path gen u til it no lo ger retains
pathogenicity. As pathogenicity is associated with an energy expense, e.g. the
production of a specific toxin or a protein based pumping system, etc. it is a
disadvantage, when growing under conditions, where pathogenicity is not a
requirement for survival. Repe ted rounds of cultivation, will therefore result in
the non-pathogenic variant outcompeting the pathogen variant. A similar
outcome can be obtained by using radiation [98]. Is has been argued that using
an attenuated approach for malaria vaccination, may protect as much as 90% [74].
There are however several drawbacks using the live ttenuated vaccine sy tem.
The primary one b ng he risk of reverting from non-pathogenic to pathogenic.
An example of vaccine reversion is the case, where the pathog nicity is located
on a small extra-chromosomal cir ular piece of DNA, a plasm d, which can be
transferred between organisms and thus result i wha i known as horizontal
gene transfer. In cases where the lack of pathogenicity is a result of a single
mutation, the inverted mutation may result in a regain of pathogenicity. In the
case of viruses, the combination of two non-pathogenic variants, may result in
reformed virulence [95]. Once inside the human body again, the reason for the
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original development of pathogenicity, i.e. the ability to proliferate by immune
evasion, once againg represent a prerequisite for survival. Furthermore many
pathogens are notoriously diﬃcult to culture in vitro [118] making vaccine
production complicated and therefore costly.
Since reversions poses a great risk, another approach is to identify the exact
structure responsible for the elicited response. Moreover one may even identify
the exact substructure and if feasible one can produce a so called subunit vaccine.
By identifying the exact epitope(s), one may identify the ”minimal immunogenic
region of a protein antigen” [118]. Smaller structure may often be produced
recombinantly and thus oﬀers a cheap way of mass production. This
minimum-region approach however poses the challenge of covering the diversity
in cases where the immunogenic region displays a high degree of polymorphism.
Furthermore when aiming at a cellular response, where epitopes must be
matched with the specific variant of the MHC complex (the human leukocyte
antigen (HLA) haplotype), the challenge is to make a vaccine, which cover the
entire HLA haplotype diversity within the population. This complication arises
from the fact that diﬀerent populations carry diﬀerent HLA haplotypes and since
the haplotype:peptide interaction is unique, a peptide inducing an adequate
response in one individual, may have no eﬀect in another, see [118] for review.
Lastly subunit vaccine may have a high eﬃcacy, when looking only at the
haplotype::peptide interaction, but when challenged with the complete
pathogen, the subunit vaccine, may direct the response against parts, which are
not targets.
1.3 Malaria
1.3.1 Historic Background
Malaria as a word, was first used in scientific context in 1827 by JohnMacCulloch
[67]. The word malaria is derived from italian meaning ’bad air’ [67, 101],
recognising that the symptom could be observed in people living in damp and
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swampy areas. Malaria-like symptoms is described in ancient Chinese writings
dated approximately 2700 BC and later in writings of the greek philosopher
Hippocrates from approximately 400 BC [97]. Using ancient DNA as evidence,
it has been argued, that Malaria had a significant impact on mortality rates in
ancient roman Italy [131]. Up until 1860 malaria posed a significant health risk
to people living in the Lambeth andWestminster areas of London, only after
drainage the risk was markedly reduced [101]. In summary, it is evident, that
malaria has been with us for a very long time and more importantly, in the
context of vaccine development, that Malaria has co-evolved with humans.
1.3.2 Malaria in the modernworld
Today malaria aﬀects the world on a global scale. In the 2013WorldMalaria
Report, WHO estimates that in 2012 there were approximately 207 million
malaria cases, 627 000 malaria deaths [155] and that half the world population at
risk of being infected with malaria [155]. Themajority of infections occur in
infants and small children under the age of 5 [155]. Parents are forced to stay
home and take care of the children, the consequence of which is a markedly
labour force reduction in malaria endemic countries [128]. This way malaria is
not only aﬀecting people on a personal level, but to a high degree also aﬀecting
the economy of the developing world [154]. Fig. 1.3.1 show the worldwide
distribution of malaria along with the areas contribution to the total death toll
[3]. From this, it is clear that sub-saharan by far bears the heaviest burden, when
it comes to malaria.
1.3.3 Malaria Biology
Humanmalaria is caused by a small protozoan parasite of the genus Plasmodium
[38]. 4 diﬀerent species capable of human infection exists, namely: P. falciparum,
P. vivax, P. ovale and P. malariae [122]. The closest known non-human malaria
species is P. reichenowi, which causes mild malaria in chimpanzees [117]. P.
14
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of deaths, particularly in sub-Saharan Africa, take place outside health 
facilities. Different modeling approaches combining routine informa-
tion, malaria-prevalence survey data, verbal autopsies, demographic 
and health surveys, and surveillance-based approaches are being 
used, leading to different estimates1,6. We urgently need a renewed 
 consensus on which approaches should be used to obtain accurate 
estimates and to be used for planning within a health system.
Why is it difficult to measure burden of disease? Several biologi-
cal and epidemiological questions that influence our assessment of 
malaria remain unresolved. For instance, the relationship between 
transmission intensity and the outcome as infection, clinical disease 
and death remains uncertain. This relationship can vary in both space 
and time, depending on factors such as the species of parasite, pub-
lic access to and performance of the available health services, and 
co-morbidity, particularly bacterial diseases such as those caused by 
Streptococcus pneumoniae or non-typhi Salmonella5.
During the past decade, all regions worldwide, including sub-
Saharan Africa, have been undergoing profound social, demographic 
and epidemiological changes and economic development—
 accelerated urbanization has improved water quality and sanitation, 
strengthened health services and systems, 
and provided new vaccines against different 
preventable diseases, as well as better immu-
nization services, food programs reducing 
malnutrition and vitamin deficiencies, and 
better communications and political stabil-
ity. These are contributors to a virtuous cycle 
of improved health and reduced poverty that 
is having an impact on the distribution, fre-
quency and disease burden associated with 
malaria. How can we then assess the contri-
bution of the efforts of countries, donors and 
international agencies deploying effective 
tools for controlling malaria to the observed 
reductions in infection, disease incidence 
and all-cause mortality? The scientific chal-
lenge is to attribute the causality and impact 
of ‘single’ interventions. But, at a time when 
accountability and policy decisions are 
guided at global and national levels by the 
concept of ‘value for money’—the business 
term for cost-effectiveness—we unfortu-
nately lack the approaches to quantitatively 
appraise the complex interplay of multiple epidemiological, social, 
cultural, economic and systems factors that govern interven-
tional mixes in time and space. Common sense—beyond political 
correctness—supported by efficacy and effectiveness data for the 
different tools applied strongly supports the notion that the national 
and international efforts over the past decade are translating into a 
real impact (Fig. 1). Furthermore, data from independent research 
groups also show large reductions in disease rates and prevalence of 
infection in several areas across Africa1,7–13. However, careful scru-
tiny of these findings ratified by the expert opinion of the present 
authors often casts doubt on the ability entirely to attribute drops 
in disease incidence to the deployment of specific tools. As we look 
ahead, the availability of validated approaches that accurately esti-
mate the malaria burden consistently over time will be crucial if we 
wish to demonstrate progress. The quality and timeliness of malario-
metric surveillance combined with vital registration must therefore 
dramatically improve in all countries, particularly in those with large 
populations at risk1.
Today’s needs—increasing coverage and managing resistance
The current international financial crisis has already affected donors’ 
contributions and may challenge currently available financing mecha-
nisms, including the Global Fund to Fight AIDS, Tuberculosis and 
Malaria, which has invested close to $7 billion in malaria in the 
ten years of its existence. This comes at a particularly bad time, as 
coverage needs to further expand in virtually all areas, particularly 
in areas where we still have no indication of a substantial decrease of 
malaria burden. In addition, in areas where high coverage has been 
attained, a considerable proportion of the insecticide-treated nets 
will need to be replaced. The World Malaria Report 2012 provides an 
 excellent analysis of the coverage levels achieved by intervention and 
thus the basis for informed discussions on the efforts that still need to 
be made1. The gains witnessed over the past decade are still modest 
and fragile; they could be easily lost and reversed if financial support 
for malaria control is not sustained or increased.
Therapeutic resistance to some key components of our tools to 
fight malaria is a growing problem1 (http://wwarn.org/explorer/app). 
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Figure 1 The current biggest threat for malaria control and elimination is 
insufficient funding. Available funds are unlikely to increase at the necessary 
pace to achieve the goals for malaria control and elimination proposed by 
the Roll Back Malaria Partnership for the end of 2015 (refs. 1–3).
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Figure 1.3.1: Worldwide distribution of malaria and contribution to death toll. Adapted from [3]
reichenowi / P. falciparum divergence is thought to have occurred 6 to 10 million
years ago [46].
In 2009 a new Plasmodium species, isolated from two Chimpanzees living in
close contact with humans, capable of both Chimpanzee and human infection,
was identified [112]. Also P. knowlesi has been isolated from humans living in
close contact with macaques [42]. Furthermore Plasmodium lineages have been
identified in Gorillas along with P. falciparum [117]. The fact that several
Plasmodium species have been found capable of host switching emphasises the
capability of malaria to adjust.
A specific subtype of malaria is ’pregnancy associated malaria’ (PAM) or
placental malaria, which is caused by the P. falciparum species [50]. As the overall
focus of this PhD programme has been on placental malaria, the focus will
henceforth be on P. falciparummalaria.
The life cycle of Plasmodium falciparum
The lifecycle of the malaria parasite is complex and involves several distinct stages
in both the human host and the Anophelesmosquito transmission vector [37].
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The sporozoite form of the malaria parasite is found in the salivary glands of the
mosquito [38] and infection occurs just after the mosquito bite [105]. During
the bite, the mosquito injects saliva containing anticoagulants in the blood,
preventing the blood from clotting [126]. Upon infection the parasites will seek
out the liver and enter the hepatocytes, where it will generate thousands of
merozoites [102]. The hepatocyte eventually ruptures releasing the merozoites
into the blood stream, each of which is capable of infecting an erythrocyte [38].
After 48 hours the infected erythrocyte (IE) ruptures [63] and releases 16-32
daughter merozoites into the blood stream[102] and the cycle continues. This
cycle is the reason for the 48hour fever attacks malaria gives rise to [63]. Inside
the erythrocyte some of the parasites will formmale and female gametocytes,
which can then be taken up of another mosquito [90]. This way, the parasite has a
asexual stage in the host and a sexual stage in the vector [121], the regulation of
gametocytogenesis is not fully understood [43]. Figure 1.3.2 depicts this
lifecycle.
Plasmodium falciparum immunity
The human immune system detects extracellular infections by activating systems,
which labels and neutralises the pathogen [96]. Intracellular infections of
nucleated cells are detected via surface presentation of pathogen antigens [91]
(See sec 1.2). Upon malaria infection, an immune response will be elicited
directed at diﬀerent stages of the malaria life cycle [27]. The parasite has evolved
a series of mechanisms of immune evasion [142]. By invading erythrocytes, the
parasite exploits the erythrocytes lack of a nucleus, thereby circumventing the
primary intracellular pathogen detection system [72]. As erythrocytes are
non-nucleated cells, they lack the ability to present peptides derived from
intracellular proteins on the surface via theMHC-I pathway. Erythrocytic
invasion is rapid and propelled by motor proteins [47]. After erythrocytic
rupture, the released merozoites recognise new erythrocytes within 1 minute and
following recognition and erythrocytic attachment, the parasite completes
16
General Overview of Plasmodium Invasion
To invade the host cell, the parasite must firstly initiate
egress from its infected cell, and this process involves dis-
ruption of its vacuolar home, known as the parasitopho-
rous vacuole, and the host-cell membrane. Egress of
P. falciparum involves a sudden increase in intracellular
pressure late in the blood-stage cycle, together with bio-
chemical changes that destabilize the infected cell cyto-
skeleton, and these combine to promote an explosive
event effectively dispersing the nonmotile merozoites
(Glushakova et al., 2005) (Figure 3). The underlying cause
of the increased pressure and destruction of the cytoskel-
eton preceding rupture is not completely clear. With re-
spect to the latter, however, it would appear that prote-
ases are involved (Salmon et al., 2001) and that this
occurs in a two-step process such that destruction and
rupture of the internal vacuolar membrane occur distinctly
and just prior to that of the erythrocyte membrane (Wick-
ham et al., 2003). Candidate proteases include members
of the serine repeat antigen (SERA) family that localize to
the parasitophorous vacuole (Hodder et al., 2003; Miller
et al., 2002b). The SERA family is required in mosquito
stages for sporozoite egress from oocysts (a stage of
the parasite in the mosquito vector), validating a role in
host-cell rupture for proteases in general and this family
in particular (Aly and Matuschewski, 2005). After exiting
the host, merozoites recognize, attach, and enter erythro-
cytes, and this process occurs rapidly, probably on the or-
der of 60 s. It is not surprising that this time frame is short
and highly efficient, as the antigens on the surface of the
extracellular form of the parasite are particularly vulnera-
ble to immune attack.
The initial contact between the merozoite and erythro-
cyte is a crucial step, as the parasite must distinguish
between erythrocytes competent for invasion and other
cell types (Figure 4). At a gross level, this recognition
and primary adherence is relatively long distance, ap-
parently of low affinity, and reversible (Bannister and
Dluzewski, 1990). Primary attachment of the polar mer-
ozoite appears to occur at any point on the surface of
this parasite stage. Reorientation then ensues (Figure 4),
an event that seems to involve the erythrocyte surface
wrapping around the merozoite. The purpose of this
event is to juxtapose the apical end of the merozoite
with the erythrocyte membrane, allowing a much closer
interaction.
To enter the cell, a so-called tight junction is formed be-
tween the parasite and host membrane. The tight junction
moves from the apical to the posterior end of the merozo-
ite in a complex series of events powered by the parasite
actin-myosin motor (Keeley and Soldati, 2004). One of the
most conspicuous events is the removal or ‘‘shedding’’ of
the fuzzy coating covering themerozoite surface, a proteo-
lytic event involving SUB2, a serine protease localized in
the apical microneme organelles (Figure 2 and Figure 4)
(Harris et al., 2005). As the tight junction moves toward
the posterior end the ligands mediating the invasion pro-
cess must be removed. By analogy with T. gondii, it ap-
pears likely that, in P. falciparum, this may involve the
rhomboid family of serine proteases which, unusually,
clip proteins fromwithin the phospholipid bilayer (Brossier
et al., 2005; Dowse et al., 2005). As the parasite pushes its
way into its host cell, it creates a parasitophorous vacuole
to seal itself from the host-cell cytoplasm and form an en-
vironment hospitable for its development.
Figure 1. The Life Cycle of P. falciparum in the Human Host
and the Anopheles Mosquito Vector
The Plasmodium-infected mosquito injects sporozoite forms into the
human host, and these migrate to the liver, where they can pass
through Kuppfer cells and invade hepatocytes within which they de-
velop into liver merozoites. These merozoites are released into the
bloodstream, where they invade erythrocytes. They develop through
ring, trophozoite, and schizont stages, replicating to produce from
16 to 32 daughter merozoites that are released during egress. The
free merozoite is then able to invade other erythrocytes to continue
the asexual blood-stage life cycle. All clinical symptoms arise during
this asexual blood cycle. In the blood, some intraerythrocytic stages
develop into male or female gametocytes, the sexual forms of the par-
asite. These are taken up by the mosquito during feeding, develop into
gametes in the insect gut, and fuse to form zygotes. The zygote de-
velops to form an invasive ookinete, which traverses the midgut and
transforms into an oocyst fromwhich sporozoites are released that mi-
grate to the salivary glands for injection into a human host during the
next blood meal.
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Figure 1.3.2: Lifecycle and pathogenesis
of Plasmodium falciparum [37]. The female
Anopheles mosquito is the transmission vec-
tor for the malaria parasite. Just after the bite,
the mosquito injects saliva containing anti-
clotting proteins. Along with the saliva travels
the sporozoite form of the malaria parasite. It
seeks out the liver, where it will penetrate the
cellular wall of liver cells and begin transfor-
mation to the next step in the lifecycle. The
malaria parasites leave the liver cell as mero-
zoites. The parasite is now ready to begin
infe tion of the red blo d cells (RBCs). Every
48 hours a hoard of merozoites are released
from e h ruptured iRBC, each r ady to in-
fect a new RBC. Along with the merozoites,
imma ure male and female gametocytes are
released. These will be taken in with the next
blood meal of nother Anopheles m squ to,
thus initiating the mosquito life cycle [37].
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invasion of the erythrocyte after approximately 27 seconds [59]. The 90 second
window of antigenic availability in the merozoite extraerythrocytic stage is
therefore highly limited compared to the 48 h intraerythrocytic cycle. The
intraerythrocytic stage provide a beneficial niche for merozoite propagation, by
providing not only protection from immune detection, but also plenty of
nutrition in the form of hemoglobin [32]. As much as 95% of the protein content
of an erythrocyte is haemoglobin [52]. The erythrocytic lack of antigen
presentation capabilities, may seem odd in this context but several reasons have
been proposed as to why erythrocytes lack a nucleus, e.g. oxidative stress
avoidance [159], maximise oxygen carrier capacity and cell flexibility for passage
of capillary network [79]. To ensure a well functioning population of
erythrocytes and thusly an optimised oxygen carrier capability, erythrocytes will,
under normal circumstances, undergo senescence after 100-120 days [48].
Erythrocyte membrane changes signify ageing, which macrophages in the spleen
will detect and destroy the erythrocyte [56]. This process is known as eryptosis
[58]. As with aged erythrocytes, IEs are likewise detected and filtered in the
spleen [157]. The induction of eryptosis reduces parasitemia, diseases and
genetic traits, resulting in an increase in eryptosis, e.g. sickle cell anemia,
therefore provide protection against severe malaria [89]. A crucial step in the
pathogenesis of malaria is to avoid this filtering system. The parasite alters the
exterior of the IE, expressing surface adhesion proteins [125] known as
Plasmodium falciparum erythrocytic membrane protein type 1 (PfEMP1) [11].
These proteins facilitate adhesion to a wide variety of host receptors in the
microvascular epithelium, e.g. CD36, ICAM-1 and CSA [86]. This way PfEMP-1
mediated cytoadherence facilitates parasitemia, by avoiding splenal destruction
of the IE [73].
Unlike the intracellular structures in the IE, the surface adhesion proteins are
visible and accessible to the human immune system as small ’knobs’ on the
surface [26, 146]. The surface displayed antigens, will be recognised by
antibodies and high titers of antibodies against IEs are associated with immunity
[29]. The antibodies potentially block the PfEMP1:receptor formation thereby
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hindering cytoadherence and simultaneously labelling the IE for
macrophagocytosis [29]. The blocking is only potential in that non-blocking
antibodies are raised against immunodominant B-cell epitopes [72], creating an
immunological ’smoke-screen’ [90]. The function of this ’smoke-screen’ is to
divert the immune response away from epitopes located close to the
PfEMP1:receptor interaction site. Thereby the IE retains its cytoadherence
capability. Furthermore PfEMP1 exhibits an extreme variability [85]. The family
of genes encoding the PfEMP1 are known as the var gene family [115]. Each
parasite harbours approximately 60 var gene copies [102]. Each parasite express
only one PfEMP1 variant at any given time [152]. Parasites expressing a variant,
against which no antibodies exists, will be selected for and flourish causing a new
wave of parasiteamia [27]. This phenotype switching is known as clonal or
antigenic variation [125]. The consequence of the PfEMP1 antigenic variation is
that P falciparummalaria immunity is gradually acquired after multiple exposures
[62]. This gradual acquisition of immunity is primarily antibody based [5],
innate immunity however also play a role [144]. The gradual acquisition of
immunity follows as the immune system is exposed to diﬀerent PfEMP1 variants
[42]. With each exposure memory b-cells will produced ready to produce
anti-adhesion antibodies upon infection [145]. In the context of placental
malaria, it is important to note that the acquired immunity does not lead to a
sterile immunity, but rather a symptom free infection [142].
Studies have indicated that in some cases two PfEMP1 variants may be
simultaneously expressed [21, 80]. In a 2010 study a parasite was found to bind
both the CD31/PECAM1 and the CD54/ ICAM1 receptors, the result of which
was a 2-fold increase in binding eﬃciency to human endothelial cells, when
compared to parasites expressing only one PfEMP1 variant [80]. This
emphasises not only that many aspects of malaria pathogenesis remain
non-elucidated, but also the ability of malaria to adapt.
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confounds understanding of malaria immunity. 
Plasmodium species evade adaptive immunity 
by producing polymorphic antigenic proteins 
(such as PfEMP-1) within a strain, antigenic 
variation among species or strains, and ana-
tomical sequestration. In addition, plasmodium 
parasites are believed to circumvent innate 
immune responses by producing proteins that 
actively inhibit the activity of transcription 
factor NF-KB and cytokine expression, block 
complement activity and allow evasion of the 
host inflammasome. Some evidence suggests 
that infected erythrocytes or parasite products 
may alter antigen-presenting cell functions. 
However, these mechanisms have not been fully 
explored and it is likely that additional evasion 
mechanisms exist.
Many immune-evasion mechanisms have 
been described in other infectious diseases, but 
it is not clear which operate in malaria infec-
tion. Additional work is needed to fully appre-
ciate the mechanisms used by malaria parasites 
to bypass host immune responses.
Immune-mediated pathogenesis
Malaria pathogenesis encompasses a spectrum 
of disease manifestations including severe 
anemia; renal failure; pulmonary edema and 
respiratory distress; lactic acidosis; placental 
malaria; and cerebral syndrome. Host immune 
responses contribute to both severe anemia and 
cerebral malaria. In severe malaria-induced 
anemia in the mouse model, neutralization of 
interferon-G, produced by CD4+ T cells, GD T 
cells and NK cells, alleviates parasite-induced 
erythropoietic suppression and lifts the block-
ade on erthryoid gene expression in bone mar-
row. Furthermore, depletion of mouse CD4+ 
T cells or macrophages protects against severe 
malaria-associated anemia, and depletion of 
CD4+ T cells diminishes splenomegaly. These 
observations provide evidence for involvement 
of CD4+ T cells, macrophages and cytokines in 
the anemia of severe malaria; however, defini-
tive mechanistic studies are needed to confirm 
and extend these observations and to ascertain 
their importance in human malaria.
Cerebral malaria occurs mainly in young 
children and includes fever, unconsciousness, 
coma that can be reversible, and neurological 
sequelae. Many of these signs and symptoms 
are associated with adherence of infected 
erythrocytes to cerebral post-capillary venules, 
although clinical observations suggest that cere-
bral malaria is not a thrombotic or ischemic 
process. In addition, parasite sequestration 
occurs in all P. falciparum malaria infections, 
but only a small percentage of patients develop 
cerebral malaria. The difficulties associated 
with studying human cerebral malaria limit the 
understanding of immune and inflammatory 
responses in the brain and the long-term effects 
of cerebral malaria on cognitive and neurologi-
cal function; mouse models have afforded only 
limited insight.
A clearer picture of host cytokine responses 
and identification of malaria toxins that alter 
immunity are needed to further elucidate dis-
ease pathogenesis. Genetic studies may begin 
to provide some clues, as polymorphic immu-
nity-related loci have been identified that are 
associated with greater incidence of or decrease 
in severe malaria. For example, deficiencies in 
complement C5 are associated with resistance 
to cerebral malaria, and polymorphisms in 
complement receptor 1 protect against severe 
malaria. Other loci have also been identified, 
although additional studies are required to 
fully understand their role in disease severity.
Placental malaria
Placental malaria is a significant cause of mor-
bidity and mortality in pregnant women and 
neonates in malaria-endemic areas. P. falci-
parum is the main cause of placental malaria, 
which occurs when parasite-infected erythro-
cytes are sequestered in the placenta and trig-
ger disease. The P. falciparum parasites found 
in pregnant women have gene-expression 
Figure 3  Population indices of immunity in an endemic area of P. falciparum transmission. Change 
over time of various indices of malaria-induced disease in a population living in an endemic area of  
P. falciparum transmission: pink, asymptomatic infection; blue, mild disease (febrile episodes caused 
by malaria); green, severe or life-threatening disease (severe anemia, cerebral malaria and so on). Data 
are normalized and are presented as the percent of maximum cases for each population index (adapted 
from ref. 4). 
Figure 2  Women wait with their sick babies receiving treatment for malaria. Municipal hospital of 
M’banza Congo, Zaíre province. Photo by A. Bird (USAID/Congo 2008).
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Figure 1.3.3: Gradual acquisiation of immunity to Plasmodium falciparum mal ri [90]. Malaria
immunity is gradually acquired. Infants and children up to the age of 5 experience severe, often
fatal, malaria. From the ages of 5 to 10, children experience a milder form of malaria and ﬁnally
after the age of 10, asymptomatic infections are seen [6, 90, 103].
1.4 Placental malaria
”So long as woman has walked the earth, malaria may have stalked her” [45]. A
special case of malaria is pregnancy associated malaria (PAM) or placental
malaria. As the name suggests, this type of malaria aﬀects only pregnant women.
The clinical consequences of placental malaria include: maternal anaemia, low
birth weight, preterm delivery, which leads to increased perinatal and infant
mortality [106]. Around 100,000 - 200,000 infants die every year from placental
malaria [107]. Women living in malaria-endemic areas will have acquired
immunity once they reach child-bearing age, however upon pregnancy a new
wave of parasitemia hits [135]. The reason for this sudden set back is the
prevalence of novel IE sequestering receptors in the intervillous space of the
placenta [76]. The intervillous space is where nutrients and oxygen is exchanged
from the maternal blood to the blood of the fetus. Where normal P. falciparum
primarily utilises the abundantly available human CD36 receptor [73], placental
malaria is the result of the interaction of one particular PfEMP1 variant with the
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chondroitin sulphate A (CSA) [16] part of placental Chondroitin sulfate
proteoglycans (CSPG) [23] found on syncytiotrophoblast cells in the
intervillous space of the placenta [1].
The PfEMP1 variant of placental malaria binds exclusively to CSA [24, 75] and
since women pre-pregnancy exposure to CSA-binding parasites is limited, the
acquired immunity against non-placental malaria, provide no protection against
CSA-binding parasites [51]. Thus the infected women fall sick to malaria once
again [148]. As with normal malaria, placental malaria immunity is mediated by
gradual acquisition of blocking-capable anti-PfEMP1 antibodies and is hence a
function of the parity of the woman [42] (See figure 1.4.1). Multigravidae
women experience only asymptomatic infection despite high parasitemia [132].
Since placental malaria is a consequence of a very specific receptor:ligand
interaction, as described above, the placental PfEMP1makes for a good vaccine
target [17].
1.4.1 PfEMP1 variant VAR2CSA is responsible for placentalmalaria
In 2004 Salanti and co-workers identified VAR2CSA, a single and uniquely
structured molecule belonging to the PfEMP1 family, as the protein responsible
for placental malaria [129]. As VAR2CSA is the parasite ligand for placental
binding, VAR2CSA is recognised as the leading PAM vaccine candidate.
VAR2CSA is a very large 350 kDa [105] multidomain protein [19], divided into
6 duﬀy binding like domains (DBL) [33]. In total, VAR2CSA consists of
approximately 3,000 amino acids residues and equence similarity ranges from
80-98% [39]. VAR2CSA contains both conserved folds and high sequence
variation. [69]. VAR2CSA epitopes are predominantly located as conformational
epitopes in the polymorphic regions of VAR2CSA [9] and it is likely that the
variable regions acts as immunological smoke-screens, directing the immune
response towards non-protective epitopes [38, 72, 90]. In 2010 Salanti and
co-workers managed to express the entire full-length recombinant VAR2CSA
[83]. They also showed that the recombinant VAR2CSA induced potently
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Figure 1.4.1: Placental malaria. Placental malaria arises when otherwise immune women living
in areas endemic to malaria, suddenly fall sick to malaria during ﬁrst pregnancy. The cause of
this is the presence of novel receptors, Chondroitin sulfate A (CSA), in the intervillous space
of the placenta presented at the syncytiotrophoblast of the endothelial lining. These receptors
facilitate sequestration of infected erythrocytes, which causes a new wave of parasitemia, by
interacting with the VAR2CSA variant Plasmodium falciparum Erythrocyte Membrane Protein
1 (PfEMP1). Immunity is acquired gradually with increasing parity and is antibody mediated by
blocking the CSA:PfEMPP1 interaction. Adapted from [140].
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A B C
Figure 1.4.2: Crystal structures of VAR2CSA domains A: DBL3X at 1.80Å [68] and B: DBL6ε at
1.84Å [54] and C: DBL3X and DBL6ε aligned. Colour legend: Red = α-helices, green = loops
and yellow = β-sheets. The ﬁgure illustrates the high similarity of the two VAR2CSA domains.
homologues inhibiting antibodies [83], i.e. when immunised with a given
variant, the raised antibodies potently inhibited the same variant. It is however
also possible to induce single-domain inhibiting antibodies [7, 110, 130].
Extensive work has gone in to solving the crystal structure of VAR2CSA [33],
despite this so far only the single domains DBL3X [68] and DBL6ε [82] have
been solved (See figure 1.4.2 for structural comparison).
However the hunt continued by producing truncated versions of VAR2CSA
aiming at identifying the smallest possible part of the protein, while still retaining
activity, the so called minimum binding region [40]. Theminimum binding
region is ID1-DBL2Xb (See figure 1.4.3). This region is the minimum part of
VAR2CSA required to retain the ability to bind to CSA. As seen in figure 1.4.3
the proposed structure illustrates how the before mentioned immunological
smokescreen works by hiding away the active site of the protein and allowing
antibodies to adhere to insignificant epitopes located at the exterior of the
protein and away from the active site.
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in GraphPad Prism. Higher salt concentrations were not
included in the analysis as binding was almost completely
inhibited. This is probably due to a change in protein struc-
ture. This notion is supported by the fact that log KD,observed
versus log [Na!] was linear only between 150 and 300 mM,
suggesting that other factors play a role at higher concentra-
tions of NaCl.
Log KD,observed versus log [Na!] shows a linear relationship
(Fig. 8). The slopem(1-f) ranges between 2.7 for ID1-ID2a and
3.4 for full-length (FV2).We do not know the value for f, but the
maximal number of ionic interactions involved in the binding
must be between 2 and 3. It is interesting that the value for the
full-length protein is higher than for the short fragments, indi-
cating that this protein makes an extra ionic interaction with
CSPG. The KD values at 150 mM NaCl serves as our reference
point, as this is the physiological NaCl concentration. By
extrapolating the linear relationship and finding the y intercept
we find that KD,nonionic" 5.9 !M for FV2, KD,nonionic" 3.4 !M
for DBL1X-ID2a, and KD,nonionic" 0.7 !M for ID1-ID2a. Com-
paring the logarithmic values of these and the reference point
(150 mM NaCl), we estimate that between 25 and 35% of the
VAR2CSA binding can be accounted for by ionic interactions.
This suggests that the high CSA affinity for VAR2CSA cannot
be explained by ionic interactions with the sulfated GAG struc-
ture alone. The high affinity may be achieved through a com-
plex binding sitemaking amultivalent interactionwith theCSA
carbohydrate backbone.
DISCUSSION
Malaria is one of the most common infectious diseases and
one of the largest global health problems. Pregnant women are
especially vulnerable to infection, despite previously acquired
immunity. In this study we have addressed key questions
related to the molecular mechanism behind the VAR2CSA-
CSA interaction in PM.
Previous work has suggested that the minimal CSA binding
region in VAR2CSA is DBL2X-ID2b, with the need for DBL1X
or DBL3X for full affinity binding (19, 20). In continuation of
this work we made further truncations of VAR2CSA, focusing
on the DBL2X region.We show that the core CSA-binding site
lies within the DBL2X domain including small parts of the
flanking interdomain regions. The binding does not depend on
the ID2b region, or on the DBL1X or DBL3X flanking domains,
as previously suggested (19). This is evident by the specific
CSPG binding of ID1-ID2a and ID1-DBL2Xb (Figs. 2 and 3).
The minimal binding region is ID1-DBL2Xb, which bound
CSPG with characteristics comparable with that of full-length
VAR2CSA.
It is interesting that these new datamaps the core CSA-bind-
ing site onto a single domain. Binding of DBL2X (and any other
single DBL domain) to CSA has previously been shown to be
nonspecific and of weak affinity (42). It is clear that the ID1 and
ID2a interdomains are essential for CSA binding. However,
data showing that DBL2X-DBL4" binds CSA (19), suggests that
ID1 is not essential for binding but rather needed for the for-
mation of a functional CSA-binding protein. DBL1X-DBL2Xa
and ID1-DBL2Xa did not bind CSPG. The two C-terminal
DBL2X borders (DBL2Xa and DBL2Xb) differ by 93 amino
acids. Because deletion of these amino acids eliminates binding
they must be important for CSA binding.
The ID1-DBL2Xb minimal binding region is much smaller
than full-length VAR2CSA, having a molecular mass of only 62
kDa. It is unlikely that further substantial truncations of
VAR2CSA will be functional in binding CSA. Our data rede-
fines DBL2X as a larger functional domain, incorporating parts
of the flanking ID1 and ID2a interdomains.
A VAR2CSA-based vaccine against PM must be able to
induce a strong anti-adhesive immune response. Rat sera raised
against all fragments containing the CSA-binding site inhibited
parasite adhesion to CSA (Fig. 4). Importantly, sera raised
against ID1-ID2a resulted in almost complete inhibition. This
suggests that the minimal CSA-binding fragments retain the
capacity for inducing a strong antiadhesive immune response.
FIGURE 6. Experimental SAXS curves, pair-distance distribution functions P(r), and ab initio shape reconstructions. A, a schematic representation of
VAR2CSA fragments used in the SAXS analysis together with color-coded VAR2CSA crystal structure homologues (PDB codes 1ZRO (25) and 3C64 (21)) used in
the docking processes for the presentation in Fig. 7.White boxes refer to poorly homologous inter-domain linker regions of VAR2CSA (ID’s) separating single
DBL domains. B, left, SAXS curves for DBL1X-ID2a, ID1-DBL4", DBL1X-DBL4", and FV2 (DBL1X-DBL6"). The logarithmof the scattering intensity (log(I)) is shown
as a function of themomentum transfer q in units of Å#1.Gray solid lines show the fit of the shape reconstructions to the experimental data. #2 valueswere 2.5,
1.3, 1.5, and 1.1, respectively. The Guinier fit are shown as the natural logarithm of the scattering intensity as a function of the squared momentum transfer.
Center, P(r) functions calculated from each scattering curve are plotted in relative units as a function of the distance in nanometers. Right, the average ab initio
shape reconstructions are shownwith spheres representing the dummy-atoms used byDAMMIF. The orientation on the right is after a 90° right-hand rotation.
FIGURE 7. Docking of crystal structure homologues into the molecular
envelopes obtained fromSAXS. Themolecular envelopes are depicted as a
mesh. The docked crystal structure homologues are shown as domainswith a
surface representation. A, DBL1X-ID2a; B, ID1-DBL4"; C, DBL1-DBL4"; D,
DBL1X-DBL6". The left panel shows a side view and the right panel shows the
top view after a 90° rotation.
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Figure 1.4.3: Proposed structure of VAR2CSA and minimum binding region. Adapted from [33].
Malaria vaccine
The use of experimental human challenges for promoting vaccine developm nt
has been proposed [133]. The idea being that the resulting P. falciparum infection
can be cleared using anti-malarial drugs. The first malaria vaccine, RTS,S/AS01, is
expected to be licensed in 2015 [124]. Initial phase III results are promising [2].
The target of the vaccine is the pre-erythrocytic phase of malaria and has been
shown to induce potent antibody response against P. falciparum circumsporozoite
protein (CSP), along with a moderate CD4+ T cell response [49]
Antibody mediated pathogen neutralisation has shown great potential as a
therapeutic drug [28]. The downside of using antibodies as a drug, is that the
protection only lasts for as long as the antibodies are in the bloodstream.
Traditional vaccines on th contrary can potentially induce long lasting antibody
media ed immunity [145]. Synthetic approaches, such as RTS,S/AS01, are being
applied aiming at mimicking the ’n ural’ antibody mediated immunity [77].
This protein-plus-adjuvant approach for vaccine developme t against a specific
malaria stage has previously been applied [70].
Henceforth the focus will be on VAR2CSA as vaccine target, it should
however be noted that many other targets are available [124]
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”Despite the clear importance of PfEMP1 as an immune target, antigenic
diversity is a key obstacle that must be overcome for PfEMP1 to be pursued as a
major malaria vaccine candidate.” [17]
1.5 HighDensity PeptideMicroarrays
1.5.1 Introduction
One approach for the analysis of VAR2CSA sequence variation is by scanning
fragments of the VAR2CSA protein (peptides) for biological activity. Using
conventional technology peptide scanning is a costly aﬀair, costing arounde30
per ten amino acids. The aim of the PepChipOmics projects, was to develop a
high throughput chip, lowering the price to a mere few cents per peptide. It may
eventually be possible to have 500,000 peptides on a single chip. When dealing
with data of such magnitude, the risk of identifying false positives increases
dramatically. This calls for the development of robust statistical methods for data
analysis. TheHigh Density Peptide Microarray (HDPMa) project, acronym:
PepChipOmics, was initiated under the EU’s 7th Framework Programme for
Research and Technological Development (FP7).
1.5.2 Technical description
The novelty of the HDPMa technology is the use of photo activated amino acid
residue coupling. The targeted photo activation is achieved by having a light
source shining rays of light onto a collimating lens system. After collimation, all
the rays of light are parallel and directed at the Digital Micro mirror Device
(DMD) chip. The DMD chip consists of micro mirrors, each capable of rotation
and by doing so producing a binary system. The rays are reflected through an
imaging lens system onto the peptide chip. This way each field on the peptide
chip can be either illuminated or not (See figure 1.5.1).
TheDMD chip is no diﬀerent from the one used in a normal projector used for
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In situ synthesis of peptides 
Figure 1.5.1: The DMD chip generates an image, which is projected onto the peptide synthesis
support. This determines the location, where the growing peptide is de-protected i.e. prepared
for amino acid extension. [ Picture from: High-Density Peptide MicroArrays and Parallel On-Line Detection of Peptide-
Ligand Interactions (High-Throughput Research in Biotechnology. Acronym: PepChipOmics EU-grant application FP7-HEALTH-
2007-B. Coordinator: Søren Buus Professor, MD, PhD. Laboratory of Experimental Immunology, Faculty of Health Sciences,
University of Copenhagen, Denmark ].
presentations. The DMD chip used is HD, yielding a theoretical capacity of
1920x1080 = 2; 073; 600 peptides, however in order to minimise the eﬀect of
adjacent coupling fields, blank fields are required in a checkerboard manor. Also
the edges are excluded and more than one field with the same peptide is required
to estimate signal. Thusly the capacity is reduced to around 200,000 unique
peptides.
1.5.3 In situ synthesis
The peptides are synthesised in situ on the surface of the HDPMa chip. The
principle synthesising is similar to that of the standard Fmoc-polyamide
synthesis protocol, only the HDPMa chip synthesis utilises photo-sensitive
groups for elongation initiation.
1. The chip surface is prepared with c-terminus spacers consisting of 4
aspartic acid residues ’DDDD’, lifting the final peptide up from the surface.
Each spacer has a photo-sensitive group placed at the N-terminus
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Figure 1.5.2: HDPMa In situ peptide synthesis. Filled triangles: Fmoc protection group, ﬁlled
circles: photosensitive group. Synthesis details in text. [ Picture from: High-Density Peptide MicroArrays and
Parallel On-Line Detection of Peptide-Ligand Interactions (High-Throughput Research in Biotechnology. Acronym: PepChipOmics
EU-grant application FP7-HEALTH-2007-B. Coordinator: Søren Buus Professor, MD, PhD. Laboratory of Experimental Immunol-
ogy, Faculty of Health Sciences, University of Copenhagen, Denmark ].
2. Targeted light rays from the DMD hits target peptides on the HDPMa
surface
3. Targeted peptides are de-protected
4. The surface is flushed with an amino acid of choice, coupling the amino
acid to the de-protected N-terminus of the target peptide
5. Steps 5-10 are repeats of steps 2-4. Lastly the Fmoc groups (filled
triangles) are exchanged with photosensitive groups (filled circles)
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1.5.4 Epitope mapping usingHDPMa
One application of the HDPMa technology is the scan for linear B-cell epitopes
in proteins (See section 1.2 for epitope explanation). A given protein can be
traversed using a window of 15 amino acid residues (creating 15-mers). Each of
the 15-mers is then synthesised in situ onto a spacer on the peptide support. The
spacer is used to increase the availability of each peptide. For the VAR2CSA scan
a spacer of 4 aspartic acid residues was used. Once the chip is fully synthesised, it
is incubated with relevant fluorophor conjugated primary antibodies. (see
fig1.5.3A) and the chip, with potentially fluorescent fields (see fig. 1.5.3B), is
photographed.
TheHDPMa chip was in this case constructed in a manor similar to that of a
chequerboard, where blank fields surrounds the actual peptide field. This allows
the signal from each peptide field to be normalised with that of the blank fields
surrounding it. Thus resulting in 15-mer sequences and associated signal-to-noise
ratio (S=N). The signal is quantified using the red-green-blue (RGB) colour
model, in which (0,0,0) is black and (255,255,255) is white. This way 256 shades
from black to white can be quantified.
1.5.5 HDPMa development
The technology is not fully developed and is therefore subject to further
development. The latest addition is the use of 2x2 mirror setup per field [25].
This reduces the risk of having a dead field. Also field spaces have been eliminated
increasing the capacity to 518; 000 peptides. For this study the system
described above was utilised. However since this study, the antibody detection
system has been altered, such that the peptide:antibody binding is quantified
using a secondary fluorophor conjugated antibody.
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Epitope Identification
To determine if the mean signal within a particular position
deviates significantly from 100%, a one-way ANOVA analysis was
performed for each of the 595 PSSM’s. The F-value calculated
during the ANOVA is traditionally used to determine if the
calculated variances are distributed randomly (our null hypothe-
sis). With the large amount of data used in each PSSM, significant
deviations (p,0.01, F.2. 04 for a given 15-mer individually) were
found in 90% of the peptides. Considering that 595 F-tests were
performed, we corrected for multiple testing and applied a
threshold of F.3.54 corresponding to a 1% risk of one of 595 tests
representing a type 1 error (p,1.68961025, F.3.54) (Table S1).
When correcting for multiple testing, 78% of the peptides showed
significant deviation from the null hypothesis. Due to the large
number ANOVA positive PSSM’s (F.3.54) we performed
Tukey’s HSD post hoc analysis for all columns in each PSSM
irrespective of the calculated F-values. The HSD-value indicates
how much the observed normalized mean of a given position must
differ from 100% before the deviation is considered significant at
the chosen level of significance (in casu p,0.01). Significant
positions were found in approximately 18 peptide regions in HSA,
which is exemplified in Figure 3a showing an epitope region
sliding through peptide 507–516. In at least 4 of these regions two
or more different patterns of significant positions were observed to
slide through the region suggesting the existence of several
different adjacent epitopes. This is exemplified in Figure 3b by
peptides 309–333, and all the significant positions are given in its
entirety in Table S1. It is not possible to determine whether the
long stretches identified using a polyclonal antibody is bound by
more than one antibody clone. Thus, it cannot be decided whether
these regions contain one or more epitopes and no exact
conclusion about the total number of epitopes recognized by our
chosen polyclonal HSA-antibody are made. About 190 ‘‘epitope-
significant’’ residue positions were found in HSA corresponding to
about one-third of the amino acids in the mature form of HSA.
Interactions Assigned at the Single-residue Level
Tukey’s HSD post-hoc analysis identified positions where
substitutions significantly affected binding of antibody, but it did
not quantitate the relative significance of the different residues. As
described in the methods section, a measure of the relative
significance was obtained by calculating the ratio between the
obtained q-value (qobt) and the critical q-value (qcrit). This ratio,
Rq, can be calculated for each individual position in each peptide,
and it describes the deviation of the signal in the position from
100% in units of significant differences (HSD).
In the extensive substitution analysis employed here, each
position in the original HSA sequence was represented in each of
15 different peptides with different reading frames. The 15 Rq-
values of a given residue differs with its position in a 15-mer
peptide. However, when looking at given residue in all positions in
the different 15-mers, a good statistical measure is obtained of the
contribution of the residue compared to the other residues in the
same epitope region. Two examples of the epitope Rq-values are
Figure 1. Image of array. A small section of the peptide array used for identification and fine specificity mapping of HSA epitopes: The section
shows approximately 300 of the total 220.428 peptide fields in this array. The peptides were synthesized in predefined, addressable fields generated
by 262 mirrors on the DMD each measuring 10610 mm resulting in peptide fields with the size 20620 of mm. The peptide fields were spaced by
10 mmwide empty zones. Binding of polyclonal rabbit anti-HSA antibody to the fields was recorded by fluorescence microscopy after incubation with
Cy3-conjugated goat anti-rabbit IgG.
doi:10.1371/journal.pone.0068902.g001
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Figure 1.5.3: A: Peptide scan of linear B-cell itopes by method of ﬂuorophor conjugated
antibody interaction. The fully synthesised peptide chip is incubated with ﬂuorophor conju-
gated antibodies raised against the native protein. After washing, the ﬂu rescence is record d.
B: Example of peptide chip image[64]. Ea h 2x2 quar epresents the signal from a peptide
single ﬁeld. The raw signal can then be rea by computing t e m an RGB value of the ﬁeld
(sf 2 [0; 255]). [ Picture from: High-Density Peptide MicroArrays and Parallel On-Line Detection of Peptide-Ligand In-
teractions (High-Throughput Research in Biotechnology. Acronym: PepChipOmics EU-grant application FP7-HEALTH-2007-B.
Coordinator: Søren Buus Professor, MD, PhD. Laboratory of Experimental Im unology, Faculty of Health Sciences, University of
Copenhagen, Denmark ].
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1.6 On statistics
Introduction and background on the statistics used in this thesis is given in
context with part II.
30
Part II
Paper I: SigniSite: Identification of
residue-level genotype-phenotype
correlations in proteinmultiple
sequence alignments
31
There are three kinds of lies: lies, damned lies, and statistics.
Mark Twain
2
SigniSite
2.1 Brief introduction to SigniSite
The challenge of genotype-phenotype correlation can be stated as follow: ”Given
a protein of interest, with a phenotype, which can be numerically quantified, e.g. the
binding aﬃnity, catalytic eﬃciency, fluorescent signal, immunogenicity or similar,
which residue(s) constitute the genotype determining the observable phenotype?”.
SigniSite addresses this challenge by analysing a multiple sequence alignment
(MSA) of variants of a protein of interest, where each variant is associated with
numerical value quantifying a phenotype of interest. The phenotype determining
residues are then identified by means of a non-parametric mean rank-test analysis
of each unique residue at each position in theMSA.
Within this framework each unique residue at each position constitute a test.
In order to address the multiple testing scenario originating from this framework,
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either the ’Holm step-down’ or ’Bonferroni single-step’ [44] methods for
correction for multiple testing (CMT) can be applied.
However as SigniSitewas intended to (also) be used by experimentalists
performing wet-lab mutation-analysis, it is envisioned that relatively small MSAs
could be submitted to SigniSite. One down-side of using CMT is that while the
risk of false positives is markedly reduced, the risk of false negatives is markedly
increased. In other words applying a CMT, which is too harsh, may in the end
quench the significance of more subtle genotype-phenotype correlations. The
challenge of controlling the ’harshness’ of the correction, is the oﬀset for the
work described in this part of the thesis. Moreover:
”Is it possible to reduce the total number of tests by identifying and eliminating any
superfluous tests based on an unbiased evaluation of the system prior to SigniSite
analysis?”
2.2 Briefly on the SigniSitemethod
Details can be found in the SigniSite paper and supplementary materials. As
prerequisite for the SigniSite analysis, each sequences in the submittedMSAmust
be associated with a value v 2 R representing the phenotype to be analysed.
SigniSite sorts and ranks the sequences based on v. Then for each unique amino
acid residue aa present at each position pi in theMSA, SigniSite performs a
non-parametric test by computing the observed mean rank, xobs, and comparing
it to the expected mean rank μexp, given that we expect that the residue aapi has
no preference for neither high nor low phenotypic values and therefore is
expected to be uniformly distributed at a given position pi, i = f1; 2; :::;mg, in a
MSA of lengthm. The expected mean is given by:
μexp =
N+ 1
2
(2.1)
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WhereN is the number of sequences in theMSA.The standard deviation can be
approximated by:
σ =
s
(N  naa)(N+ 1)
12naa
(2.2)
Where naa is the number of unique amino acid residues aa, observed at pi. The
parameters μexp and σ describes the expected distribution. We can therefore
calculate a z-score representing the probability of observing xobs or a value ’more
extreme’, given that μexp is the ’true’ mean:
z =
μexp   xobs
σ
(2.3)
This obtained z-scores can be approximated by the normal distribution and
p-values can therefore be obtained by standard method.
2.3 Introduction tomultiple testing
For any position pi in a givenMSA, where at least two amino acid residues are
present, SigniSitewill perform one test for each unique residue. From this it is
obvious, that multiple tests are performed. However, as multiple tests are
performed, the likelihood of identifying ’something’ as being significant by
chance, rather than ’actual’ significance increases. This can be addressed by
applying what is known as ’Correction for Multiple Testing’ (CMT).
In classical statistics the first step is to state a null-hypothesis and an alternative
hypothesis. Within the SigniSite framework, the null-hypothesisH0 is:
H0 : xobs = μexp (2.4)
and the alternative hypothesisH1 is:
H1 : xobs 6= μexp (2.5)
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Subsequently either the null-hypothesis or the alternative hypothesis is rejected,
based on a chosen level of significance 0 < α < 1. By convention usually 5% or
1%, referred to a ’significant’ or ’highly significant’ respectively. The level of
significance is used as a ’critical value’ to evaluate the outcome of a test
quantifying the probability of observing a value as, or more extreme than the
tested value, given that the null-hypothesis is true. The result of this tests is known
as the p-value. If the p-value is less than or equal to the level of significance α, i.e.
p  α, then the null-hypothesis is rejected. If p > α, then the null-hypothesis
cannot be rejected. Note, neither the null- or alternative hypothesis can be
accepted, only rejected or not rejected. Given the SigniSite framework, we do not
know beforehand whether xobs < μexp or xobs > μexp, we therefore clearly need a
two-sided hypothesis test. In a two-sided hypothesis test it is evaluated if p < α2 .
In either case, when conducting such tests, two types of errors can occur:
1. Type I error occurs, when a true null-hypothesis is incorrectly rejected.
This type of error is also know as a ’false positive’.
2. Type II error occurs, when a one fails to reject a false null-hypothesis. This
type of error is also know as a ’false negative’.
When performing multiple tests, the risk of type I errors increase, CMT is
introduced in order decrease this risk. Often the default way of performing CMT
is using the ’Bonferroni single-step’ method for CMT, in which the adjusted p-value,
padj is obtained bymultiplying the p-valuewith the number of tests performed nt:
padj = min (1; p  nt) (2.6)
Another method often used is the ’Holm step-down’ method for CMT, in which a
set of k obtained p-values fp1; p2; :::; pkg are sorted ascending and the lowest, i.e.
the strongest, p-value is multiplied with nt, the second lowest with nt   1 and so
on, yielding a vector Padj:
Padj = (min (1; pi  nt) ;min (1; pi+1  (nt   1)) ; :::;min (1; pm  1)) (2.7)
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A given p-value is subsequently considered significant, if padj is smaller than the
chosen level of significance α, i.e.
padj  α (2.8)
It should be noted that in both the ’Bonferroni single-step’ and the ’Holm
step-down’ method for CMT, the most significant/strongest p-value is multiplied
with the total number of tests nt. Therefore, when looking at the lowest p-value in
the case of the ’Holm step-down’ method and all p-values in the case of
’Bonferroni single-step’ method, we can adjust the α-value with the number of
tests nt rather than the p-value and eq. 2.8 becomes:
padj  α ) min (1; p  nt)  α ) p  αnt = αadj (2.9)
Themin() function is lifted, as 0 < α < 1; nt > 0) αadj < 1. Using eq. 2.9, we
can take a closer look at how CMT impacts the significance threshold for the
strongest obtained p-value in a multiple testing scenario.
2.4 CMT impact on significance threshold
We can evaluate the impact of the Bonferroni and Holmmethods on the
strongest p-value by looking at both the adjusted α value, αadj, and the
corresponding adjusted z-score threshold, zadj = z1 α=nt (see eq. 2.9). Here the
function z(αadj) refers to the normal distributionN (μ = 0; σ2 = 1). In order to
quantify the CMT impact, we define a vector n, from which αadj(n) and
subsequently z(αadj(n)) follow:
n = [1; 2; ::; 100]) (2.10)
αadj(n) = [0:05; 0:025; :::; 0:0005]) (2.11)
z(αadj(n)) = [1:96; 2:24; :::; 3:48] (2.12)
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Figure 2.4.1: Bonferroni corrected jzj and p thresholds as a function of the number of tests
performed nt. A: padj(nt). B: jzadj(nt)j.
We can now depict the functions αadj(n) and z(αadj(n)) (See fig. 2.4.1). From
this, it is evident that CMT strongly impact the signficance threshold and
especially with the first approximately 20 tests, as fig. 2.4.1 clearly shows.
Calculating that:
αadj(1; 20; 100) = (0:05; 0:0025; 0:0005)
z(αadj(1; 20; 100)) = (1:96; 3:02; 3:48)
We can calculate that the first 20% of the tests constitute 70% of the total
increase in the z-score threshold, zadj and 96% of the total decrease in the p-value
threshold αadj.
SigniSite performs molecular-scale genotype-phenotype inference. In smaller
alignments, the conservative CMT, may quench the significance of a subtle
genotype-phenotype association. In more general terms, CMT increases the risk
of type II errors. However as we will discuss in the following the number of tests,
which controls the ’harshness’ of the CMT, can be reduced.
37
2.5 CMTof inhomogeneous systems
The purpose of applying CMT, is to reduce the risk of type I errors, by increasing
the significance threshold. However a consequence of increasing the significance
threshold is that the risk of type II errors is increased. The threshold adjustment
is a trade-oﬀ between type I and type II errors.
Both the ’Bonferroni single-step’ and the ’Holm step-down’ method for CMT,
assumes that the system being tested is homogenous with respect to the
information content of each test. However this is far from always the case. The
problem can be illustrated using the following ’flip-a-coin’ example: We wish to
test 40 coins aiming at identifying any unfair coins. Our null-hypothesis is that
the coin is fair, i.e. 50/50 chance of heads/tail. The first coin is flipped 20 times,
producing 16 heads, under the null-hypothesis the probability of this is
p = 0:0046, the second is flipped 20 times, producing 15 heads, corresponding
to p = 0:015. However the remaining 38 coins are only flipped twice.
Nevertheless the number of tests is 40, yielding CMT p-values of p = 0:18 and
p = 0:59 respectively. Had we been able to identify the 38 tests with only 2 coin
flips as superfluous, the CMT p-valueswould instead have been p = 0:0092 and
p = 0:030 respectively.
The ’flip-a-coin’ system is inhomogeneous in that we have much more
information from the first two coin flips than the following 38. Adjusting for
multiple testing, the first coins cannot be significantly identified. When
considering the uneven distribution of information in the system, it intuitively
seems too harsh to adjust the trial of the first coins this way. If we can somehow
identify which test should be performed and which should not before
performing the actual testing, we would, in this case, be able to identify the first
two coins as being unfair, which seems intuitively likely.
The inhomogeneous system content in the ’flip-a-coin’ example is analogous to
aMSA. In aMSA the amino acid distributions will diﬀer between positions, i.e.
both the number of unique residues at a position and the frequency of these will
diﬀer. From this it is therefore obvious that a MSA constitute an inhomogeneous
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system and that some positions will have a higher information content than
others.
2.6 EstimatingMSA positional information content
One approach for reducing the number of tests, could be filtering based on the
positional information content prior to performing the statistical evaluation.
Thus as previously mentioned, aiming to reduce the number of tests performed
and thereby allowing identification of more subtle associations. The assumption
was that highly conservedMSA positions were less likely to be impacting the
observable phenotype.
The proposed approach was to calculate the positional information content
and then choosing a conservation cut-oﬀ for whether or not to include theMSA
position in the set of test. This is the approach, which was utilised in the analysis
of the VAR2CSA-dbl5ε sequence analysis [61].
Traditionally the positional information content, for a given position pi in a
MSA is evaluated using the following 3 measures [99]: i. the Shannon entropy
[137] Η(pi), ii. the Kullback-Leibler divergence [88]D(pijjq) and iii. the
Shannon information content I:
Η(pi) =  
X
a
palog2(pa) (2.13)
D(pijjq) =
X
a
palog2

pa
qa

(2.14)
I(pi) = log2(20) +
X
a
palog2(pa) (2.15)
Where a denotes all unique amino acid residues present at pi, pa is the frequency
of residue type a at pi and qa is the global background frequency for residue type
a. If a given pi is completely conserved, i.e. only one type of residue is present,
then Η(pi) = 0. By convention 0 < Η(pi)  1 is considered ’highly conserved’
[57], 1 < Η(pi)  2 is conserved and 2 < Η(pi)  4:3 is variable. It should be
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noted that since I(pi) = log2(20) Η(pi), the inversed cut-oﬀs are applicable for
I(pi). However choosing to omit position based on a ’highly conserved’ cut-oﬀ
posed a problem in that the maximum obtainable SigniSite z-score for an amino
acid residue aa at position pi in a MSA ofN sequences occurs, when naa = N2
(will be shown later). E.g. given a position pi, with 2 unique residues, for which
the frequency faa1 = faa2 = 0:5 then the Shannon entropy would be:
Η(p) =  
X
a
palog2(pa) =  2
 1
2
log2
 1
2

= 1 (2.16)
If we then chose to omit ’highly conserved positions’, i.e. by convention,
positions for which 0 < Η(pi)  1, we would omit position harbouring the
potential of obtaining the maximum possible SigniSite z-score. It was therefore
concluded that given the SigniSite framework, neither Η(pi) nor I(p) provided a
good measure for pre-test filtering based on the positional degree of
conservation. With respect toD(pjjq), thenD(pjjq) is equal to I(p), when
q = 120 for all types of residues. The approach of positional exclusion based on
conventional evaluation of information content was therefore abandoned and we
instead turned to investigate if we could find an intrinsic property of the SigniSite
framework, which could provide us with a measure for determining whether or
not to include a given residue in the set of tests to be performed.
2.7 Analysis of SigniSite framework
First let us start with evaluating the maximum obtainable z-score. Themaximum
obtainable z-scoremust occur, when the distance δ between the expected mean
rank μexp and the observed mean rank xobs reaches its maximum δmax: For a given
number naa of a given amino acid residue aa at pi, δmax occurs if the occupied
ranks of aa are raa;pi = f1; 2; :::; naag, i.e. all the residues of type a are top-ranked
(or bottom-ranked), fig. 2.7.1 illustrates this situation.
Themaximum obtainable mean rank can then be calculated similarly to the
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xmax 
μexp 
δmax 
naa 
N 
pi 
Figure 2.7.1: Graphical representation of δmax. xmax is the maximum observable mean rank,
μexp is the expected mean rank, N is the number of sequences in the MSA, naa is the number
of a given unique amino acid residue at a given position pi in a MSA. xmax occurs when all the
residues of a given type are ’top-ranked’ (or bottom ranked).
calculation of μexp, i.e.:
xmax(naa) =
naa + 1
2
(2.17)
Since the SigniSite z-score quantifies the distance from the expected rank, μexp, to
the observed rank, xobs, then the maximum obtainable z-scoremust occur, when
the distance between μexp and xobs is as large as possible and this is the case, when:
xobs = xmax =
naa + 1
2
(2.18)
Recalling that z = μexp xobsσ , we can derive an expression for zmax(naa;N), by
combining eqn. 2.17 and eqn. 2.3:
zmax =
μ   xmax
σ
=
N+1
2   naa+12q
(N naa)(N+1)
12naa
=
r
3naa(N  naa)
N+ 1
(2.19)
If we then chooseN = 100, we can plot zmax(naa;N = 100) recalling that
0 < naa < Nwe get the depiction in fig. 2.7.2. Looking at fig. 2.7.2 it becomes
clear that the maximum of the computed zmax(naa) values occurs, when naa = N2 .
This can be shown, by first diﬀerentiating eqn. 2.19 with respect to naa at
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Figure 2.7.2: zmax(naa) for N = 100. On the x-axis is 0 < naa < N and on the y-axis it
zmax(naa). The vertical red dotted line marks max (zmax(naa)). The horizontal black dotted
lines marks the adjusted z-score threshold zadj for nt = (1; 10; 100; 1000; 10000) ) zadj =
(1:96; 2:81; 3:48; 4:06; 4:56).
constantN:
z0max =
 r
3naa(N  naa)
N+ 1
!0
=
3(N  2naa)p
12naa(N  naa)(N+ 1)
(2.20)
Then the function optimum is found by solving the equation for naa, when
z0max = 0:
z0max = 0)
3(N  2naa)p
12naa(N  naa)(N+ 1)
= 0, n = N
2
(2.21)
So the optimal conditions for a given set of residues at a given position are when
all residues are top-ranked and naa is N2 .
Furthermore the depiction in fig. 2.7.2 show how whether or not a given
residue can obtain significance under optimal conditions is a function of that
particular residue and the number of tests performed, e.g. in a MSA where
N = 100 and naa = 1 or naa = 99 (fig. 2.7.2 clearly show the symmetry around
N
2 ), the maximum obtainable a-score is zmax = 1:71 (See eqn. 2.19). This means
that if the count of one unique residue is naa = 1 in a MSA of 100 sequences and
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that the level of significance of 95%) α = 0:05) z = 1:96, then this residue
can never obtain a significant p-value even if we do not perform CMT (See fig.
2.7.2, the lower horizontal dotted line). If we perform CMT at a 10; 000 tests,
then z = 1:96) zadj = 4:56 and the prerequisite for naa in order to obtain
significance under optimal conditions become 8 < naa < 92 (See fig. 2.7.2, the
upper horizontal dotted line). This means that performing a test in either of these
cases for the particular residue regardless of the observed rank is completely
superfluous. The observation, that a given residue never can obtain significance
even under optimal conditions spawned the idea that a residue count-threshold
based on the number of sequences and the number of tests could be used to
reduce the total number of tests being performed, by filtering these low-count
residues. The challenge was to identify the magnitude of the threshold.
2.8 Filtering on naa as a function ofN and nt
The idea of a residue count-threshold can be illustrated by choosing a threshold t,
as illustrated in eqn. 2.22:
0+ t < naa < N  t (2.22)
The challenge however is how to estimate the value of the parameter t. In any
given alignment withm positions, we know the number of sequencesN and the
total number of tests can be calculated (regardless of associated values) as the
sum of the number of unique amino acid residues nuniqueaa at each position pi,
skipping completely conserved positions, i.e. when naa = N:
mX
i=1
nuniqueaa;pi j
 
nuniqueaa;pi 6= N

(2.23)
Knowing the number of tests, we can calculate the adjusted z-score threshold.
Given the corrected threshold, we can calculate the minimum (and maximum)
number of residues required to obtain a z-score larger than or equal to the
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adjusted threshold. This is done by solving letting zmax = zadj and n = nthres and
then solving for nthres eq. 2.19 for n:
zmax =
r
3n(N  n)
N+ 1
)
zadj =
r
3nthres(N  nthres)
N+ 1
)
0 =  3n2thres + 3Nnthres   z2adj(N+ 1)
Solving this by aid of a computer algebra system (CAS) tool yields:
nthres(N; zadj)lower =
1
2
N  1
6
q
( 12Nz2adj + 9N2   12z2adj) (2.24)
nthres(N; zadj)upper =
1
2
N+ 1
6
q
( 12Nz2adj + 9N2   12z2adj) (2.25)
Where ’lower’ and ’upper’ denote the minimum and maximum boundaries for
whether or not a given residue should be included. It should be noted that as
expected nthres(N; zadj)upper = N  nthres(N; zadj)lower, which corresponds with
the symmetry we observed in fig. 2.7.2. This way we can make an evaluation of
the minimum and maximum number a given residue must have to be included in
the final statistical analysis, based on the number of sequencesN in theMSA and
the number of tests nt, by combining eqn. 2.22 with the solution:
t < naa < N  t
Where:
t = 1
2
N  1
6
q
( 12Nz2adj + 9N2   12z2adj) (2.26)
Figure 2.8.1 illustrates eqn. 2.8, for an alignment ofN = 20 sequences and where
the number of tests is nt = 20 for fig. 2.8.1A and nt = 300 for fig. 2.8.1B:
44
Al l
l l l l l
l l l l l l l l l l l l l
0 5 10 15 20
0
5
10
15
20
Number of tests
Th
e 
nu
m
be
r o
f a
 g
ive
n
 r
e
si
du
e
l l
l l l l l
l l l l l l l l l l l l l
B
0 50 100 150 200 250 300 350
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Number of tests
Th
e 
fre
qu
en
cy
 o
f a
 g
ive
n
 r
e
si
du
e
Figure 2.8.1: Depiction of the lower and upper count boundaries for inclusion of a given amino
acid residue aa in the set of tests, as given by eqn. 2.8, when the number of sequences in the
MSA is N = 20. A: On the x-axis is nt = (1; 2; :::; 20). Each number of tests corresponds
to an adjusted z-score threshold, zadj(nt) = (1:96; 2:24; :::; 3:02), where the initial level of
signiﬁcance is 95%, whereby α = 0:05 and z1 α=2 = 1:96. On the y-axis is the lower and
upper boundaries of naa 2 N for inclusion in set of tests, e.g. if 10 tests are performed any
residues aa at pi for which 3 < naa < 17 will be included in the set of tests to be performed.
The red line represent the optimal naa, i.e. naa = N2 . B: Like A, except nt = (1; 2; :::; 350)
and the values on y-axis are given as frequencies f 2 R. Here the red line marks fopt = 0:5.
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2.9 Filtering on naa as a function ofN
When conducting clinical trials, where e.g. the eﬀect of a particular drug is to be
investigated, a common challenge is howmany subjects to enrol in the trial. If the
sample size is too small, it may not be possible to identify a given drug eﬀect as
significant, even though there truly is an eﬀect. It is therefore important to
estimate the necessary sample size in order to identify a ’meaningful diﬀerence’
between two groups. One might be in a situation, where it will be simply be too
costly to involve the required number of people. Of course it is more convenient
to come to this conclusion, before beginning the trial.
In this context, it is important to note that when computing p-values by
comparing two samples assumed normally distributed, any (!) diﬀerence, no
matter how small, can be identified as significant, given enough data - Hence the
before mentioned ’meaningful diﬀerence’.
Given two samples, where we assume that there is truly a diﬀerence between
the two samples, then the power of the test relates to the likelihood of identifying
that diﬀerence. If the sample size is too small, then the test cannot identify the
diﬀerence no matter how significant it may be. From this we can estimate how
large a sample is needed if we wish to be able to identify a ’meaningful diﬀerence’
between two samples of interest. This can be extrapolated to the analysis
performed by SigniSite, in that given a position, where ’too few’ resides are
present, we can estimate if the sample size is large enough for us to find a
significant diﬀerence. If this is not the case, then the test is superfluous. In order
to estimate the necessary sample size, we introduce the concept of ’power of a
statistical test’. Recall that within the SigniSite framework, the null-hypothesisH0
is:
H0 : xobs = μexp (2.27)
and the alternative hypothesisH1 is:
H1 : xobs 6= μexp (2.28)
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We do not know beforehand whether xobs < μexp or xobs > μexp, therefore we
clearly need a two-sided hypothesis test. The test will be conducted at a level of
significance of α. This means thatH0 cannot be rejected if:
μ + σ  zα=2  xobs  μ + σ  z1 α=2 (2.29)
Note that if α = 0:05, then zα=2 =  1:96 and z1 α=2 = 1:96. For any other value
of xobs,H0 will be rejected. Let us say, that the alternative hypothesisH1 is in fact
true, then it would be convenient to have some idea as to what we would like the
probability of rejectingH0 to be. This probability of rejectingH0, given thatH1 is
actually true is the power of the test. The power of the test is denoted 1  β and
typically a power of 80% is chosen, for which β = 0:20. For the sake of
maintaining overview of α and β values in relation to hypothesis testing, table
2.9.1 summarises, what has been described so far.
Actual Pred. Category Error type Probability Value
1 1 True positive - P(R(H0)jH0 = F) = 1  β
1 0 False negative Type II P(A(H0)jH0 = F) = β
0 1 False Positive Type I P(R(H0)jH0 = T) = α
0 0 True Negative - P(A(H0)jH0 = T) = 1  α
Table 2.9.1: Overview of α and β values in relation to hypothesis testing. α is the probability of
a type I error and referred to as the level of signiﬁcance. β is the probability of a type II error.
The power of a test is deﬁned as 1   β. Common values are α = 0:05 and β = 0:20. The
probability syntax is P(decisionjactual), where R is ’reject’, A is ’not-reject’, T is ’true’ and F
is ’false’. Adapted from [127].
Choosing sample size relates to the power of test, in that we wish to estimate
the sample size needed to be able to detect a significant diﬀerence with a
probability of 1  β. Fig. 2.9.1 illustrates the situation for xobs = xmax < μexp.
Here,H0 cannot be rejected if:
μ +
σ  zα=2p
n
 xobs  σ  z1 α=2pn (2.30)
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Figure 2.9.1: Plot of distributions of expected and observed rank. xmax is the maximum ob-
tainable of the observed mean rank, m 2]0; 1] determines the fraction of δmax, which is not to
be overlooked, i.e. the ’meaningful diﬀerence’ to be identiﬁed, μexp is the expected mean rank,
δmax = jμexp   xmaxj is the maximum possible diﬀerence between the observed and ex-
pected mean rank, zα=2 and z1 α=2 are the critical values for a two-sided level of signiﬁcance,
the dark grey shaded areas are α=2, z1 β is the critical value for the power of the test and the
light grey shaded area is 1  β. Adapted from [127]
And as before,H0 will be rejected for any other value of xobs. Note that the
standard error SE is σ=
p
n. The SE is used here since we are sampling multiple
times, each time calculating the mean, the standard deviation SD of these
calculated means is the SE. The ’location’ of this critical value determining
whether to reject or not rejectH0, is controlled by the level of significance α, the
power of the test however relates to the area under the distribution of the
alternative hypothesis,H1, to the left of μexp + zα=2σ=
p
n and it is this area we
want to control by choosing a certain power, e.g. 80% or 90%. So the challenge
is, choosing a value ofm 2]0; 1], such that the distancemδmax is of a ’meaningful
magnitude’, how to ensure that the area 1  β is exactly e.g. 80% at a given level of
significance? The ’distance’ between the two distributions in fig. 2.9.1 can be
controlled by changing the number of elements n in each distribution. The
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reason for this is that the variance of each of the distributions is given by σ2n . As n
increases, the variance will decrease and the distributions will drift apart.
Therefore:
μexp + zα=2σ=
p
n = xmax + z1 βσ=
p
n,
μexp   xmax = z1 βσ=
p
n  zα=2σ=
p
n,
mδmax =
σp
n
(z1 β   zα=2),
p
n =
σ(z1 β   zα=2)
mδmax
Squaring both sides of the equation and recalling that zα=2 = z1 α=2, yields:
n =
σ2(z1 β + z1 α=2)2
m2δ2max
(2.31)
However this assumes that the number of elements in each distribution is the
same. When SigniSite analysis is performed, this is only the case, when naa = N2 .
Due to the before mentioned symmetry, it does not make a diﬀerence whether
we look at naa > N  n or naa < N  n (see fig. 2.7.1). In the following we will
let n1 = naa be the smaller sample size and n2 = N  n the larger. This
discrepancy in sample sizes can be corrected by introducing a ratio k, such that
k = n2n1 , where n1 < n2 , n < N  n, n < N2 , we get:
k = n2
n1
=
N  n
n
(2.32)
If we assume that the variances are similar, except for the ratio k, we can calculate
the estimated variance for both, by letting σ1 = σ2 and calculating the sum:
σ21 +
σ22
k
= σ2 + σ
2
k
=
kσ2
k
+
σ2
k
=
σ2(k+ 1)
k
=
k+ 1
k
 σ2 (2.33)
The calculated corrections for diﬀerence in elements, can be combined with eqn.
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2.31, whereby:
n = k+ 1
k
 σ
2  z2
m2δ2max
(2.34)
Where z = z1 β + z1 α=2 (equivalent with eqn. 8.27 in [127]). Knowing that:
σ =
r
(N  n)(N+ 1)
12n
(2.35)
and:
δmax = jμexp   xmaxj =
N+ 12   n+ 12
 = N  n2 (2.36)
We can solve eqn. 2.34 for n, yielding 4 solutions:
1
2
N
r
1
4
N2  z
3m
p
3N2 + 3N (2.37)
However given constraints 0 < n < N, where n;N 2 N, 2 solutions can be
excluded and we get:
nlower =
1
2
N 
r
1
4
N2   z
3m
p
3N2 + 3N (2.38)
nupper =
1
2
N+
r
1
4
N2   z
3m
p
3N2 + 3N (2.39)
Thus if a given residue aa at a given position pi in an alignment ofN sequences to
be included in the set of tests, then nlower < naa < nupper. Once again as expected
the solutions are symmetrical, such that nupper = N  nlower, in other words
t < naa < N  t, where t = nlower. z = z1 β + z1 α=2, where standard values are
z = 0:84+ 1:96 = 2:8. Recall thatm 2]0; 1] is the fraction of the distance
between the expected mean rank and the maximum obtainable, which is not to
be overlooked, i.e. δtarget = mδmax. Example: Given an alignment ofN = 50
sequences, a level of significance of 95%, a power of 80% andm = 0:5, the
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Figure 2.9.2: Power based residue count ﬁltering. Depiction of the solutions given in eqn. 2.38
and eqn. 2.39. On the x-axis is m 2]0; 1] in steps of 0:05. On the y-axis is nmin and nmax.
N = 50, level of signiﬁcance is 95% ) z1 α=2 = 1:96 and power is 80% ) z1 β = 0:84.
residue count cut-oﬀ t is calculated as:
t = 1
2
N 
r
1
4
N2   z
3m
p
3N2 + 3N
=
1
2
50 
r
1
4
502   2:8
3  0:5
p
3  502 + 3  50
= 3:5
Since n 2 N, this corresponds to nlower = 4 and nupper = 46. Fig. 2.9.2 depicts
this calculation for diﬀerent values ofm. Fig. 2.9.2 illustrates how a larger number
of residues naa is needed if one wishes to be 80% of detecting a gradually smaller
diﬀerence between xobs and μexp, compared to xmax (m = 1:0).
2.10 Filtering on a desired number of tests
An alternative approach could be to filter on a desired number of tests, rather
than the number of a given residue. One might set an upper limit of 100 tests,
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which are to be performed and then start with the residues with the best
prerequisites, i.e. the ones which are at the theoretical optimal conditions, i.e.
naa = N2 . Once the number of these residues have been computed, the next step
is to include the residues with the second best theoretical optimal conditions, i.e.
naa = N2   1 and naa = N2 + 1. This way more and more residues can be included
based on their count distance to theoretical optimal conditions:
N
2
  t  naa  N2 + t (2.40)
Where t 2 N is expanded in a step interval around N2 , thus including more and
more residues until a certain number of tests are reached. This way one would be
able to choose only to perform the before mentioned 100 tests and the step t
where the number of tests exceed the limit for the first time can be calculated.
Note that this does not mean that they will obtain a high z-score, the residues
could easily be uniformly distributed over the entire pi, it just means that, given
their count, they have the potential to obtain a high z-score.
2.11 Summary
By analysing the SigniSite framework, we propose the following 3 methods for
reducing the total number of tests performed. Filtering on positional residue
count naa based on:
1. N and zadj(α; nt)
t < naa < N  t; t = 12N 
q
1
4N2   13

zadj(α; nt)
2
(N+ 1)
2. N and power (z1 β + z1 α=2)
t < naa < N  t; t = 12N 
q
1
4N2   13m

z1 β + z1 α=2
p
3N(N+ 1)
3. nt
N
2   t  naa  N2 + t; 0  t 2 N  N2
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Figure 2.12.1: VAR2CSA-DBL5ε-infant birth weight sequence logo. 56 VAR2CSA-DBL5ε se-
quences sorted on infant birth weight was submitted to SigniSite with default settings, except
for no correction for multiple testing. The sequence logo quantiﬁes the strength of the residue
associations to the infant birth weight. Amino acid residues, for which y > 0 are associated
with a high infant birth weight and residues for which y < 0, with low infant birth weight.
Residues with a SigniSite z-score larger than zero and are predominantly found among the top
ranks of the sorted aligned VAR2CSA-DBL5ε sequences. The amino acids are colored accord-
ing to their chemical properties as follows: Acidic [DE]: red, Basic [HKR]: blue, Hydrophobic
[ACFILMPVW]: black and Neutral [GNQSTY]: green. [78]
2.12 Results
In order to apply the proposed methods for reducing the total number of tests
performed, when analysing inhomogeneous systems, we turned to a multiple
alignment ofN = 56 sequences from the analysis of VAR2CSA-DBL5ε [61]. The
phenotype of this particular alignment is the recorded birthweight of the infant.
Submitting to SigniSitewith default settings (α = 0:05, CMT using ’Bonferroni
single-step’), no residues can be identified as significantly associated with the
dataset phenotype. Re-submitting with no CMT, produces the logo in fig. 2.12.1.
Themotif ’TFKNI’ at p275  279 was predicted in the analysis of
VAR2CSA-DBL5ε [61] and subsequently confirmed using the HDPMa
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technique (VAR2CSA 3D7, Sector 2, ɵɵɹɶ-GMDEFKNTFKNIKE-ɵɵɺɹ). This motif
will therefore be used as true positive in the following. Tables 2.12.1 and 2.12.2
summarises the residue count and computed z-scores for the ’TFKNI’-motif. So
pi A N I K F T V -
275 0 0 0 0 0 13 43 0
276 0 0 0 0 26 0 0 30
277 0 13 0 13 0 0 0 30
278 0 26 0 0 0 0 0 30
279 13 0 13 0 0 0 0 30
Table 2.12.1: VAR2CSA-DBL5ε TFKNI-motif residue counts. pi refers to the position in
VAR2CSA. The header are one-letter codes for amino acid residues, where ’-’ denotes a gap.
pi A N I K F T V -
275 0 0 0 0 0 3.41 -3.41 0
276 0 0 0 0 3.21 0 0 -3.21
277 0 0.38 0 3.41 0 0 0 -3.21
278 0 3.21 0 0 0 0 0 -3.21
279 0.38 0 3.41 0 0 0 0 -3.21
Table 2.12.2: VAR2CSA-DBL5ε TFKNI SigniSite z-scores. pi refers to the position in
VAR2CSA. The header are one-letter codes for amino acid residues, where ’-’ denotes a gap.
the question is if any of the 3 proposed methods are able of reducing the number
of tests suﬃciently for us to identify the motif ’TFKNI’ as significantly associated
with the birth weight?
Calculating the sum of all unique amino acid resides at each position, we get
nt = 533 (zadj = 3:91), from this we subtract all the fully conserved positions and
we get nt = 347 (zadj = 3:80). If we then apply proposed method 1, we get
6  naa  50, further reducing the number of tests to nt = 252 (zadj = 3:72).
Proposed method 2 applied, at α = 0:05) z1 α=2 = 1:96,
β = 0:20) z1 β = 0:84 andm = 0:25 yields 8  naa  48, further reducing
the number of tests to nt = 227 (zadj = 3:69). Next we apply proposed method 3
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and choose to perform nt = 100 tests. This gives a total of nt = 101 tests
performed, when t=10, i.e. 18  naa  38 (zadj = 3:48). If we lastly apply
proposed method 3 and choose to perform 50 tests, we get nt = 52 tests
(zadj = 3:30) performed, when t=5, i.e. 23  naa  33. Table 2.12.3 summarises
these results:
Method nmin nmax nt zadj Δ(nt)[%] Δ(zadj)[%]
0 1 55 347 3.80 0 0
1 6 50 252 3.72 -27.4 -2.1
2 8 48 227 3.69 -34.6 -2.9
3a 18 38 101 3.48 -70.9 -8.4
3b 23 33 52 3.30 -85.0 -13.2
Table 2.12.3: Reduction of tests using 3 proposed methods. Prerequisites where applicable
are α = 0:05 ) z1 α=2 = 1:96, β = 0:20 ) z1 β = 0:84, ’Bonferroni single-step’
method for correcting for multiple testing, m = 0:25. m denotes the fraction of the distance
δmax = mjμexp   xmaxj, which we do not wish to overlook, with a power of 1  β.
If we compare table 2.12.3 with tables 2.12.1 and 2.12.2, we see that only when
using method ’3b’ are we able to lower the significance threshold, such that
zmax(’TFKNI’)> zadj, however this limits naa, such that only residues for which
23  naa  33 are included in the set of tested residues. This however excludes
’T-K-I’, leaving only ’-F-N-’ (see table 2.12.1).
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2.13 EvaluatingMSA size required for SigniSite analysis
We can calculate howmany sequences are required to obtain a significant result
under optimal conditions, i.e. N(z), by combining eqn. 2.21 and eqn. 2.19:
zmax =
r
3n(N  naa)
N+ 1
=
s
3N2 (N  N2 )
N+ 1
=
Nq
4
3 (N+ 1)
This gives us an expression for the maximum obtainable z-score as a function of n,
but since we are interested in evaluating the inverse, we solve the equation for z,
yielding:
0 =  N(z)2 + 4
3
z2N(z) + 4
3
z2 (2.41)
Using CAS tool to solve the equation yields:
N(z) = 2
3
z
 
z+
p
z2 + 3

(2.42)
Setting α = 0:05) z1 0:05=2 = 1:96 and rounding up to nearest integer yields
Nmin(1:96) = 6. So if only 1 test is performed or no correction is applied a
minimum of 6 sequences are required to obtain z > zadj. Table 2.13.1 gives a
short overview of the impact of performing n = (1; 100; 1000) tests. Second to
last column is the number of sequences required under optimal conditions, i.e.
rank = naa+12 andN =
N
2 , however biology rarely oﬀer optimal conditions for
mathematical systems. The last column therefore are the minimum number of
sequences, when the rank is twice the optimum and only half the number of
optimal residues are present, i.e. rank = 2  n+12 and naa = 12  N2 :
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n α zadj Noptmin Nmin
1 0.05 1.96 6 20
100 0.0005 3.48 18 54
1,000 0.00005 4.06 23 71
Table 2.13.1: Threshold impact of the number of tests.
2.14 Discussion
Here we have demonstrated how it is possible to reduce the total number of tests
performed in a system prior to analysis, based on intrinsic properties of the
SigniSite framework. So why is that despite reducing the number of tests with as
much as 85%, we are only barely able to identify two of the five residues in the
VAR2CSA TFKNImotif? Looking at fig. 2.4.1B it becomes evident that when
correcting the α-value with the number of tests, the resulting depiction of
(nt; zadj(nt)) plateaus relatively fast. The consequence of this is, that once the
number of tests are in a ’plateau’ range, it does not aﬀect the adjusted z-score
threshold if e.g. 100 tests can be excluded. It is simply a property of the
non-linearity of the CMT.
Also it is important to realise that sometimes, you may have something which
is a true positive, but due to lack of data and thereby lack of ability to suﬃciently
separate theH0 andH1 hypotheses, you are not able to identify the true positive
and it therefore remains a false negative. Basically given enough data, you can
’prove’ anything, given to little data, you can prove ’nothing’.
Excluding entire MSA positions from analysis using information content is
problematic in that, as previously shown, the strongest significance is when
f = 0:5. Using e.g. the Shannon Entropy and choosing a conservation cut-oﬀ of
conventionally 1 is thus diﬃcult in that given a position with 2 residues, f1 = 0:5
and f2 = 0:5, then the Shannon entropy will be 1 and if f1 = 0:49 and f2 = 0:51,
then the Shannon entropy would be less than 1. If the most variable positions are
sought, positions with a 50/50 distribution will be considered conserved and
thus left out. Furthermore filtering is applied per position for variability versus
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per residue for power calculation. Thus risking to exclude single residues based
on the composition of the rest of the residues at the position.
So all 3 methods will allow parameter adjustment. However to be statistically
correct, one should always decide on a set of parameters of choice, run the
analysis and accept the results, otherwise we will slowly but steadily be
embarking on the dangerous path of p-value hacking.
2.15 SigniSite analysis ofMHCI:peptide binding complex
2.15.1 Introduction
Given the benchmark in [78], where SigniSite clearly outperformed competing
state-of-the-art methods, we found it interesting to apply the method to an
in-house data set of 9-mer peptides with measured binding aﬃnities to a set of
MHC-I HLA-A and HLA-B alleles.
2.15.2 Materials
Tables 2.15.1 and 2.15.2 summarises the data set submitted to SigniSite analysis.
Number of HLA-A HLA-B
Measurements 76,716 52,256
Unique measurements 29,351 13,291
Unique peptides 16,998 11,094
Unique alleles 42 49
Table 2.15.1: Overview of MHCI:peptide data.
Combining the two HLA-A and HLA-B datasets, yielded a total of 128,972
datapoints. This is the dataset used in the well proven NetMHC-3.0 [100],
currently in version 3.4. Tables 2.15.1 and 2.15.2 illustrates that the data is biased
towards strong binders and also fairly tied, with respect to the values of the
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Description HLA-A HLA-B
Minimum 0.00 0.00
Maximum 1.00 1.00
Mean 0.26 0.20
Standard deviation 0.29 0.25
Median 0.08 0.08
Table 2.15.2: Overview of MHCI:peptide stats.
measurements. This is clear, when comparing the total number of measurements,
with the number of unique measurements.
2.15.3 Methods
As a proof of concept, we identified the number of diﬀerent peptides, with
measured binding aﬃnity to the sameHLA-A/B allele. Then we took the HLA-A
and HLA-B allele with most measurements, i.e. HLA-A0201 (9,120) and
HLA-B1501 (4,214). This way we could create two SigniSite compatible
alignments and compute the SigniSite position-specific scoring matrices (PSSM).
These could then be correlated with the last PSSM for the same alleles computed
by theMHCmotif viewer [119] using the non-parametric Spearman’s
Correlation Coeﬃcient. (non-parametric since in this context it is not interesting
whether the exact same values are assigned, but rather the decision on which
position and residues are the most important).
SigniSite compatible datasets were compiled, by identifying peptides, with
associated binding aﬃnity to multiple HLA-A and HLA-B alleles. MSAs was
then created, each containing the set of diﬀerentHLA-A and HLA-B α1 domain
sequences (p1   p180), which all had been measured to the same peptide. This
way the two largest MSAs contained 43 HLA-A/B sequences. In order to address
the previous mentioned problem of ties in the dataset, we only included the
MSAs which contained at leastNseqs=2 (rounding odd numbers down) unique
associated values. Lastly the minimum number of sequences in theMSAs was set
to 20. This way, the final data set consisted of 415MSAs, which were submitted
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to SigniSite analysis and the resulting PSSMs were stored.
In order to evaluate the predictive performance of SigniSite based on the
computed PSSMs, we defined specificity determining positions as thoseMHCI
α1 positions, which was found to be in contact with the 9-mer peptide within a
distance of 4 angstroms, based on a structural analysis of HLA structures available
in the PDB as defined in [100]. This yielded a list of 34 actual positives and 146
actual negatives. These 34 actual positives is referred to as the ’pseudo-sequence’ of
the MHCI α1. Per position we then transformed the SigniSite z-scores to
positional predictions, by computing the maximum of the absolute z-scores,
jzjmax(pi), and the sum of the absolute z-scores,
P
pi jzj. These measures were
then compared with the Shannon Entropy and the Kullback-Leibler Divergence.
Furthermore a meta analysis was performed aiming at identifyingMHC-I
positions, which were consistently identified as binding determinants. A data set
was constructed by selecting all HLA-A/BMSAs, containing at least 20
sequences and for eachMSA the number of unique associated values must be at
least half the number of sequences. This resulted in a total of 415MSAs. Foreach
of theseMSA, Η(p) and
P
pi jzjwas calculated and ranked, such that the result of
each calculation was a single column, where the highest values was assigned a
rank of 1. Each column was added to a matrix, such that the final matrix had a
dimension of 180 rows and 415 columns. Foreach row in this matrix, the mean of
the ranks was calculated and the resulting vector was once again ranked, assigned
rank 1 to the lowest value. This way we could not only assess the degree of
agreement between the Η(p) and
P
pi jzj scores, but also intersect the ranked
mean of ranks with the list of known contact positions.
2.15.4 Results
Correlating the SigniSite PSSMwith that of the MHCmotif viewer yielded
SCC(A*02:01) = 0.845 and SCC(B*15:01) = 0.804.
Fig. 2.15.1 show computed AUC values for the 415MSA containingN = 20
or more HLA-A/B sequences and at leastN=2 unique associated values. Target
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Figure 2.15.1: Graphical representation of the performance of SigniSite. Overview of AUC val-
ues. D(pjjq) is the Kullback-Leibler divergence, Η(p) is the Shannon Entropy and max(jzj)
is the positional absolute maximum SigniSite z-score and lastly sum(jzj) is the positional ab-
solute sum hereof. The AUC values were computed based on the 4 methods of scoring each of
the 180 positions in the MHC-I α1 domain against a list of 34 positional true positives and 146
true negatives deﬁned as residues being within a distance of 4 angstrom to the 9-mer peptide
in the binding groove [100].
positions were assigned based onMHCI residues potentially in contact with the
9-mer peptide in the binding groove within a distance of 4 angstrom, as defined
in [100]. SigniSite z-scoreswere transformed to positional scores by assigning
maximum absolute z-score (max(jzj)) and positional sum of absolute z-scores
(
P jzj). Figure 2.15.1 depicts the means and standard deviation for the
performance measured using the measure of Area under the Receiver operating
characteristic (ROC) curve (AUC) [111]. Values are:
D(pjjq) = 0:7148 0:0055, Η(p) = 0:8477 0:01,
max(jzj) = 0:8283 0:0179 and sum(jzj) = 0:8375 0:0165.
Table 2.15.3 summarises results for Welch Two Sample t-test of SigniSite
performance.
Fig. 2.15.2 depict the results of the meta-rank analysis. Details in figure legend.
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D(pjjq) Η(p) max(jzj) sum(jzj)
D(pjjq) <2.2e-16 <2.2e-16 <2.2e-16
Η(p) <2.2e-16 <2.2e-16
max(jzj) 4.232e-14
sum(jzj)
Table 2.15.3: Welch Two Sample t-test of SigniSite performance.
Both scoring methods were in agreement regarding the ranking of the positions,
with relation to impact onMHCI:peptide binding SCC = 0:996.
Fig. 2.15.3 mapsMHCI α1 positions 9, 45, 62, 66, 67, 70, 95, 97, 114, 116, 156
and 163, which are consistently top-ranked by SigniSite and the Shannon entropy,
mapped onto HLA-A*02:01, PDB-ID 1i4f [71].
Fig. 2.15.3 depict how the amino acid residues of the top-ranked positions
have side-chains facing the the binding groove.
2.15.5 Discussion
The transformed SigniSite scores outperforms Kullback-Leibler Divergence, but
not the Shannon Entropy. When comparing to simple Shannon entropy, it seems
we fall victims to Ockham’s razor. However SigniSite oﬀers positional residue
resolution, in fact SigniSite assigns z-scores to each unique residue at each position
and in order to be compared with the Shannon entropy, we must transform the
SigniSite z-scores. It can be argued, that we are comparing two methods, which
really are not comparable.
Computational analysis of binding interactions reveal that the sites denoted as
contact sites are distributed evenly across the meta-ranks. Fig. 2.15.3 show the
side-chains of the amino acid residues of the top-ranked positions have
side-chains facing the binding groove. By visual inspection of the HLA-A*02:01
structure it seems likely that the identified position does indeed constitute the
primary binding determinant. Based in this, it could be interesting to re-evaluate
which positions should define theMHC-I pseudo sequence. This could be done
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Figure 2.15.2: Meta-ranking of MHC-I α1 po-
sitions. On the axes are the meta-ranks com-
puted using x, the positional SigniSite
P jzj
and y, the positional Shannon Entropy. (Note
the axes have been reversed). The numbers
in the plot represent each of the 180 positions
of the MHC α1 domain. If a number is in red
font, it indicated that it is part of the pseudo-
sequence, i.e. the set of 34 residues known
to be in physical contact with the bound pep-
tide. Positions in black font, the position is not
part of the pseudo-sequence. From top plot
to bottom plot, each plot is zoomed in com-
pared to the prior. Top: The data-point in the
lower left corner represent the fully conserved
positions, where both the SigniSite z-score and
the Shannon Entropy have zero values. The
red dotted line seem to separate the positions
with a consistent high rank, from what could be
less impacting positions. Middle: Zooming fur-
ther in, it becomes evident that both positional
scoring methods assign low ranks to positions
in the pseudo-sequence. Bottom: Positions
9, 45, 62, 66, 67, 70, 95, 97, 114, 116, 156
and 163 are consistently top-ranked by both
methods.
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Figure 2.15.3: HLA-A*02:01 mapping of top meta-ranked α1 positions 9, 45, 62, 66, 67, 70,
95, 97, 114, 116, 156 and 163. Positions and one-letter coded amino acid residues relative to
HLA-A*02:01 are given beside the side-chains of the top-ranked positions.
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by redefining the pseudo-sequence according to the top-ranked positions and
then re-train the NetMHC-3.0 method to see if any diﬀerence in performance
can be obtained.
2.16 Paper I
The following paper was published in Nucleic Acids Research in July 2013. The
paper focuses on the use of the web server available at
http://www.cbs.dtu.dk/services/SigniSite/. For details on the SigniSitemethod,
please see the supplementary materials.
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ABSTRACT
Identifying which mutation(s) within a given
genotype is responsible for an observable
phenotype is important in many aspects of
molecular biology. Here, we present SigniSite, an
online application for subgroup-free residue-level
genotype–phenotype correlation. In contrast to
similar methods, SigniSite does not require any
pre-definition of subgroups or binary classification.
Input is a set of protein sequences where each
sequence has an associated real number, quantify-
ing a given phenotype. SigniSite will then identify
which amino acid residues are significantly
associated with the data set phenotype. As output,
SigniSite displays a sequence logo, depicting the
strength of the phenotype association of each
residue and a heat-map identifying ‘hot’ or ‘cold’
regions. SigniSite was benchmarked against
SPEER, a state-of-the-art method for the prediction
of specificity determining positions (SDP) using a
set of human immunodeficiency virus protease-in-
hibitor genotype–phenotype data and correspond-
ing resistance mutation scores from the Stanford
University HIV Drug Resistance Database, and a
data set of protein families with experimentally
annotated SDPs. For both data sets, SigniSite was
found to outperform SPEER. SigniSite is available at:
http://www.cbs.dtu.dk/services/SigniSite/.
INTRODUCTION
Whether conducting research in vaccine design or trying
to elucidate the intimate details of a given receptor::ligand
interaction, genotype–phenotype correlation is a powerful
tool to enhance the understanding of the minute subtleties,
often characterizing research within the ﬁeld of molecular
biology.
The traditional approach for wet-laboratory analysis of
genotype–phenotype correlations involves site-directed
mutagenesis and subsequent quantiﬁcation of mutation-
impact on the phenotype, e.g. binding-afﬁnity or catalytic
efﬁciency. This approach of mutating all amino acid
residues in a given protein is a time consuming and
tedious task. Random mutagenesis has the advantage of
introducing a large number of random mutations
throughout the protein. One example of application of
random mutagenesis is to increase the signal from near-
infrared ﬂuorescent proteins (1). In such a panel of
sequenced variants with multiple mutations, it is a
complex task to systematically pinpoint the exact amino
acid residue(s), i.e. the genotype, associated with a given
phenotype (e.g. ﬂuorescence). Another area of application
is genotype–phenotype association studies in proteins,
which show inherent natural variability, as is the case
for instance for proteins involved in the pathogenesis of
malaria (2).
Here, we present SigniSite, an online application for
subgroup-free residue-level genotype–phenotype correl-
ation in protein multiple sequence alignments (MSAs). A
number of methods have been developed for the identiﬁ-
cation of functional sites in protein sequences (3–10), most
requiring a deﬁnition of functional subgroups before
analysis. However, if the phenotype associated with the
sequences is not categorical (e.g. substrate-speciﬁcity)
but continuous (e.g. catalytic efﬁciency), a pre-division
of sequences subgroups is none trivial. In contrast,
SigniSite does not require any subgroup division or
binary classiﬁcation. Instead, SigniSite directly analyses
the raw sequences and associated continuous values. The
main novelty of SigniSite is that unlike conventional
methods for the prediction of speciﬁcity determining
*To whom correspondence should be addressed. Tel: +45 45 25 61 27; Fax: +45 45 93 15 85; Email: jessen@cbs.dtu.dk
W286–W291 Nucleic Acids Research, 2013, Vol. 41, Web Server issue Published online 12 June 2013
doi:10.1093/nar/gkt497
 The Author(s) 2013. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial
re-use, please contact journals.permissions@oup.com
 at D
TU
 Library on January 23, 2014
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
positions (SDP), it not only predicts the positions in the
MSA determining a given protein function but also makes
a statistical evaluation of which types of amino acid
residue substitutions (genotype) are associated with the
observable phenotype at the SDP.
The web server implementation of the SigniSite method
described here is an automatized online application with
an easy-to-interpret graphical output. The application is
easy to use for the non-expert end-user and aims at aiding
researchers in the analysis of sequence data, where the
phenotype is quantiﬁed by a real number. A list of abbre-
viations is available in the Supplementary Data.
THE WEB SERVER
User interface
The SigniSite server is intended to provide the non-expert
user with a simple interface. At default settings, an amino
acid residue is considered signiﬁcantly associated with the
MSA phenotype, if the P-value for the speciﬁc residue is
smaller than or equal to  ¼ 0:05 after Bonferroni Single-
Step Correction for Multiple Testing (CMT) (11). On the
submission page, sequences can be submitted to the server
either as paste-in or via the ﬁle upload ﬁeld. On submis-
sion, SigniSite will check whether the submitted sequences
are aligned. If not, an MSA will be created using MAFFT
(12). SigniSite will exclude any characters other than the
one-letter representation of the 20 standard proteogenic
amino acids from the analysis.
Input
As input SigniSite takes an MSA in FASTA-format
(minimum two sequences). Each sequence must have an
associated real number, stated white-space-separated as
the last element in its FASTA header. At least two differ-
ent values must exist in the MSA. The MSA is assumed
pre-sorted, if the end-placed value is absent. A section
with options for customizing the analysis is available.
The following parameters are user-adjustable: (i) the
level of signiﬁcance ‘a’, 0    1 (default is 0.05). (ii)
The method for CMT: ‘Bonferroni Single-Step’ (default),
‘Holm Step-Down’ (11) or ‘no correction’. (iii) The sorting
of the sequences: ‘Decreasing’, highest sequence-
associated value is considered the strongest, e.g. ﬂuores-
cent protein signals, and vice versa for ‘Increasing’, e.g.
binding afﬁnity. Furthermore, the user can choose a ref-
erence sequence to assign sequence-speciﬁc positional
output numbering. This is useful, when the MSA
contains insertions. Finally, the user can modify the logo
output by choosing to include either ‘Signiﬁcant positions’
(default, displays all residues at positions where at least
one amino acid residue has been identiﬁed as signiﬁcantly
associated with the data set phenotype), ‘Signiﬁcant
Residues’ (as for signiﬁcant positions, but only including
signiﬁcant residues) or ‘Full Logo’ (all residues at all pos-
itions). At the results page, a button below the generated
logo allows the user to fully customize the logo using
Seq2Logo (13).
Output
The SigniSite output is intended to provide the end-user
with an easily interpretable graphical representation of the
statistical evaluations performed by SigniSite. An example
of a sequence logo (13) generated by SigniSite is shown in
Figure 1. The logo gives an overview of residue associ-
ations. See Figure 1 legend for further details. SigniSite
will also generate a heatmap (Figure 2). The heatmap is
intended to give a graphic overview of ‘hot’ and ‘cold’
regions in the MSA, with respect to the data set pheno-
type. See Figure 2 legend for details.
RESULTS
As an initial performance evaluation, we chose to analyse
18 human immunodeﬁciency virus type 1 (HIV-1) MSAs
compiled from the Stanford University HIV Drug
Resistance Database (15,16) (HIVdb) using Spearman’s
rank correlation (SCC) to correlate the obtained
SigniSite Z-scores (zp,a for each residue a at each
position p) with the table of resistance mutation scores
(RMS) also available from the HIVdb (see ‘Materials
and Methods’ section), i.e. SCC zp,a  RMS
 
. Results
are given in Table 1.
As the SCC evaluation is threshold dependent, a
threshold-independent performance evaluation was
added using the area under the receiver operator
Figure 1. Sequence logo. Example of sequence logo (13) output from
SigniSite from the analysis of the ATV Antivirogram multiple
sequence alignment (MSA), truncated to p1 – p35 for the purpose of
illustration (see ‘Materials and Methods’ section). The analysis was
performed with default settings. On the x-axis are the MSA positions
p and on the y-axis the Z-scores for each amino acid residue a (zp,a).
The height of each letter representing the residues is proportional to
zp,a, i.e. the strength of the statistical association between the residue
and the data set-phenotype. Residues above the Z=0 line have a
zp,a > 0, i.e. enhances the phenotype, whereas residues below the
Z=0 line have a zp,a < 0, i.e. inhibits the phenotype, e.g. the
presence of a certain residue with favourable chemical properties may
enhance binding (zp,a > 0), whereas a residue with unfavourable
properties may inhibit binding (zp,a < 0). Colour-coding: acidic [DE]:
red, basic [HKR]: blue, hydrophobic [ACFILMPVW]: black and
neutral [GNQSTY]: green (14).
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characteristics curve (AUC) measure, resulting in
AUC zp,a  RMSbin
  ¼ 0:791 0:010. Certain mutations
not included in the RMS were repeatedly identiﬁed by
SigniSite. As the majority of these mutations were
found in the binary resistance annotations from the
international antiviral society-USA (IAS) (17), we
enriched the RMSbin with the IAS and re-calculated
the AUC, obtaining a signiﬁcant performance increase
of AUC zp,a  ðRMS+IASÞmut
 ¼ 0:822 0.011(P=
5.16  104), two-tailed paired t-test).
Furthermore, we evaluated the performance of
SigniSite using performance measures: Matthew’s correl-
ation coefﬁcient (MCC), sensitivity (SENS) and speciﬁcity
(SPEC) against (RMS+IAS)mut. See Table 1 for results.
Having obtained good results for both the threshold-
dependent and -independent performance evaluations,
we turned to benchmark SigniSite against similar
existing methods. In a 2009 benchmark study (18),
SPEER (5,19) was identiﬁed as the state-of-the-art
method for prediction of speciﬁcity deﬁnition positions
(SDP). We, therefore, here compared the performances
of SigniSite and SPEER on each of their original bench-
marks data sets (see ‘Materials and Methods’ section)
against (RMS+IAS)pos. The results are shown in
Figure 3. The results show that SigniSite outperforms
SPEER on both data sets. The difference in predictive
performance was, however, only found to be statistically
signiﬁcant for the HIVdb data set.
DISCUSSION
SigniSite aims at providing a simple-to-use method
for subgroup-free residue-level genotype–phenotype cor-
relation in protein MSAs. SigniSite, thus, addresses a
long-existing challenge in molecular biology; genotype-
phenotype mapping. Genotype–phenotype mapping has
a wide range of purposes in molecular biology, e.g. struc-
tural regions responsible for immunity (2), identifying
protein-variants responsible for the severity of a disease
(20) or coupling receptor polymorphisms to surface
expression (21) etc.
Site-directed mutagenesis in proteins and subsequent
quantiﬁcation of mutation-impact on a given phenotype
is a time consuming and tedious task. High-throughput
methods such as e.g. random mutagenesis (1) have, there-
fore, been developed. However, the challenge of analysing
the increasingly larger volumes of data being generated
only becomes greater. Additionally, large genotype–
phenotype data sets (GPDs) can be compiled from
publicly available databases, such as the HIVdb (15,16).
SigniSite addresses this exact challenge.
Figure 2. SigniSite heatmap from the analysis of the
ATV Antivirogram multiple sequence alignment (MSA), truncated
to p1 – p35 for the purpose of illustration (see ‘Materials and
Methods’ section). The analysis was performed with default settings.
On the x-axis are the 20 proteogenic amino acids a and on the y-axis
the positions p in the analysed MSA. The colour coding of the ﬁelds is
such that ﬁelds reﬂecting zp,a  5 are blue, whereas zp,a  5 results in
a red ﬁeld. For 5 < zp,a < 5, nuances in between are used. If a residue
has a zp,a of 0, the cell is coloured grey. Absent residues are coloured
black. If only one grey cell is present at a given position, this implies
that the position is fully conserved, harbouring only this residue. If
more grey cells are present, their associated P-values have become
P ¼ 1) zp,a ¼ 0 after correction for multiple testing.
Table 1. Benchmark results
Measure jzj  0 jzj  1:96 jzj  1:96CMT
SCCa 0:451 0:015 0:506 0:016 0:542 0:020
MCCb 0:492 0:028 0:387 0:027 0:297 0:040
SENSb 0:915 0:015 0:598 0:056 0:386 0:055
SPECb 0:579 0:016 0:774 0:031 0:882 0:022
aCalculated against the RMS.
bCalculated against the (RMS+IAS)mut.
Measures are means±SE. CMT: corrected for multiple testing, SCC:
Spearman’s rank correlation, MCC: Matthews Correlation Coefﬁcient,
SENS: sensitivity, SPEC: speciﬁcity.
Figure 3. Measures are mean (AUC)±SE. Columns are: HIV
[SPEER/SIGNI], SPEER and SigniSite’s predictions on the HIVdb
data set. SDP [SPEER/SIGNI] SPEER and SigniSite’s predictions on
the SDP data set. P-values quantifying the signiﬁcance of the difference
in performance were obtained using a two-tailed paired t-test.
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SigniSite was benchmarked on publicly available GPDs
and RMS from the Stanford University HIV Drug
Resistance Database (HIVdb) (15,16). We observed that
for each of the 18 different benchmark data sets, SigniSite
consistently identiﬁed certain residues, not annotated in
the RMS table, as signiﬁcantly associated with anti-viral
drug resistance. We compared these identiﬁcations with
binary resistance annotations from the International
Antiviral Society-USA (IAS) (17) and found that the
majority were indeed annotated as resistance impacting.
This observation suggests that the RMS data are not
exhaustive, and that the obtained correlation should
rather be regarded as a lower bound of the true predictive
performance.
As the SDP method SPEER (5,19) was found to be
the state-of-the-art method in a 2009 benchmark study
(18), we chose to compare SigniSite to SPEER. We
observed that SigniSite signiﬁcantly outperformed
SPEER on the HIVdb data set (P ¼ 3:77  106) and
for the SDP data set (as deﬁned in the SPEER paper),
SigniSite likewise outperformed SPEER, approaching a
signiﬁcant difference (P ¼ 0:0678). Furthermore,
SigniSite was much faster, taking only a few minutes to
analyse the largest of the MSA (nseqs ¼ 1,374). SPEER
on the other hand requires to be compiled in a slower
version, when nseqs > 200, taking 2 h to complete the
analysis.
In conclusion, SigniSite provides two important novel
features: (i) SigniSite does not require any manual anno-
tation of the data before analysis, e.g. binder/non-binder
classiﬁcation, SigniSite requires only sequences and
associated values. (ii) Unlike conventional SDP prediction
methods like SPEER, SigniSite will not only identify pos-
itions impacting the phenotype but also pinpoint the exact
amino acid residue substitution(s) responsible for the
impact detected at the identiﬁed position. To the best of
our knowledge, this level of resolution has so far not been
available.
MATERIALS AND METHODS
Benchmark data sets
Summary, see Supplementary Data for details.
HIVdb resistance mutation scores
The table of RMS was downloaded from the
HIVdb (15,16), available at http://hivdb.stanford.
edu/DR/cgi-bin/rules_scores_hivdb.cgi?class=PI. The
table of RMS contains information about positions
known to harbour mutations (n=688) compared with
wild-type (WT) and their impact on resistance towards
eight different protease inhibitors (PIs). Positive
scores range is [3,60] (n=296) and indicates that the
mutation increases the resistance towards a given PI.
Negative score range is ½5,  10 (n=15) and indicates
a decreased resistance. Scores of 0 (n=377) indicate lack
of resistance impact. At each position annotated in the
table of RMS, the consensus residue was assigned an
RMS of 0.
IAS resistance annotations
Protease mutations known to impact PI resistance were
retrieved from the table ‘mutations in the protease gene
associated with resistance to protease inhibitors’, in the
International Antiviral Society USA (IAS)’s Update of
the Drug Resistance Mutations in HIV-1: March 2013
(17). Also here, the consensus residue at annotated resist-
ance positions was assigned an IAS score of 0.
Table transformations
The following table transformations were performed:
RMS! RMSbin, such that RMS > 0) RMSbin ¼ 1,
otherwise RMSbin ¼ 0: RMSbin+IAS! ðRMS+IASÞmut,
such that RMSbin > 0 or IAS > 0) ðRMS+IASÞmut ¼ 1,
otherwise ðRMS+IASÞmut ¼ 0: ðRMS+ IASÞpos, such that
for each position in (RMS+IAS)mut the resulting
ðRMS+IASÞpos ¼ 1 if at least one ðRMS+IASÞmut > 0,
otherwise ðRMS+IASÞpos ¼ 0. In all tables, any score
stable > 0 is considered an actual positive and any score
stable  0 is considered an actual negative (Table 2).
MSAs from the HIVdb protease GPDs
GPDs were downloaded from the Stanford University
HIV Drug Resistance Database (HIVdb) (15,16) Version
5.0, March, 2012, available at http://HIVdb.stanford.edu/
cgi-bin/GenoPhenoDS.cgi. MSAs were compiled from the
GPDs. Each MSA contains the sequences of a set of
HIV-1 protease variants with measured fold change in
resistance (compared with WT) towards the same PI,
measured using the same assay. Only PIs present in both
the table of RMS and the GPDs were used limiting the
analysis to 6 PIs: ATV, IDV, LPV, NFV, SQV and TPV
each of which was assayed using the three assays:
‘Antivirogram’ (VircoTM), ‘PhenoSense’ (ViroLogicTM)
and ‘All Others’. A total of 12 714 sequences were con-
structed and compiled into 18 MSAs. The length of each
of the protease variants is 99 amino acid residues.
The SPEER program and SDP benchmark data
SPEER, MSAs and corresponding experimentally
annotated speciﬁcity determining sites were downloaded
from the SPEER repository available at: ftp://ftp.ncbi.nih.
gov/pub/SPEER/ (5,19). We downloaded the latest
curated version of the data as described by Chakrabarti
and Panchenko (18).
The SigniSite method
The method takes a set of (protein) sequences as input.
If the sequences are not aligned, Signisite will use
MAFFT (12) to make an MSA from the input
sequences. Subsequently, the sequences are ranked with
respect to a real number associated with each sequence,
e.g. the replicative capacity or catalytic efﬁciency. For
each amino acid at each position in the MSA, a non-
parametric test is performed to test whether the
observed ranks deviate signiﬁcantly from the expected
ranks. CMT of the resulting P-values may be performed
using Bonferroni single-step or Holm step-down proced-
ures. The resulting Z-scores per residue are visualized in a
logo plot and a heatmap.
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Brief description of the method underlying SigniSite
(see Supplementary Data for details). Initially each
sequence is assigned a rank by sorting the sequence
associated values (either ascending or descending depend-
ing on type of value) and then assigning a rank of ‘1’ to the
ﬁrst sequence after sorting, ‘2’ to the second and so forth.
Each amino acid residue a observed at position p (resp,a) in
the MSA is then assigned the rank of the sequence to
which it belongs. This way each resp,a is associated with
a speciﬁc rank. At each position in the MSA, the mean
ranks of each residue type are then calculated and placed
in a rank matrix, where each row corresponds to a
position in the MSA and each column to one of the 20
standard proteogenic amino acids, sorted according to A,
R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y and V
(SigniSite will exclude any characters but these 20).
Subsequently, SigniSite evaluates for each position and
residue type the difference between the mean of the
observed and expected ranks. The mean of the expected
ranks is the mean of the ranks we would observe if the
residue type resp,a was randomly distributed over the
column p in the MSA. This difference between observed
and expected ranks is quantiﬁed by a Z-score assigned to
each residue type at each position, yielding a Z-score-
matrix. If a given position is fully conserved, z=0 is
assigned to the conserved residue. If a given residue type
is absent at a given position, z ¼ 0NA0 is assigned.
The non-parametric statistics, on which SigniSite is
based, are similar to that of Wilcoxon test statistics (22),
where the obtained evaluation scores can be approximated
by the standard normal distribution, thus allowing
Z-score conversion to P-values by standard method. As
one test is performed per residue type, per position,
SigniSite will by default apply Bonferroni single-step
(11) CMT to adjust the reported P-values.
Benchmarking
For each of the 18 MSAs compiled from the HIVdb GPDs
(see ‘Materials and Methods’ section), a set of predictions
were made (Z-scores) estimating the strength of the asso-
ciation of each residue type a at each position p (zp,a) to
the phenotype of the MSA. The obtained set of zp,a’s was
then correlated with the RMS using Spearman’s rank cor-
relation (SCC) at three signiﬁcance thresholds: including
residues for which: (i) P  1, (ii) P  0:05 and (iii)
P  0:05 after CMT. The SCC was recorded for each of
the 18 MSAs, and the mean and standard error (SE) of the
means were calculated.
For evaluating threshold-independent performance, the
AUC measure was applied. The AUC was calculated
against two sets of targets: RMSbin and the enriched set
of targets (RMS+IAS)mut. The mean AUC and SE were
calculated for each set of targets.
Finally, the sensitivity, speciﬁcity and MCC were
calculated at the same thresholds as the SCC against the
enriched set of targets (RMS+IAS)mut. The sensitivity,
speciﬁcity and MCC were recorded for each of the 18
MSAs, and the means and SEs were calculated.
Comparing SigniSite and SPEER
To compare the performance of SigniSite with that of
existing methods, we turned to a 2009 benchmark study
by Chakrabarti and Panchenko (18) comparing the pre-
dictive performance of ﬁve SDP prediction methods, on a
set of protein families with experimentally annotated
SDPs. As SPEER (5,19) in this benchmark was found to
be the best performing method, we here limit our analysis
to comparing SigniSite and SPEER by applying both
methods to their respective GPDs.
SPEER outputs positional predictions, whereas
SigniSite assigns a Z-score for each residue type at each
position. To cast the SigniSite Z-scores into one score per
positions, the maximum of the absolute Z-scores was
chosen.
SigniSite assigns a prediction value to all positions re-
gardless of residue composition, whereas SPEER by
default will skip any fully conserved and positions with
>20% gaps. To get prediction values for all positions,
we assign a value of ‘100’ to positions not predicted by
SPEER (this value is lower than any score predicted
by SPEER).
SPEER requires each sequence in an MSA to be
subgroup-annotated before analysis. To accommodate
this requirement, each HIV MSA was split into two sub-
groups, by sorting the sequences in the MSA descending
on their associated real values and then splitting the se-
quences into subgroup ‘1’ or ‘2’ on the median of the
sorted values.
To perform the rank analysis SigniSite requires that
each sequence in the MSA has an associated real
number. Of the 20 SDP MSAs, 13 contain only subgroups
‘1’ and ‘2’. We chose to use these 13 MSAs for the bench-
mark, using ‘1’ or ‘2’ as ‘SigniSite real number values’.
This way the following two comparisons were made:
SigniSite versus SPEER on the HIV protease data set
and SigniSite versus SPEER in the SDP data set. The
AUC measure was used to quantify the performance of
each method on each benchmark data set.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary description of the SigniSite Method,
Table 2. Overview of target table notation
Notation Format Level Annotating
RMSa Real num. Residue Fold-change in PI resistance
IASb Binary Residue PI ass. resistance mutations
RMSbin
c Binary Residue PI ass. resistance mutations
(RMS+IAS)mut
d Binary Residue PI ass. resistance mutations
(RMS+IAS)pos
e Binary Position Positions ass. with PI
resistance
aIt is used when calculating SCC, bit is used to look up mutations not
annotated in 1, but repeatedly identiﬁed by SigniSite, cit is used when
calculating AUC, dit is used for the enriched AUC calculation and
when calculating the MCC, SENS and SPEC, eit is used as positional
targets, when comparing the predictive performances of SigniSite and
SPEER.
‘num.’, ‘ass.’, ‘PI’ abbreviates ‘numbers’, ‘association’ and ‘protease
inhibitor’. In all tables, any score stable > 0 is considered an actual
positive and any score stable  0 is considered an actual negative.
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Supplementary descriptions of the benchmark data sets,
Supplementary section on the impact of chosen seed for
random number generation, Supplementary description of
the benchmarks strategy, Supplementary Tables of HIV-1
PIs and abbreviations.
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Part III
Paper II: Insight into Antigenic
Diversity of VAR2CSA-DBL5εDomain
fromMultiple Plasmodium falciparum
Placental Isolates
72
[On the future of the Bill & Melinda Gates Foundation]
”We are committed to the diseases that aﬀects the poorest,
malaria, tuberculosis, HIV, all the childhood conditions and
until we treat the health of that poor child as being as impor-
tant as the health of a rich child we will still have work to
do”
Bill Gates
3
Insight into Antigenic Diversity of
VAR2CSA-DBL5εDomain fromMultiple
Plasmodium falciparumPlacental Isolates
3.1 Introduction
Thework in this paper is based on the fact that immunity towards placental
malaria is gradually acquired as a function of parity. The aim of the sequence
analysis was to identify parity dependent sequence motifs. I.e. if a given sequence
motif is found exclusively in primigravidae women, this means that the motif
most likely is immunogenic and an antibody response has been raised against this
particular motif. The result of the raised antibody response, is that upon the
second pregnancy, infecting parasites expressing a VAR2CSA-DBL5ε variant
73
containing this particular motif is prevented from cyto-adherence and thus will
undergo splenal destruction, the result of which is that the sequence motif will be
found in multigravidae women. The extrapolation of the sequence motif
identification naturally is identifying vaccine candidates.
3.1.1 Materials
The data set consisted of 70 VAR2CSA-DBL5ε sequences. For each of these
sequences the following phenotypes had been recorded: Maternal age, peripheral
parasite conc. [/μl], placental parasite conc. [/μl], maternal blood type, the parity,
child gender, child birth weight [g], mean CSA and mean CSPG binding densities
[/mm2]. It should be noted that not all of the phenotypes had been recorded for
each sequence. SigniSitewas used for parity dependant phenotypic sequence
motif identification. Furthermore each of the numerical phenotypes were
analysed for parity dependancies.
3.1.2 Methods
Where pairwise complete observations existed, the numerical recorded
phenotypes, were correlated with parity and Pearson’s correlation coeﬃcient
(PCC) [? ] and Spearman’s correlation coeﬃcient (SCC) [? ] were recorded.
Furthermore, the data was split into two groups, such that group 1 contained all
phenotypic data from primigravidae women and group 2 all phenotypic data
frommultigravidae women. Upon this split, the phenotypic data in group 1 and
group 2 was compared using ’Welch Two Sample t-test’ [4] and ’Wilcoxon rank
sum test with continuity correction’ [4], the resulting p-valueswere recorded.
3.1.3 Results
Table 3.1.1 summarise results from the parity-correlation of phenotypic values.
Only maternal age is found to correlate with parity.
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Parity vs. Age Loadperi Loadplac Birth weight CSA CSPG
PCC 0.758 -0.389 -0.188 0.135 0.108 0.0802
SCC 0.671 -0.402 -0.248 0.218 0.118 0.0811
Table 3.1.1: VAR2CSA-dbl5ε phenotypic correlations.
Table 3.1.2 summarise the results of testing for phenotypic diﬀerences
between primigravidae and multigravidae women.
Par0 vs. Par>0 Age Loadperi Loadplac Birth weight CSA CSPG
t-test 0.000403 0.271 0.0781 0.0168 0.931 0.902
Rank-test 0.00275 0.252 0.0474 0.0592 0.679 0.566
Table 3.1.2: VAR2CSA-dbl5ε primi- vs. multigravidae phenotypic comparisons. p-values calcu-
lated using ’Welch Two Sample t-test’ and ’Wilcoxon rank sum test with continuity correction’
are stated. Signiﬁcant p-values at a level of signiﬁcance of α = 0:05 are highlighted in red.
3.1.4 Discussion
Significant phenotypic diﬀerences are identified between primigravidae and
multigravidae women, based on maternal age, parasite load in the placenta and
birth weight of the child. All of these findings are in line with the gradual
acquisition of immunity towards PM.The parasite load is reduced, with
increasing immunity and as a result hereof the fetus receives more nutrition and
is thus able to obtain a higher birth weight.
One major challenge in the analysis of this set of VAR2CSA-DBL5ε data, was
the lack of data. A total of 70 VAR2CSA-DBL5ε sequences lay the foundation for
the anaylsis, however as several isolates were lacking phenotypic annotation. The
actual number of sequences included in each part of the analysis was as low as 33.
The consequence of this naturally is that it is diﬃcult to make extrapolations and
conclusions based on a data set of this size.
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3.2 Paper II
The following paper was published in PLOSONE in October 2010 as a
collaboration between ’Département Santé. Institut de Recherche pour le
Développement (IRD). Faculté de pharmacie, Université Paris René Descartes -
Paris 5, Paris, France.’ and the Center for Biological Sequence Analysis (CBS),
Department of Systems Biology, Technical University of Denmark (DTU).The
IRD collected samples and obtained phenotypic profiles and CBS/DTU
subsequently performed the in silico sequence analysis.
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Abstract
Background: Protection against pregnancy associated malaria (PAM) is associated with high levels of anti-VAR2CSA
antibodies. This protection is obtained by the parity dependent acquisition of anti-VAR2CSA antibodies. Distinct parity-
associated molecular signatures have been identified in VAR2CSA domains. These two observations combined point to the
importance of identifying VAR2CSA sequence variation, which facilitate parasitic evasion or subversion of host immune
response. Highly conserved domains of VAR2CSA such as DBL5e are likely to contain conserved epitopes, and therefore do
constitute attractive targets for vaccine development.
Methodology/Principal Findings: VAR2CSA DBL5e-domain sequences obtained from cDNA of 40 placental isolates were
analysed by a combination of experimental and in silico methods. Competition ELISA assays on two DBL5e variants, using
plasma samples from women from two different areas and specific mice hyperimmune plasma, indicated that DBL5e possess
conserved and cross-reactive B cell epitopes. Peptide ELISA identified conserved areas that are recognised by naturally
acquired antibodies. Specific antibodies against these peptides labelled the native proteins on the surface of placental
parasites. Despite high DBL5e sequence homology among parasite isolates, sequence analyses identified motifs in DBL5e that
discriminate parasites according to donor’s parity. Moreover, recombinant proteins of two VAR2CSA DBL5e variants displayed
diverse recognition patterns by plasma from malaria-exposed women, and diverse proteoglycan binding abilities.
Conclusions/Significance: This study provides insights into conserved and exposed B cell epitopes in DBL5e that might be a
focus for cross reactivity. The importance of sequence variation in VAR2CSA as a critical challenge for vaccine development is
highlighted. VAR2CSA conformation seems to be essential to its functionality. Therefore, identification of sequence variation
sites in distinct locations within VAR2CSA, affecting antigenicity and/or binding properties, is critical to the effort of developing
an efficient VAR2CSA-based vaccine. Motifs associated with parasite segregation according to parity constitute one such site.
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Introduction
Women suffering from pregnancy-associated malaria (PAM)
develop antibodies that protect them and their offspring during
subsequent pregnancies [1]. Protection against PAM is rapidly
acquired as from the second pregnancy, and is associated with
increasing plasma levels of PAM-specific anti-Variant Surface
Antigen (VSA) antibodies. PAM parasites from distinct geographic
areas specifically bind Chondroitin-Sulfate A (CSA) [2,3,4], and the
immune response in pregnant women living in malaria endemic areas
is highly directed against var2csa encoded PfEMP1 (Plasmodium
falciparum erythrocyte membrane protein) protein [5,6,7]. Protective
antibodies in PAM immunity are thought to recognize a relatively
conserved antigen that mediates parasite binding to placental CSA, as
plasma and parasites from pregnant women of different malaria
endemic areas cross-react [5], [8]. Antibodies against VAR2CSA are
sex-specific and parity-dependent, and high levels of such antibodies
are associated with reduced consequences of PAM, making
VAR2CSA a promising target for vaccine development [6,7].
The VAR2CSA protein is a large antigenic molecule (350 kDa),
exposed to host antibodies on the surface of erythrocytes [9,10]. It
has been shown that disruption of var2csa results in the loss of CSA
adhesion ability of infected erythrocytes (IE) [11]. The VAR2CSA
protein is structurally composed of six Duffy Binding-Like (DBL)
domains. Several of these domains, including DBL5e, have, to
some extent, displayed affinity for CSA in vitro [12,13,14,15] [16].
Antibodies raised against CSA-binding VAR2CSA domains have
so far not been able to exhibit strong adhesion-inhibitory
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capabilities. However, antibodies raised against the recombinant
DBL5e domain amplified from a placental parasite, have been
shown to bind native VAR2CSA expressed on the surface of P.
falciparum IEs from placental isolates [16].
Var2csa is a polymorphic gene [17], and intra strain variability
represents a great challenge for vaccine development. In a previous
study, using genomic DNA from P. falciparum parasites from
Senegalese women, the DBL5e domain was found to be highly
conserved among parasite isolates [18]. Mapping on a structural
model revealed the localization of the DBL5e identified polymorphic
and some conserved regions in the exposed loops and helices [8,18].
Although most VAR2CSA DBL domains contain conserved and
polymorphic domain regions that can be targeted by surface reactive
antibodies [8], conserved regions are most prominent in DBL3X,
DBL4X and DBL5e. This may explain why antibodies raised against
DBL3X and DBL5e recombinant proteins exhibited most cross-
reactivity with heterologous parasites compared to antibodies raised
against the other domains [19]. Interestingly, these antibodies (raised
against a single variant of DBL3X or DBL5e) cross-reacted with
placental parasite isolates from Tanzania [20]. Moreover, human
monoclonal antibodies produced by immortalized B cells from
malaria-exposed pregnant women predominantly recognized DBL3X
and DBL5e [21], suggesting the natural acquisition of a specific
immune memory to these VAR2CSA domains.
Together, these observations highlight that DBL5e may
represent an interesting target for vaccine development. Under-
standing the molecular basis controlling the broad and/or
differential antibody recognition of this VAR2CSA domain may
help define essential structural features of a potential interest in
vaccine perspectives. The two main objectives of this study were:
(i) To analyse the consequence of sequence variation in the
VAR2CSA DBL5e domain using the transcripts from a large
panel of fresh placental parasite isolates and, (ii) to express and to
characterize selected VAR2CSA DBL5e variants from two
parasite isolates. Novel conserved linear epitopes which are
recognised by naturally acquired antibodies were found in the
conserved regions of the DBL5e domain and significant motifs
were identified in the variable regions.
Results
Identification of significant sites in VAR2CSA DBL5e
sequences
Figure 1 shows a multiple alignment of 70 VAR2CSA DBL5e
sequences (All sequence data are available at GenBank (http://
www.ncbi.nlm.nih.gov/Genbank) under the accession numbers
HM751723–HM751795) using cDNA from 40 placental parasites
isolated at delivery from 39 Senegalese women [2,15,22] and one
Figure 1. High conservation of DBL5e-VAR2CSA sequences. (A) Plot of DBL5e Shannon entropy (H): H= 0: Complete conservation, only one
residue present at the given position. 0,H#1: Considered highly conserved. 1,H#2: Considered conserved. 2,H#4.3 considered variable. (B)
Three-dimensional model of DBL5e showing the sequence variability. Heat-map colouring is dark blue (conserved) to red (variable).
doi:10.1371/journal.pone.0013105.g001
VAR2CSA-DBL5e Domain Analysis
PLoS ONE | www.plosone.org 2 October 2010 | Volume 5 | Issue 10 | e13105
Tanzanian woman [20]. The var2csa region corresponding to
DBL5e plus Id5 (the non-DBL Interdomain sequence located
between DBL5e and DBL6e) was cloned and sequenced. A total of
70 VAR2CSA DBL5e sequences were obtained from these 40
placental parasites. The multiple alignment of DBL5e sequences
using the calculated Shannon entropy values show that the
sequences consist of constant and variable blocks (Figure S1,
Figure 1A). Conservation of 85% was obtained with DBL5e and
80% when we considered DBL5e plus Id5. The variability
mapping on the DBL5e structural model revealed that conserved
and variable areas were located in loops and protruding helices
(Figure 1B). In a previous study, it was found that VAR2CSA
DBL3X sequence motifs can be linked to the parity of the infected
women [15]. In order to assess such sequence variation behaviour
in another highly immunogenic and conserved VAR2CSA
domain, all DBL5e sequences generated from cDNA of PAM
isolates were analysed using SigniSite [23]. Analysis revealed that
certain amino acids of VAR2CSA DBL5e+Id5 sequences appear
to be of particular interest. In the multiple alignment of all DBL5e
sequences, significantly distributed residues were identified at
positions 277, 279, 303 (Fig 2A and 2B). High CSPG (Chondroitin
Sulphate Proteoglycan) binding density is correlated with amino
Figure 2. VAR2CSA DBL5e patterns distribution. (A, B): Sequence logo showing the identified significantly distributed residues I, K and Q The
sequence logo displays the residues present at each position, where at least one residue was identified as being significantly distributed with respect
to associated numerical parameter. Each letter denotes a given residue and the height corresponds to increasing z-score. The residues are coloured
according to: Acidic [ED]: red, Basic [RKH]: blue, Neutral [GNQSTY] = green, Hydrophobic [ACFILMPVW] =black. Numbers below each column denotes
corresponding position in the multiple alignment. Letters positioned correctly are associated with high values and upside down letters with low. An
asterisk denotes a deletion. It should be noted that in the sequence logos other residues appears (*, E, K), these are however not identified as
significantly distributed (i.e. p.0.05). DBL5e models showing the position of the identified significant residues (red), T277, I279 (C) and Q303 (D).
doi:10.1371/journal.pone.0013105.g002
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acid Q303 (p = 0.017). Homology modelling of DBL5e-3d7
furthermore revealed that identified residues that were significant-
ly different among groups were surface-exposed (Figure 2C,
Figure 2D).
From visual inspection of the regions around the amino acid
residues found by SigniSite analysis in the multiple alignment of
DBL5e, distinct motifs were identified when comparing sequences
from primigravidae and multigravidae. Motifs VFNNA, gap,
TFKNI were identified in the area spanning amino acids 275 to
279 and EDTKQ, EYTGN and QYTGN were defined between
the amino acid 303 and 313 (this area is located at the end of DBL5e
and in Id5). These patterns have a differential distribution according
to parity. Indeed, gap, EDTKQ and EYTGN motifs were
predominantly found among samples from primigravidae
(p= 0.02, Fisher’s exact test) whereas TFKNI and QYTGN were
mainly or exclusively found in multigravidae (p= 0.013). These
patterns clearly discriminate parasites infecting multigravidae and
primigravidae women. At the level of sequence types obtained from
each sample, DBL5e sequences expressing gap, EDTKQ and
EYTGN signatures were found mostly in primigravidae (p= 0.036)
while those expressing TFKNI (p= 0.0019) and/or QYTGN
preferentially infect (p= 0.038) multigravidae (Table 1). Interest-
ingly the TFKNI motif was also associated with high maternal age
and low placental parasite density (data not shown). The VFNNA
motif was found in primigravidae as well as multigravidae without
significant bias in its distribution. From the mapping of TFKNI and
deletion motifs on the DBL5e structural model from multigravidae
CYK008 sequence and primigravidae CYK040 respectively, it can
be hypothesised that TFKNI insertion can cause a conformational
change of the domain structure (Figure 3).
Expression of distinct variants of recombinant VAR2CSA
DBL5e from placental parasites
Two VAR2CSA DBL5e variants (CYK39 and CYK49) were
produced in Rosetta gami DE3 strains. Both variants were chosen for
analysis as P. falciparum IEs corresponding to isolate CYK39 have
been described as high CSPG binders and parasites from CYK49 as
low binders [2]. The Rosetta gami bacteria strain allows the formation
of disulfide bonds that could favour production of biologically active
proteins. Protein production was induced with 0.1 and 1 mM
IPTG. The soluble protein produced was affinity-purified, subjected
to gel filtration, and the purity was checked by SDS-PAGE
(Figure 4A) and Western blotting. An average of 5 mg of pure
protein was obtained after the different purification steps. Western
blot analysis showed that total IgG purified from a plasma pool of
malaria exposed multigravidae labelled a single dominant band of
37 kDa in 1 mM IPTG induced bacterial extract and in purified
DBL5e (Figure 4B). The same product (37 kDa) was identified by
specific IgG generated in mice by DNA vaccination with DBL5e_
CYK39 (Figure 4C) and DBL5e_ CYK49 IgG (Figure 4D), as well as
with anti-histidine tag monoclonal antibodies (Figure 4E). Bands of
expected size were observed neither in the untransformed nor
uninduced bacterial extracts (Figure 4).
In vitro binding ability of placental parasite recombinant
DBL5e VAR2CSA variants to CSPG
The CSPG binding capacity of the two DBL5e variants was
estimated by ELISA. Both variants showed a relatively higher
binding ability to CSPG compared to NTS-DBL1a domain of
VARO (Figure 5A). This interaction was concentration-depen-
dent. In this model, the NTS-DBL1a domain of VARO also
produced in Rosetta gami displayed weak binding ability to CSPG.
To determine whether this interaction was CSPG-specific, we
tested the ability of soluble CSPG (decorin) or CSA (bovine
trachea CSA) to compete for protein binding on a CSPG pre-
coated plate. As shown in Figure 5B, soluble CSPG like soluble
CSA (data not shown) indeed competed for binding observed on
CSPG. Sequence comparison of both DBL5e variants expressed
showed that they were highly similar but contained 31 different
residues. Moreover, positively charged amino acids appeared to be
differentially expressed in both variants (Figure 5C). As position
303 seemed to be associated with binding density, the sequences
were analysed for mean CSA and CSPG binding densities and the
difference associated with the occurrence of the Q, E and K
residues. Indeed, high CSA or CSPG binding affinity was mainly
associated with residue Q303 (p = 0.005) whereas low CSA or
CSPG binding affinity was associated with E/K303 (Table 2).
Interestingly as shown in figure 5C, the equivalent residue for
CYK39 and CYK49 sequences was in fact Q296 and K296
respectively. The mapping of Q303 on structural model indicates
that this residue seems to be surface exposed, but located in the
bottom of what could be a binding pocket (Figure 2D).
Antibodies against DBL5e domain of VAR2CSA increase
in a parity-dependent manner
Recombinant DBL5e variants (CYK39 and CYK49) were used
to assess the plasma levels of anti-VAR2CSA IgG. Independent of
which variant was tested, antibodies with specificity for Rosetta gami-
produced DBL5e VAR2CSA were seen only in plasma from P.
falciparum-exposed pregnant women living either in Benin (Ben) or in
Table 1. Signatures in DBL5e domain of VAR2CSA expressed by placental parasites.
Category Parity VAR2CSA DBL5e motifs
VFNNA Gap TFKNI EDTKQ EYTGN QYTGN
Samples Primigravidae (n = 16) 6 12a 1 7a 6a 0
Multigravidae (n = 24) 7 9 11a 2 2 5
Sequences Primigravidae (n = 33) 11 20a 1 7a 8a 0
Multigravidae (n = 37) 11 14 12 2 2 5a
Gap, EDTKQ and EYTGN motifs are mainly found in samples from primigravidae compared to those from multigravidae (p = 0.02) whereas TFKNI and QYTGN are mostly
or exclusively found in multigravidae (p = 0.013). At the level of sequence types obtained from each sample, the EDTKQ, EYTGN and gap signatures are more frequent
among DBL5e sequences from primigravidae compared to those originating from multigravidae (p = 0.036). Similarly, the TFKNI and QYTGN motifs are mostly or
exclusively found in sequences from multigravidae (p = 0.0019 and p= 0.038 respectively).
ap,.05, Fisher’s exact test.
bp,.001, Fisher’s exact test.
doi:10.1371/journal.pone.0013105.t001
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Senegal (Sen) (Figure 6A). In contrast, plasma levels of antibodies
against the recombinant DBL5e were insignificant in both French
unexposed men (M) and pregnant women (Fra) (Figure 6A).
Detailed analysis of P. falciparum-exposed pregnant women indicated
that for each antigen tested, Senegal and Benin multigravidae (M)
had significantly higher levels of DBL5e antibodies than primigrav-
idae (P); (CYK39: both p,0.0001; CYK49: p= 0.019 for
Senegalese and p,0.0001 for Beninese; Figure 6B), however
contrary to Senegalese primigravidae, most Beninese primigravidae
presented with high DBL5e VAR2CSA antibody levels (Figure 6B).
A fine analysis of the plasma reactivity of the women demonstrates
that antibodies against DBL5e increased with parity (Figure 6C).
We compared plasma levels of VAR2CSA specific IgG using both
DBL5e recombinant proteins. Cut-off values were set to mean +
2SD (plus two standard deviations) of reading obtained with the
negative control plasma samples. The percentage of antibody
reactivity considered to be positive was 80% for DBL5e_CYK39
and 60% for DBL5e_CYK49. Despite a homology of 80%, there is
a significant difference of reactivity between both variants (Chi2 test
p= 0.005). A comparative study of the reactivity of each plasma
with respect to each of the variants shows that the response to both
variants was strongly correlated (Pearson’s test r = 0.8, p,.0001;
Figure 6D), confirming that the VAR2CSA DBL5e domain
contained conserved epitopes.
Evidence of conserved cross-reactive epitopes in DBL5e
VAR2CSA
Recombinant DBL5e variants were used in competition ELISAs
to demonstrate that DBL5e domain of VAR2CSA contains cross-
Figure 3. Mapping of VAR2CSA-DBL5e signatures. Based on the
identified region of interest and predominant motifs, two representa-
tive sequences were selected for homology modelling primigravidae
CYK040 (deletion) and multigravidae CYK008 (TFKNI). Blue is CYK040
primigravidae sequence, red is CYK008 multigravidae sequence and
dotted circle is deletion/TFKNI motif. The figure illustrates how the
conformation of the region depends on the presence or absence of the
TFKNI-motif. Using homology modelling, the motif is identified as being
surface exposed and may thus alter the immunogenicity of the region.
doi:10.1371/journal.pone.0013105.g003
Figure 4. Bacterial recombinant DBL5e domain of VAR2CSA expression. Lysates of untransformed (lane 1) bacteria, DBL5e_CYK49
[uninduced (lane 2), induced 1mM IPTG (lane 3), induced 0.1 mM IPTG (lane 4)], DBL5e_CYK49 (lane 5) and DBL5e_CYK39 (lane 6) after two
purification steps were subjected to SDS/PAGE and either stained with Coomassie blue (A) or immunoblotted with either purified IgG multigravidae
plasma (B), antisera from mice vaccinated with DBL5e_CYK39 (C), antisera from DBL5e_CYK49 vaccinated mice (D) or monoclonal anti-histidine
antibodies (E). 30 mg of bacteria-expressed-extract proteins and 2 mg of purified domains were used for analysis. Immune complexes were detected
with appropriate horseradish peroxidase coupled antibodies.
doi:10.1371/journal.pone.0013105.g004
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reactive epitopes. While one variant of the two expressed
VAR2CSA DBL5e was used for coating, the other one was used
as soluble competitor. The antibody reactivity of either a high-
titered VAR2CSA plasma pool from Beninese or Senegalese
women, or antisera to DBL5e_CYK39 and DBL5e_CYK49
generated in mice by DNA vaccination, or plasma pool from
unexposed French pregnant women was compared with or
without pre-incubation with increasing concentrations of the
competing VAR2CSA DBL5e variant. As negative control, all
plasma were incubated with VARO NTS-DBL1a domain.
Figure 7 shows that DBL5e from placental parasites contains
conserved epitopes. Indeed, whichever the DBL5e variant tested,
Figure 5. CSPG binding of the DBL5e domain of the VAR2CSA from parasite isolates. (A): Increasing concentrations of protein were added
to wells coated with 5 mg/ml of CSPG. CSPG-binding of the DBL5e_CYK39 (circle), DBL5e_CYK49 (triangle) and the non CSA-binding VARO NTS-DBL1a
domain used as control (square). Results are the means of three binding assays and the error bars indicate the standard deviation. (B) Inhibition assay.
Recombinant DBL5e variants (5 mg/ml) were pre-mixed with increasing amounts of soluble CSA 0.25–400 mg/ml, and binding to CSPG-coated plates
was determined. Results are the means of three inhibition binding assays and error bars indicate the standard deviation. (C): Sequence comparison of
VAR2CSA DBL5e domains from CYK39 and CYK49. Asterisks and circles indicate respectively Cystein residues and Lysine. Conserved amino acids are
shown in red and polymorphic residues in black. The 7 loops (L1–L7) identified according to Andersen P et al. [8] are underlined.
doi:10.1371/journal.pone.0013105.g005
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the competitor inhibited its antibody recognition in a concentra-
tion-dependant manner (Figure 7A). No significant competition
was seen with the negative VARO control protein (Figure 7B).
Due to the highly conserved nature of VAR2CSA DBL5e
sequence, it was decided to determine whether any of its conserved
regions was recognised by naturally acquired antibodies. We
synthesised a library of peptides using 3D7 DBL5e sequence. All
peptides were screened in ELISA for reactivity against a plasma
pool from Beninese or Senegalese women, French unexposed
pregnant women and men. Two peptides P4 and P13 located in
highly conserved regions of VAR2CSA displayed significant and
specific recognition by plasma of malaria exposed pregnant
women compared to control plasma from French unexposed
pregnant women and men (Kruskal-Wallis test, p,0.0001;
Figure 8A). Antibody reactivity of both peptides was higher in
multigravidae compared to primigravidae, though not significant
(Mann-Whitney U, p= 0.17).
Specific antibodies to VAR2CSA DBL5e conserved
peptides mark native VAR2CSA on the surface of infected
erythrocyte
Mapping of both peptides P4 and P13 on DBL5e structural
model indicated that both of them are surface-exposed (Figure 8B).
Furthermore, specific antibodies against both peptides were
affinity-purified from the Senegalese pregnant women plasma
pool and allowed to react with PAM parasites collected from
pregnant women from Benin. The pregnancy specific antibody
recognition of the isolates used was checked prior by FACS with
human plasma control pools (data not shown). The results
presented on Figure 8C show that the antibodies with specificity
to the selected peptides reacted with the native VAR2CSA
expressed by PAM parasites on the surface of IE.
Discussion
Pregnant women acquire protective antibodies that cross-react
with geographically diverse placental P. falciparum isolates,
suggesting that surface molecules expressed on infected erythro-
cytes (IE) by PAM parasites have conserved epitopes and, thus,
that a PAM vaccine may be possible to achieve. The search for
surface antigens of placental P. falciparum parasites is focused on the
PfEMP1 family. Most studies in recent years have shown that
VAR2CSA is the dominant PfEMP1 associated with parasite
binding to the placenta. Due to technological difficulties the exact
conformation of the entire VAR2CSA protein remains unknown.
Preliminary studies to understand its binding properties focused on
its DBLs domains and functional studies have shown that several
VAR2CSA DBLs including DBL5e can individually bind CSA
in vitro. This approach has become questionable as no efficient
anti-adhesion antibodies for IE have been obtained following
vaccination with a single domain. Recent studies have nevertheless
demonstrated that VAR2CSA DBL5e domain can induce
antibodies with a broad range of reactivity against placental
isolates [16,20] and therefore may represent a potential target for
PAM vaccine development. This study analysed sequence
variation in the DBL5e domain of the transcribed var2csa gene
from multiple placental parasite isolates. The aim was to evaluate
antigenic diversity and diversifying pressure within this attractive
VAR2CSA area. Using cDNA (complementary acid deoxyribo-
nucleic) from 40 placental parasite isolates from a previous study,
the region encoding DBL5e+Id5 of var2csa was amplified, cloned
and sequenced. Findings from our study population clearly
confirmed previous observations that the VAR2CSA DBL5e is
highly conserved [18]. Indeed, an average of 81% amino-acid
sequence identity was seen among DBL5e sequences as reported
by Guitard et al. on a different study population [18]. Variations
were mainly located in segments of variable length and mapping of
DBL5e regions to 3-D model revealed that variable areas are
located in the loops and protruding helices [8].
Two variable regions, one in the DBL5e and another one in the
Id5 sequences appeared to be of particular interest regarding the
bias in motif distribution among gravid women. Three significant
motifs (gap, VFNNA and TFKNI) were identified in the first
region spanning Aa from position 275 to 279. Despite the
relatively high variability of the Id5, another area with motif
segregation (EDTKQ, EYTGN and QYTGN) was found between
Aa 303 and 313. The major observation in these sites is the
significant difference between motif occurrence among parasites
from primigravidae and multigravidae. Certain motifs are
preferentially found in parasites from primigravidae (gap275–279,
E303D308T309K312Q313 and E303Y308T309G312N313), whereas
others are only found in parasites infecting multigravidae
(TFKNI275–279 and QYTGN303–313). Interestingly, most of the
parasites with QYTGN303–313 motif also had TFKNI275–279.
Those expressing either EDTKQ303–313 or EYTGN303–313 are
mostly associated with a gap275–279. Such selection pattern was
already seen in the DBL3X sequence and plausible explanations
can be given, based on several hypotheses: (i) either that parasites
infecting primigravidae are the most efficient mediators for
binding and therefore have a biological advantage in women with
limited immunity against PAM, (ii) or that the parasite variants
mostly found in primigravidae are the more common in the area
and therefore are more likely to infect exposed primigravidae
while multigravid women already have developed specific
antibodies during previous pregnancies. The tropism of certain
parasite variants for multigravid women suggest that some rarer
variants, probably not the most virulent can escape existing
immunity to common VAR2CSA variants. These findings have
important implications for understanding immunity to PAM in a
context where the development of a VAR2CSA-based vaccine is
gaining interest. Further analyses in this study also found a
significant difference at a site situated in the Id5 according to the
ability of IE to bind CSA or CSPG in vitro. Isolates with high
binding affinities associated with Q303 and low CSA/CSPG
binders associated with E/K303. This could indicate that
conservation of Q303 may have conformational importance for
maintaining high binding ability by the IE.
The results generated in the present study highlight the fact that
fundamental gaps remain in our knowledge and understanding of
placental parasites. Protection against PAM is consistent with
repeated exposure during pregnancy to previously unknown
antigens. Most of multigravidae infected by parasites with the
TFKNI or QYTGN motifs have a parity status above 3,
Table 2. VAR2CSA-DBL5e residues Q303, E303 and K303
distribution in relation to placental parasite CSA/CSPG
binding affinity.
Q303 E303 K303
Isolates
High binders (n =20) 10/20a 6/20 6/20
Low binders (n=16) 1/16 7/16 9/16
Those parasites ability to bind CSA or CSPG have previously been described [2].
ap,.01, t-test.
n corresponds to placental parasite isolates.
doi:10.1371/journal.pone.0013105.t002
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suggesting that despite the protection acquired during different
pregnancies, women can still be infected by new parasite variants
[18]. In the context of developing an optimal VAR2CSA-based
vaccine that can protect against placental malaria, it will be
particularly useful to overcome the challenges associated to
sequence variation in this interesting candidate. The relation
underlying the even limited variations described in this study
suggests that these can have critical implication in the functionality
of the whole molecule including its ability to subvert immunity.
Our results clearly indicate that the design of a protective vaccine
based on VAR2CSA should not be limited to a single variant. A
limited number of variants may be sufficient for broad coverage,
provided sites under significant variations are considered.
We have characterized two distinct variants of DBL5e from our
study population. The measure of plasma levels of the antibodies
against these two DBL5e variants showed that the two proteins
were broadly recognized by samples from two malaria endemic
regions with different P. falciparum transmission levels. Both
VAR2CSA DBL5e variants were recognized in a parity-
dependent manner although the acquisition of immunity against
VAR2CSA differed between the two regions. In areas of intense P.
falciparum transmission, pregnant women generally develop
protective immunity to PAM over successive pregnancies, and
only primigravidae and secundigravidae present higher placental
infection prevalence rates [24]. In P. falciparum transmission areas
such as Benin, exposure is high and results in a fast acquisition of
Figure 6. Plasma reactivity against DBL5e domains of VAR2CSA. (A): Plasma levels of IgG with specificity for DBL5e domain of VAR2CSA in 8
French unexposed men (M), 16 French unexposed pregnant women (Fra), 75 Senegalese pregnant women (Sen) and 160 Beninese pregnant women
(Ben). DBL5e variants CYK39 and CYK49 were tested. (B): Plasma levels of VAR2CSA DBL5e domain according to parity. DBL5e antibodies levels were
quantified in the same groups of malaria-exposed pregnant women (Benin and Senegal) as in A. 24 primigravidae (P), 51 multigravidae (M) from
Senegal; 80 primigravidae and 80 multigravidae from Benin. (C): Plasma levels of VAR2CSA DBL5e domain according to parity range. Malaria exposed
women used in (B) were separated in three groups; primigravidae (P), women whose parity level is lower or equal to 3 (M#3) [Beninese women:
n = 48, n = 26 for Senegalese women] and those whose parity status is higher than 3 (M.3) [Beninese women: n = 32, n = 25 for Senegalese women].
(D) Correlation between the reactivity to each DBL5e variant in a given plasma.
doi:10.1371/journal.pone.0013105.g006
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Figure 7. Cross-reactive antibody target between VAR2CSA DBL5e variants. Cross-reactivity was determined by competition ELISA using
either a multigravid plasma pool with high titer of VAR2CSA-specific antibodies (Beninese or Senegalese women), plasma from DBL5e_CYK39 or
CYK49 DNA genetic vaccinated mouse (A). NTS-DBL1a domain of VARO was used as negative control (B). Each colour shows the reactivity with the
indicated antibodies.
doi:10.1371/journal.pone.0013105.g007
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Figure 8. Reactivity of human specific conserved DBL5e affinity purified antibodies with P. falciparum infected erythrocytes. (A): IgG
recognition of 3D7-DBL5e peptides library. (B): Mapping of P4 and P13 peptides on DBL5e model [8]. (C): Senegalese women antibodies were affinity
purified on peptides P4 and P13 and tested for reactivity against PAM Beninese parasite isolates. Flow cytometry analysis of human affinity-purified
IgG against peptides P4 and P13 against PAM parasite isolates. Each colour shows the reactivity to native parasites with the indicated antibodies. Four
isolates were tested with each IgG. Sample without primary antibody (blank), non-exposed women plasma pool, and exposed women plasma pool
are used as control respectively.
doi:10.1371/journal.pone.0013105.g008
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immunity while the acquisition may be delayed in areas of low and
seasonal transmission such as in Senegal. In our two populations,
multigravidae presented with higher antibody levels against
VAR2CSA than primigravidae; but in Benin, where transmission
is perennial, the mean antibody level was overall higher than that
of women from Senegal. Among primigravidae, 57% of Beninese
had anti-VAR2CSA antibodies at delivery compared to 16% of
Senegalese. This could be explained by difference in malaria
exposure in the study areas. A close comparison of the two
VAR2CSA DBL5e recombinant variants demonstrated that,
despite a homology of 80% in their amino acid sequences, both
variants presented some distinguishable characteristics. The
DBL5e_CYK39 exhibited a higher CSPG binding ability and a
higher recognition by plasmas than the DBL5e_CYK49 variant,
although both constructs showed parity-dependent recognition
patterns. This observation suggests that some variants can be more
readily recognized than others. This can also be a useful
consideration in vaccine development strategy, as not all
VAR2CSA variants are likely to yield broad and high recognition
or reactivity.
In the variable regions of DBL5e distinct motifs were identified,
the sero-reactivity of peptide containing TFKNI (P19) was assessed
by ELISA. No reactivity was observed against this as shown in
Figure 8A. Nevertheless, this result is not surprising as we clearly
showed that TFKNI only were encountered in women presenting
high parity status and may be expressed by uncommon variants.
In the same effort to develop optimal VAR2CSA-based vaccine, it
is advisable to target highly conserved residues or as many residues
as possible that are accessible by host immune response to broaden
the possibility of reaching all potential parasite populations
expressing the VAR2CSA ligand. From the current observation
it is obvious that like DBL3X, the DBL5e domain variants share
common and cross-reactive motifs. We identified two peptides (P4
and P13) in the highly conserved region of the DBL5e domain that
significantly reacted with plasma pool from pregnant women of
different endemic areas. Affinity-purified antibodies against those
peptides specifically reacted with placental parasites, confirming
that these peptides are actually surface-exposed, as suggested by
the 3D model. One such epitope in DBL5e (peptide P63) was
previously described which reacted strongly with Tanzanian
female plasma [8]. DBL5e peptide P4 identified in this study has
16 amino acids out of 20 in common with P63 peptide. Existence
of such conserved and accessible epitopes supports the broad
recognition observed on this particular DBL domain and
emphasizes on its potential interest.
Knock-out studies have previously demonstrated the exclusive
need for VAR2CSA to mediate IE binding to CSA [11], and it has
been shown that four of the six Duffy-binding-like (DBL) domains
of VAR2CSA individually have the ability to bind CSA in vitro
[12,13,14,15,16], In this study, we confirmed the CSA-binding
ability of recombinant DBL5e to CSPG. Our results have
demonstrated in our experimental conditions, that both placental
isolate DBL5e variants have certain affinity for CSPG. This result
is in agreement with the fact that DBL5e _CYK39 variant is able
to bind to CSA and heparin sulfate [16]. However NTS-DBL1a
domain of the VARO PfEMP1 that is not involved in the placental
sequestration of parasites also presented a weak affinity to CSPG.
The binding of VAR2CSA to placental CSPG plays a major role
in malaria during pregnancy, and the understanding of this
interaction will be valuable to define easily producible constructs
that can induce adhesion inhibitory antibodies. Unlike CSA
binding that is unique to PAM parasites, in vitro interaction of
individual DBL with CSA is often seen with non-VAR2CSA
DBLs. Whether such interactions of individual domain can predict
for IE binding phenotype is debatable. Thus the CSPG interaction
was used in the current study only as an analytic tool to
characterize the properties of the both recombinant DBL5e
variants expressed. Recent studies have demonstrated that even
though DBL3X and DBL6e can bind to the same ligand, the sites
of interaction differ in these domains [25,26]. Nevertheless, in
each of these domains, the binding site involves residues that are
conserved in parasite isolates from different geographic locations.
We report in this study a difference in CSPG binding ability
among two VAR2CSA DBL5e variants. The structure of this
domain has not yet been solved and residues which are essential
for interaction are not identified.
In summary, we demonstrated for the first time that although
VAR2CSA DBL5e sequence has a limited antigenic diversity, it
contains some molecular signatures that distinguish parasites
according to the host parity. These findings have important
implications for vaccine design based on VAR2CSA. Malaria-
exposed women also develop antibodies against conserved parts of
VAR2CSA DBL5e domain. Two of such conserved epitopes were
identified here and, naturally acquired antibodies to them stained
native proteins on placental parasites. Our data support the
importance of DBL5e in the current effort of elucidating the parts
of the VAR2CSA protein that can induce an antibody response
with broad reactivity on placental parasites.
Materials and Methods
Parasite isolates
All P. falciparum PAM parasites for which sequences were
generated were collected at delivery in a cross-sectional study
conducted in Senegal in 2003[2]. Samples from 39 P. falciparum
isolates were available for the study. The mean 6 SD age of
women who donated the parasites was 2466.5 years. They were
composed of 15 primigravidae, 6 secundigravidae, and 18
multigravidae. P. falciparum infected erythrocytes (IEs) were
collected from parasitized placentas (parasite density ranging from
0.1% to 50%; mean 6 SD,12.8612.7) by flushing as previously
described [2]. Collected IEs were conserved in Trizol LS
(Invitrogen) and stored at 280uC until use. The binding ability
of parasite isolates to CSA were evaluated [2]. Neonate birth
weight was estimated by use of an electronic balance. There were
56% low birth weight LBW (,2500g) recorded.
Placental parasite ‘‘748’’ was collected in Tanzania, as described
elsewhere [20].
Parasites used to evaluate antibody reactivity with the surface of
IEs were freshly collected from pregnant women enrolled in the on
going STOPPAM project based in the district of Come`,
southwestern Benin [27].
Plasma samples collection
Plasma samples from malaria exposed women are from two
different malaria endemic areas: Perennial (Benin) and seasonal
(Senegal) P. falciparum transmission. Senegalese pregnant women
were enrolled in a cohort study in 2001 in Thiadiaye [7]. Women
presenting with fever and a positive blood smear were given
curative treatment with chloroquine, the drug advocated in
Senegal at the time of study for both prophylaxis and treatment.
In Benin, as described [28], pregnant women were enrolled in a
cohort study conducted from July 2005 through April 2008 in
Ouidah, a semirural town in Benin that is located 40 km west of
Cotonou, the political capital of Benin. Perennial malaria
transmission with seasonal peaks is mostly attributable to P.
falciparum [29]. Sulfadoxine-pyrimethamine or mefloquine was
given to women during the study.
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Plasma samples from 24 French pregnant women and 8 adults
men without P. falciparum exposure were used as negative controls.
All women plasma samples tested in this study were collected at
delivery time.
Cloning and sequencing of placental var2csa DBL5e
genes
All VAR2CSA DBL5e sequences were obtained from placental
parasites complementary DNA (cDNA). Total RNA was extracted
from parasites conserved in Trizol according to the manufacturer’s
instruction. The total RNA concentration was determined at
260 nm and RNA integrity was checked in 1% agarose gel. RNA
samples were pretreated with DNAse I (Sigma-Aldrich). 5 U of
RNase-free DNase per 5 ug of RNA was incubated at 37uC for
30 min, followed by 10 min heat inactivation at 65uC. All RNA
samples were subsequently tested in real-time PCR for contam-
ination with genomic DNA using a primer set for the
housekeeping gene seryl-tRNA synthetase. cDNA was synthetised by
reverse trancriptase (Superscript II, Invitrogen) and random
hexamer primers, as described by the manufacturer. All
VAR2CSA DBL5e sequences were amplified using high fidelity
enzyme (Phusion) with the following universal primers designed in
highly conserved areas flanking the DBL5 DBL5e+the hypervari-
able interdomain (Id5): DBL5e Forward: 59-GTC ACC CCC
GGG GAC AAT GCA ATA AAA GAT TAC and DBL5e
Reverse: 59-TAG GCA TTT GCG GCC GCC TTC AAG TTC
AGC TGG AAT ATT. Two ml of cDNA was used for the PCR
reactions. PCR products were inserted into a pAcGP67C
Baculovirus Transfer Vector (BD). Ten to 15 colonies of each
cloning were sequenced by GATC (www.gatc.com).
Cloning, expression and purification of recombinant
VAR2CSA DBL5e variants proteins
DBL5e sequence from placental parasite isolate CYK 49 [2]
was amplified from the corresponding cDNA with the following
primers: 59 ACT GGC AGG AAT TCA TGT TTG ATG ATC
AGA CA and 39 ATC GAC TGG CAG GCG GCC GCT TAA
TGG TGA TGG TGA TGG TGT TTC ATA TCA TTA. PCR
product was digested with EcoR1 and Not1 for cloning into the
modified bacterial expression vector pET-21 (Novagen, http://
www.novagen.com) to produce His-tagged recombinant proteins
in Rosetta gami strain. The ligated vectors were transformed into E.
coli DH5a strain, and positive clones were selected with ampicillin
resistance. Rosetta gami cells transformed with recombinant
plasmids, were cultured into LB broth containing ampicillin
(50 mg/ml) at 30uC, and treated at the mid-log phase
(OD600 = 0.4) with IPTG, to induce protein production. Cells
were cultured at 25uC overnight, and harvested by centrifugation
at 6,000 g at 4uC for 15 min. The pellet was washed, resuspended
in cold buffer containing 10 mM Tris, 500 mM NaCl and
protease inhibitor cocktail (Cocktail set NuIII, Calbiochem), and
sonicated. DBL5e recombinant protein was purified from bacterial
soluble fraction on Ni2+ metal-chelate agarose columns (GE
Healthcare), and eluted with 10 mM Tris, 500 mM NaCl and
150 mM imidazole. Affinity chromatography step was followed by
gel filtration. Recombinant DBL5e protein from isolate CYK 39
[16] and NTS-DBL1a VARO [30,31] were produced, and
purified under the same conditions.
Antibodies production
Specific antibodies to DBL5e CYK39 or DBL5e CYK49 were
induced in mice by genetic immunization. Briefly, DNA injections
were subcutaneously electro-transferred to 6-week-old Swiss
female mice (Janvier, France) using 40 mg of plasmid DNA
encoding either DBL5e_CYK39 or DBL5e_CYK49. All plasmids
used for genetic vaccination are based on a pVax1 vector back-
bone (Invitrogen) in which the original cytomegalovirus (CMV)
promoter has been replaced with the CMV promoter of the
pCMVb plasmid (Clontech), as described [32]. Mice were electro-
transferred on days 0, 21 and 45. Mice were bled before each
electroporation, and a full bleed was collected 80 days (D80) after
the first electroporation. Immune response was checked by ELISA
on consecutive bleeds. All procedures complied with European
and National regulations.
IgG from plasma of multigravidae living in an endemic area
were purified on a Hi-Trap protein G HP column according to the
manufacturer’s recommendations (GE-Healthcare). The specific-
ity of the purified antibodies was tested in ELISA against
recombinant DBL5e recombinant proteins (CYK39 and CYK49).
VAR2CSA proteins characterization by Western blotting
The soluble recombinant VAR2CSA DBL5e proteins were
checked by Sodium Dodecyl Sulfate-polyacrylamide gel electro-
phoresis and Western blotting. Protein samples (2–50 mg) were
suspended in Laemmli-buffer (Tris/HCl 62.5mM, pH6.8, 2%
SDS, 5% b-mercaptoethanol and 10% glycerol), subjected to
SDS-PAGE [33] using a 4–12% acrylamide slab minigel
(Invitrogen, Carisbad, CA, USA). Western blotting was performed
with (2–30 mg) bacterial (induced, uninduced and nontransformed)
lysates or purified eluates electrophoresed through 4–12% SDS-
PAGE gels and electro-transferred to 0.2 mm Protan BA 83
nitrocellulose sheets (Schleicher & Schuell) for immunodetection.
The membranes were blocked for 1 h with 5% nonfat dry milk in
phosphate-buffered saline (PBS) with 0.1% TweenH and then
incubated separately with either a 1:5000 dilution of a monoclonal
anti-histidine HRP conjugated antibody (46-0707, Invitrogen) or a
1:1000 dilution of DBL5e_CYK39 or DBL5e_CYK49 antiserum
from vaccinated mouse D50 (day 50) or 1:1000 of IgG purified
from plasma of multigravidae living in an endemic area. Immune
complexes were detected with a HRP coupled with either anti-
mouse IgG antibody (1:10 000, AP127P Sigma-Aldrich) or anti-
human IgG antibody (1:10 000, A0170 Sigma-Aldrich).
Competition ELISA, peptide ELISA and affinity
purification of antibodies
Prior to competition ELISA, both VAR2CSA DBL5e con-
structs were used to assess the plasma levels of anti VAR2CSA IgG
of 160 malaria exposed pregnant women from Benin (primigrav-
idae n= 80, multigravidae n= 80) and Senegal (primigravidae
n= 24; multigravidae n= 50), French unexposed pregnant women
(n= 16), and French unexposed men (n= 8). ELISA was carried
out on plates coated with 0.5 mg/ml of the DBL5e. The IgG
plasma levels were expressed as Optical densities (OD) values read
at 450nm. A pool of plasma samples from unexposed French
pregnant women was used as a negative control whereas a pool of
plasma samples from multigravidae pregnant Senegalese women,
previously demonstrated to have high levels of anti-VSA IgG
(VSA: Variant surface antigen) against placental isolates, was used
as a positive control.
For competition ELISA, microtiter plates (Nunc 442404) were
coated with each antigen (DBL5e_CYK39, DBL5e_CYK49,
NTS-DBL1a-VARO, 0.5 mg/ml in PBS). Five different plasma
pools were individually pre-incubated for 2 h at room temperature
(RT) with increasing concentrations of competing antigen (0.5, 1,
1.5, and 3 mg/ml): Beninese pregnant women plasma pool (diluted
1:500), Senegalese pregnant women plasma pool (diluted 1:500),
DBL5e_CYK39 plasma from DNA vaccinated D50 (1:100 000),
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DBL5e_CYK49 plasma from DNA vaccinated D50 (1:40 000),
and French unexposed women plasma pool (1:100). After
incubating the plates with blocking buffer (PBS, 0.5 M NaCl,
1% Triton X-100, 1% BSA) for 2 h at RT, the pre-absorbed pool
were added to the antigen-coated wells in duplicate and incubated
overnight at 4uC. In addition to the pre-absorbed plasma pool, a
non-absorbed pool was included for each coating antigen.
Following washing of the plates four times with washing buffer
(PBS, 0.5 M NaCl, 1% Triton X-100, pH 7.4), the secondary
antibody (Goat anti-human IgG HRP, A0170, Sigma-Aldrich for
human plasma and Goat anti-mouse IgG HRP, AP127P,
Chemicon) diluted 1:4000 in blocking buffer was added, and
incubated for 1 h at RT. Plates were washed four times, and
antibody reactivity visualized by the addition of TMB (Tetra-
methylbenzidine). Coloured reactions were stopped by the
addition of 0.5 M H2SO4 and OD was measured at 450 nm.
Peptides and antibodies affinity purification of antibodies
DBL5e of 3D7 PFL0030c var2csa sequence (Genbank accession
number. XM_001350379) was used to design peptides. A library
of 23 peptides (70% purity) each consisting of 20 amino acids and
having an overlap of 6 amino acids was synthesized (Sigma
Genosys). All peptides had a free amine at the N- and a free acid at
the OH-terminus. ELISA was carried out on plates coated with
5 mg/ml of each peptide. VAR2CSA antibodies reactivity against
those peptides was measured using Senegalese pregnant women
plasma pool 1:100 (pool was obtained with n= 30 multigravidae
plasma) and Beninese pregnant women plasma pool 1:100 (pool
was obtained with n= 30 multigravidae plasma). Plasma samples
from Unexposed French men (n= 8) and pregnant women (n= 16)
were used as negative controls.
The two peptides (P4: 2037RRQLCFSRIVRGPANLRNLK2056
and P13: 2163SWCTIPTTETPPQFLRWIKE2182) which reacted
with malaria exposed pregnant women plasma pool were used for
affinity purification of antibodies. This was done using HiTrap
NHS-activated HP columns (GE Healthcare) according to the
manufacturer’s instructions. In brief, 1 mg of each synthetic peptide
was dissolved in coupling buffer 0.2 M NaHCO3, 0.5 M NaCl
(pH 8.3), and applied to the 1 ml column previously equilibrated
with 362 ml of ice-cold 1 mM HCl. After coupling, the columns
were washed alternating 0.5 M ethanolamine, 0.5 M NaCl (pH 8.3)
and 0.1 M acetate, 0.5 M NaCl (pH 4), followed by a final wash
with PBS (pH 7.4). One ml of Senegalese pregnant women plasma
pool was diluted in PBS (1:1), filtered through a 0.45-mm filter and
applied to the column at a flow rate of 1 ml / min. After washing the
column in 7 ml PBS, affinity-bound antibodies were eluted in
fractions with a total volume of 3 ml of 0.1 M glycine-HCl (pH 2.8)
and neutralized in 1 M Tris (pH 8). The specificity of the purified
antibodies was tested in ELISA against the peptide used for affinity
purification.
Antibody recognition of surface VAR2CSA
P. falciparum-IEs collected ex vivo from the placenta of Beninese
women were used without additional in vitro culture. Flow
cytometry was used to test the reactivity of the antibodies against
either the P4 or P13 peptides with parasite isolates, as described
elsewhere [34]. Briefly, mature parasites (four placental isolates)
were enriched to contain .75% PE at late-stage trophozoite and
schizont stages by exposure to a strong magnetic field. Aliquots of
,26105 PE were labeled by ethidium bromide and sequentially
exposed to 20 ml human purified IgG (,0.2 mg IgG) and 1 ml goat
anti-human IgG-FITC (Sigma). Data were acquired using FACS
Calibur (BD Biosciences, Franklin 10 Lakes, NJ). All samples
relating to a particular parasite isolate were processed and
analyzed in a single assay.
Interaction properties of the recombinant DBL5e proteins
Binding to CSPG (decorin D8428, Sigma-Aldrich) was per-
formed mainly as described elsewhere [35]. Briefly falcon plates
(351172, Becton Dickinson) were coated with either 5 mg/ml
of CSPG in PBS or with 1% BSA in PBS for background
measurement (overnight at 4uC). Following coating, the wells were
blocked with TSM binding buffer (20 mM Tris–HCl, 90 mM
NaCl, 2 mMCaCl2, 2 mMMgCl2, 0.05%Tween-20 and 1% BSA,
pH 7.4 at 25uC) at room temperature for 6h. A dilution series
(0.4–40 mg/ml) of the DBL5e recombinant domains in TSM
binding buffer was added in each well and incubated overnight at
4uC with gentle shaking. After washing three times in TSM washing
buffer, 100 ml of anti-His tag-HRP antibody diluted 1:3 000 in
binding buffer was added to each well and incubated for 2h at room
temperature. The assay was finalised with three washes and
developed using 100 ml per well of TMB substrate for 30 min.
Absorbance was measured at 450 nm after quenching the reaction
with 100 ml of 0.5 M H2SO4.
Inhibition of recombinant domain binding to CSPG was
performed mainly as the above described ELISA analysis, but
using a constant protein concentration (5 mg/ml) pre-mixed with
increasing amounts of soluble CSA (0.5–400 mg/ml).
In silico analyses of VAR2CSA sequences from field
isolates
Multiple alignment. Initially a master data file was created,
containing sequence ids, experimental parameters (where
available) and unaligned sequences. The DBL5e were aligned
using ClustalW2 [36] with default options. The resulting
alignment was inspected and manually adjusted. Aligned
sequences were then inserted in the master file.
Evaluation of system diversity by calculation of Shannon
entropy. The Shannon entropy [37] was calculated for each
position in the multiple alignment as:
H pð Þ~{
X
a
palog2 pað Þ
Briefly on values of H: H=0: Complete conservation, only one
residue present at the given position. 0,H#1: Considered highly
conserved. 1,H#2: Considered conserved. 2,H#4.3 considered
variable. The calculated Shannon Entropy per multiple alignment
position was subsequently depicted.
Homology modeling. DBL5e homology models were
created by submitting the multiple alignment to the HHpred
server [38]. Best hit was chosen based on an evaluation of score
and structure resolution (VAR2CSA DBL3x domain, PDB ID:
3bqk) [26]. One primi- and one multigravidae representative
sequence were chosen and submitted individually to HHpred. The
resulting models were loaded into PyMOL [39] and aligned for
visual analysis of structural impact of motifs. The models were
validated by submission to the ProQ server [40]. Likewise was a
model of DBL5e-3d7 created for mapping purposes.
Mapping of sequence variability. The sequence variability
was mapped onto a homology model of DBL5e-3d7 by submission
to the H2PDB server [41]. The resulting pdb-file was loaded into
PyMOL and variability was visualised by heat-map colouring
(colour by b-factor).
SigniSite analysis. A statistical In silico analysis of the
multiple alignment was performed using the SigniSite server
[23]. Briefly: The SigniSite server performs a non-parametric
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statistical evaluation of the distribution of each residue at each
position, aiming at identifying any significant association with a
sequence associated numerical parameter, specified at submission.
As a prerequisite for submission to SigniSite is the association of a
numerical parameter to each sequence, sequence files were created
for each numerical parameter containing the DBL5e sequences
and the associated numerical parameter (where available).
Numerical isolate parameters were: Maternal age at delivery
[year(s)], Concentration of parasites in peripheral blood of the
mother [/mL], Concentration of parasites in the placental blood
[/mL], Parity, Birth weight [g], CSA binding density [mean/
mm2], CSPG binding density [mean/mm2]. Some of the women
were infected with more than one parasite and thus some isolates
contain more than one sequence. It should be noted that (i)
numerical values associated with a particular isolate were assigned
to all the sequences identified in that particular isolate and (ii) not
all parameters were available for all sequences, if no parameter
was available, the sequence was excluded from evaluation. As
SigniSite performs multiple testing, it was imperative to reduce the
number of tests performed prior to submission. This was done in
two steps: (i) Exclusion of all positions in the multiple alignment
with H=0 (If just one residue is present at a given position, no
significant distribution is possible). (ii) Evaluating only the top 15%
most variable positions as estimated by the entropy calculation (It
is more likely to identify a significant distribution at the most
variable positions). Following this, the before mentioned sequence
files were reduced to only contain the positions selected for testing.
The sequence files were subsequently submitted to evaluation by
SigniSite with the following settings: Significance threshold = 0.05,
Correction for multiple testing using the Bonferroni single-step,
Consider values given in fasta header and Choose decreasing
order. The normal distributed Z-scores were converted to p-values
by standard method.
Statistical analysis
Comparison of anti-VAR2CSA antibodies levels between
groups was tested by nonparametric Mann-Whitney test. Corre-
lations were examined by use of Pearson’s test. The chi2 test was
used to examine differences between categorical variables. The
Fisher’s exact test was used to evaluate significance when analysing
motifs and parasite expressing specific motifs identified. The
significance limit was P,0.05. When evaluating DBL5e sequences
containing Q303 vs. E/K303, population means, with respect to
placental parasites CSA/CSPG binding, were calculated and a
two sample t-test was applied to test if differences in means were
significant (p,0.01).
Supporting Information
Figure S1 Multiple alignment of parasite isolates VAR2CSA
DBL5e sequences. cDNA from 40 placental parasites isolates (39
placental isolates from Senegal and one from Tanzania) were
amplified, cloned, and sequenced. Sequence ids are given at the
far left. The Tanzanian isolate was isolate 748 (sequences 748_1/
2a and 748_1/2b) corresponding to the DBL5e domain amplified
in this isolate. The remaining sequences correspond to those
obtained in isolates from Senegal. The remaining CYK are
Senegalese isolates. The CYK suffix corresponds to the placenta id
from which the isolate was extracted. The DBL5e and ID5 highly
conserved (blue, Shannon entropy 0#H#1), conserved (green,
1,H,1.5), and relatively variable (red, 1.5#H#2) blocks, are
indicated. The 15% most variable positions were selected and
marked with ‘‘x’’.
Found at: doi:10.1371/journal.pone.0013105.s001 (0.11 MB
PDF)
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The ability to speak does not make you intelligent.
Qui-Gon Jinn
4
VAR2CSA linear B-cell epitope discovery
4.1 Introduction
Immunity to placental malaria is gradually acquired and mediated by the
accumulation of antibodies capable of blocking the VAR2CSA:receptor
interaction. Obtaining a deep understanding of the immunogenicity of
VAR2CSA can facilitate not only the identification of epitopes capable of
inducing blocking antibodies, but also the immunodominant epitopes acting as
an immunological smoke-screen. The purpose of these epitopes are to divert the
’attention’ of the human immune system, away from blocking antibody inducing
epitopes and thusly maintaining the cytoadherence capability. These epitopes are
naturally to be avoided in the context of vaccine development. The identification
of which epitopes are capable of inducing high titer blocking antibodies response
is paramount in the search for a vaccine against placental malaria. The purpose of
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Amodel and a hydrophilicity scale constructed by Parker
et al. (1986) has recently lead to some improvement in
linear B-cell epitope prediction (Larsen et al. 2006).
It has been estimated that >90% of B-cell epitopes are
discontinuous, i.e., consist of segments that are distantly
separated in the pathogen protein sequence and brought
into proximity by the folding of the protein (Barlow et al.
1986; Van Regenmortel 1996). Identification of discon-
tinuous epitopes is difficult, since the complete analysis
must be done in context of the native antigen structure.
The most informative and accurate method for identi-
fication of discontinuous epitopes is determination of
structures of antigen–antibody complexes by X-ray crys-
tallography (Fleury et al. 2000; Mirza et al. 2000). The
use of discontinuous epitopes derived from presently
available X-ray structures is complicated by two major
problems: First, the available data on discontinuous
epitopes in different antigens is much reduced compared
to linear epitopes; second, very few antigens have been
studied to completely identify various discontinuous
epitopes in the same antigen. The existence of undetected
epitopes that are not identified in the data set can make it
harder to develop good prediction algorithms because
they influence the measured performance. However,
detailed structural knowledge on antibody–antigen com-
plexes is growing, and allows for broader analysis of
discontinuous epitopes in various antigens and develop-
ment of better prediction methods.
Correlation between surface exposure and B-cell epi-
topes has been known for many years (Novotny et al.
1986; Thornton et al. 1986). Recently, two new methods
using protein structure and surface exposure for pre-
diction of B-cell epitopes have been published (Kulkarni-
Kale et al. 2005; Batori et al. 2006). However, none of
these new methods using protein structure as input have the
primary focus on discontinuous epitopes.
Here, we present a prediction method for residues
located in discontinuous B-cell epitopes. DiscoTope uses
a combination of amino acid statistics, spatial informa-
tion, and surface exposure. It is trained on a compiled
data set of discontinuous epitopes from 76 X-ray struc-
tures of antibody/antigen protein complexes. We present
the performance of DiscoTope compared to the Parker
hydrophilicity scale (Parker et al. 1986) for a comparison
to a classical, sequence-based method that has been
shown recently to perform well for prediction of linear
epitopes (Larsen et al. 2006). In addition, we compare the
performance with predictions based on surface accessi-
bility measured on antigen structures using the program
NACCESS (Hubbard and Thornton 1993). We demon-
strate that DiscoTope is generally the best performing
of all methods described here. Finally, we present the
delineation of epitopes in the malaria protein apical
membrane antigen 1 (AMA1) where DiscoTope success-
fully predicts epitope residues that have been identified
using either various experimental or sequence analysis
techniques.
Results
Properties of discontinuous B-cell epitopes
In order to get a well-established basis for development
and evaluation of the prediction method, we compiled
a discontinuous epitope data set from 76 X-ray structures
of complexes between antibodies and protein antigens.
We analyzed the data set to find distributions for the
number of residues per epitope, the number of residues
per sequential stretch in epitopes, and the longest se-
quential stretch per epitope. These distributions are
shown in Figure 1. The total number of residues per
epitope ranged from 9 to 22, and >60% of the epitopes
consisted of 14 to 19 residues (Fig. 1A). Segments with
a single epitope residue represented >45% of the 528
segments in the data set (Fig. 1B). The longest sequential
stretch of identified residues per epitope ranged between
3 and 12 residues, and >75% of epitopes comprised a
sequential stretch of a maximum length of 4 to 7 residues
(Fig. 1C). These findings confirm that most epitopes in
the data set are indeed discontinuous, and composed by
small parts of the antigen sequence forming a binding
region for the antibody.
The data set was analyzed with respect to surface
exposure by determining the number of intramolecular
Ca atom contacts for each residue (Fig. 2). A low contact
number correlates with localization close to the surface or
in protruding regions of antigen structures. A t-test
showed that residues identified as part of epitopes in
the data set had significantly lower numbers of contacts
compared to the nonepitope residues (P < 10!5). The
average number of contacts and standard error of mean
for epitope residues was 15.7 6 0.12, and for nonepitope
residues the average contact number and standard error of
mean was 19.2 6 0.05 (see Fig. 2, vertical lines). The
Figure 1. Analysis of the complete data set of discontinuous B-cell
epitopes. (A) Distribution of the number of residues per epitope. (B)
Distribution of the number of residues per sequential stretch of epitopes.
(C) Distribution of the maximum length of a sequential stretch per epitope.
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a tendency for epitopes to be depleted of small hydrophobic amino
acids (ALA, VAL, LEU), and enriched by tyrosines, which aligns with
previous findings (Ofran et al., 2008; Rubinstein et al., 2008; Sun
et al., 2011). Tryptophan is found to have a large, but insignificant,
log-odds score, which is related to the fact that tryptophan is a
rare amino acid in proteins. To test the influence of the surface
exposure measure used, the analysis was repeated using half-
sphere exposure. The result further validates the presented findings
and suggests that alanine and valine are significantly under-
represented in epitopes (p < 0.001 in both cases, data not shown).
Similar to the epitope amino acid composition, the composition
of amino acids in the paratope was compared to the composition of
the antibody surface (Fig. 4). 5 amino acids were significantly over-
represented and 9 amino acids significantly under-represented,
and the deviation from the overall antibody surface amino acid
composition was in general more pronounced than what was found
for epitopes. Interestingly, the 5 positively selected amino acids
possess diverse chemical properties with at least one represen-
tative from each of the four chemical groups; hydrophobic (trp),
hydrophilic (tyr and asn), negatively charged (asp) and positively
charged (his).
3.4. The epitope size and shape
The shape and size of epitopes were quantified by fitting axes of
inertia (also referred to as principle components (PCs)) to individ-
ual epitopes using atoms in contact with antibody as representative
for the epitope shape. As illustrated in Fig. 5B and Supplementary
Materials Fig. S2,  the primary and secondary axis spanned a plane
parallel to the antibody tip, describing the planer shape and size
of the epitope, whereas the tertiary axis is perpendicular to the
antibody and describes the depth (thickness) of the epitope. By pro-
jecting the epitope atoms in contact with antibody onto the epitope
plane (spanned by PC1 and PC2), it was evident that the plane in
general had an ellipse like shape (data not shown). This impression
was supported by the findings that the density of contacting atoms
in the plane (atom per Å2) was significantly higher when fitting
an ellipse to data compared to a rectangular fit (p < 10−16, paired
t-test). Approximating the epitope plane by an ellipse resulted in
an average epitope plane of 401 ± 133 A˚2 when the ellipse enclosed
∼90% of the epitope atoms projected onto the plane. The general
epitope thickness (PC3) was found to be 8.2 ± 2.0 A˚ when enclos-
ing on average 95% of epitope atoms. The size of the epitope plane
was strongly correlated to the number of contacting residues in the
epitope (Pearson correlation coefficient: PCC = 0.775 ± 0.047, 95%
confidence interval found by bootstrapping), whereas the thick-
ness of epitopes had a much lower correlation (PCC = 0.374 ± 0.095,
same method used). The tertiary axis was  found to be significantly
shorter than both the primary and secondary axis (p < 10−15 for
both axes, one-tailed paired T-test), supporting previous findings,
describing the epitope area as a flat rugged surface (Rubinstein
et al., 2008). It was investigated if the shape of the plane was
best described by a circle or an oblong ellipse, by comparing the
|PC2|/|PC1| ratio for each epitope to the ratio of a random “epitope”
generated from a uniform 3-dimensional disk-shaped distribution
(see Section 2.6). A binomial distribution was used to assess the
number of times the true |PC2|/|PC1| ratio was lower than the ran-
domly obtained ratio, and the results clearly demonstrated that the
ratios of epitopes in general were lower than random (p < 10−11),
thus suggesting that the epitope is best described as an flat oblong
ellipse shape.
3.5. Spatial orientation of epitopes in relation to antibodies
The immunoglobulin fold of the antibody light and heavy chain
gives the tip of the antibody an oblong flat squircle-like shape
(shape with properties between a circle and a square), which might
force the epitope to bind in a specific direction. The oblong shape
of the epitope described above, enabled us to represent the epi-
tope direction by the direction of first principle components. The
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Figure 4.1.1: A: 2006 structural analysis of antibody:antigen complexes in the Protein Data
Bank (PDB) [66] B: Likewise, but from 2013 [87]. Axis annotation: x-axis it the length of con-
secutive amino acid residues; y-axis it the proportion of epitopes found to have that length.
the the High Density Peptide Microarray (HDPMa) is to provide a
high-throughput technology, with the capability of screen large libraries of
peptides for an activity of choice. As with all high-throughput methods, the
downstream challenge is how to handle the large amounts of data being
generated. This challenge is the oﬀset for the work described in this part of the
thesis. The aim of this study was a 2-step process:
1. Develop a statistical robust method for signal detection in HighThroughput,
High Density Peptide Micro rray
2. Once developed, apply to VAR2CSA linear B-cell epitope discovery
An initial concern was that the consensus regarding VAR2CSA epitopes is that
the majority are conformational [41] and since it has been proposed that more
than 90% of epitopes are conformational [10, 150], this technology may at first
not seem suitable for discovery of linear b-cell epito es. However Structural
studies of epitope:antigen interactions, have shown that epitopes consists of a set
of contact-points, which combined with a linear stretch of amino acid residues,
acting as an antigenic determinant, constitute the epitope [66, 87]. The length of
the linear determinant ranges from 4 to 7 consecutive amino acid residues (See
fig. 4.1.1).
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4.2 Materials
4.2.1 Generation of 15-mers from reference sequences
VAR2CSA derived peptides were created using a ’sliding-window’ of 15 residues.
The reference sequences were from standard strains 3D7 (nres = 2; 671) and
FCR3 (nres = 2; 715), both with n-terminal and c-terminal spacer
’GAGAGAGAGAGAGAG’. The purpose of the spacer was to increase the availability of
the terminus regions. Furthermore the FCR3 sequence had the V5 epitope
’GKPIPNPLLGLDST’ incorporated in the c-terminal, along with a his-tag ’HHHHHH’
(FCR3 and 3D7 sequence are available in supplementary materials). The V5 tag
was used for positive control. Table 4.2.1 summarises 15-mer counts in the two
reference sequences.
Strain n15 mers nunique15 mers
FCR3 2,701 2,700
3D7 2,657 2,656
Pool 5,358 4,731
Table 4.2.1: Overview of sequence data.
4.2.2 HDPMa incubation
The chip used in this experiment, was subdivided into 24 sectors, each separated
by highly hydrophobic teflon-barriers, allowing us to conduct 24 separate
incubations based on the immunisations summarised in table 4.2.2.
4.2.3 HDPMa output
The output generated from reading the chip is a tab-separated text file with a total
of 134,647 lines. From this file 105,141 15-mer peptides can be extracted each of
which has an associated signal-to-noise (S=N) ratio and one of 24 sectors. Within
the total set of 15-mers 3,748 are unique.
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S Immunisation
1 Full length FCR3
2 Full length 3d7 (Without v5 epitope)
3 Full length 3d7 (With v5 epitope)
4 Full length FCR3 (As 1 but from another animal and IgG purified)
5 Full length FCR3 purified on heterologous 3D7 Full length column
6 Full length 3D7 purified on homologous 3D7 Full length column
7 Full length 3D7 purified on heterologous FCR3 Full length column
8 Full length FCR3 purified on all single domains
9 DBL4 FCR3 vaccine construct (Not blocking)
10 DBL4 3D7 vaccine construct (Not particular blocking)
11 DBL4 FCR3 vaccine construct (blocking)
12 DBL4 from placental isolate 4708 (Cannot be inhibited by FCR3 generated sera)
13 DBL4 FCR3 vaccine construct produced in coli
14 DBL4 FCR3 vaccine construct produced in coli c-terminal truncated DBL4
15 DBL4 FCR3 vaccine construct produced in coli c-terminal truncated DBL4
16 Full length FCR3 immunised and boosted with FCR3 DBL4
17 FCR3 DBL4 vaccine and boosted with Full length FCR3
18 FCR3 DBL4 + Full length FCR3 vaccinated
19 VAR 1 (irrelevant protein) control
20 DBL1-2 vaccine FCR3
21 DBL4 vaccine FCR3 c-terminal truncated
22 DBL1-3 vaccine FCR3
23 DBL1-4 vaccine FCR3
24 Negative control (May lack inhibition from serum protein)
Table 4.2.2: Overview of immunisations. S refers to one of the 24 sectors on the HDPMa chip.
DBL refers to one of the six VAR2CSA domains, FCR3 and 3D7 are standard VAR2CSA se-
quences, the V5 epitope, GKPIPNPLLGLDST, is used as positive control.
The discrepancy between the 4,731 possible 15-mers from FCR3 and 3D7 and
the 3,748 unique 15-mers in the data from the read chip is due to some of the
fields having been marked as ’excluded’. These fields are excluded because they
could not be read properly, due to e.g. a spec of dust or similar. This of course
means that not every unique FCR3/3D7 15-mer is covered in the data set,
however since we are using a sliding-window approach, each position in FCR3
and 3D7 are covered by at least one 15-mer.
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4.3 Methods
4.3.1 Direct signal mapping with standard score normalisation
Initially we applied the naive method op simply mapping the average signal to
each VAR2CSA position as follows:
For each of the 24 sectors
1. Extract all 15-mers and associated signals from the raw data file
2. Assign mean signal to any non-unique 15-mers
3. Map 15-mers and associated signal onto reference sequence
4. Assign the mean signal s to each pi in the reference sequence
5. Standard score normalise (SSN), such that z(spi) =
spi μsec
σsec
6. Assume that the signal distribution in each sector can be approximated by
the normal distribution and assign p-values underH0 : μ = 0 and
H1 : μ 6= 0
7. Use standard Bonferroni-single-step correction for multiple testing,
counting each position as a test
Where the null-hypothesis is that there is an equal amount of signal and noise,
i.e., the ratio between signal and noise is 1. SSN is performed on a set of values, by
taking each individual value, subtracting the mean of the set and dividing by the
standard score. After SSN, the mean of the set will be 0 and the standard
deviation will be 0. Therefore the after SSN equal values of signal and noise will
result in a SSN S/N value of ’0’. Following this epitopes are identified as
continuos stretches of residues, for which z(spi) > z1 α=(2ntests)
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4.3.2 Identificationofepitopelineardeterminantusingak-merbased
non-parametric approach
Based on the previous mentioned structural studies of antibody:antigen
interaction and subsequent identification of linear determinant, the aim of this
approach was to identify linear determinants, by applying a k-mer sub-division of
the 15-mers and subsequently performing a statistical evaluation of the resulting
k-mer population. Using the SigniSitemethod as inspiration, we turned to the
non-parametric Wilcoxon Rank-Sum test [4, 127]. Themethod described here
can be viewed as an expansion of the SigniSitemethod from ’1-mers’ to ’k-mers’.
Themain diﬀerence being that SigniSitemakes positional evaluations based on
the mean ranks, whereas this method evaluated all possible k-mers using the sum
of the ranks. Themethod was implemented as follows:
For each of the 24 sectors
1. Extract all 15-mers and associated signal from the raw data file
2. Subdivide each 15-mer into (15  k+ 1) k-mers, each associated with the
same signal as the 15-mer from which they originated
3. Sort the generated k-mers, with respect to descending signal
4. Rank the sorted k-mers, such that the k-mer with the highest signal gets a
rank of 1, the second highest signal 2 and so on. In case of tied values, each
tied k-mer gets a rank corresponding to the average of the ranks, the tied
k-mers would occupy, were they not tied.
5. For each unique k-mer, compute the sum of the ranks, R1
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6. For each R1, compute E(R1) and Var(R1) as follows:
E(R1) = 1
2
 n1(N+ 1) (4.1)
Var(R1) = n1n2(N+ 1)
12
(4.2)
Var(R1) = n1n2
12N(N  1)
"
N3   N 
nX
i=1
(t3i   ti)
#
(4.3)
Where E(R1) is the expected mean, Var(R1) is the variance in the absence
and presence respectively of tied values. n1 is the number of the unique
k-mer, which is currently being tested, n2 is the number of all other k-mers
andN = n1 + n2. ti is the number of tied values in the i’th of n tied group,
e.g. given ranks (1; 1; 3; 3; 5; 6; 7; 7; 7; 10), the tiesum,
Pn
i=1(t
3
i   ti), is
(23   2) + (23   2) + (33   3) = 36
7. Lastly compute the test statistic T
T = q  jR1  E(R1)j  
1
2p
Var(R1)
(4.4)
Where q =  1 if R1 > E(R1) and q = 1 otherwise. A negative T thus
implies that R1 is higher than expected and that the association therefore is
with high ranks, which is equivalent with ’weak’ values and vice versa.
Henceforth the value of the computed T statistics will referred to as the z-score of
the k-mer. Once a list of k-mers and associated z-scores have been computed, the
k-mers can be mapped onto reference sequences FCR3 and 3D7. Each position in
the reference sequence is assigned the z-scores of the k-mer starting at this pi. The
threshold for significance is adjusted using standard ’Bonferroni-single-step’
correction for multiple testing, such that zadj = z1 α=ntests , where ntests is the
number of unique mapped k-mers and α is the level of significance usually 5%.
Here we apply a one-sided test, since we are interested in identifying k-mers
which are significantly associated with a high signal, i.e. z > 0. Epitopes are
99
identified by positional traversing the mapped z-scores and identifying
continuous stretches of k-mers, for which z > zadj. Each identified stretch of
residues can then be ranked according to the k-mer with the highest z-scorewithin
the stretch. Furthermore this k-mer is recorded as the linear determinant, in that
it contributes the largest signal with the stretch. Based on the findings
summarised in fig. 4.1.1, we chose k = 5 for this analysis. Table 4.3.1 summarises
the 5-mer population, which can be generated from reference sequences FCR3
and 3D7. Prior to applying the above described k-mermethod, we filtered the
Strain n5 mers nunique5 mers
FCR3 2,711 2,667
3D7 2,667 2,627
Pool 5,378 3,923
Table 4.3.1: Overview of sequence data.
raw data. Of a total of 105,141 15-mers, 64,413 had an associated signal-to-noise
ratio of 1 or smaller. In other words 61; 26% of the data contained as much or
more noise than actual signal. We therefore chose only to include 15-mers with
an associated signal-to-noise ratio of more than 1:0. Considering that 60,168
15-mers (3,659 unique), equivalent to 57; 23% of the data, had an associated
signal-to-noise ratio of exactly 1:0, this also made intuitively sense in that no
information can be obtained from such a large set of quantitatively inseparable
peptides. Filtering away these data-point, which contain no information, we end
up with a total of 40,728 15-mers of which 3572 are unique.
4.4 Results
4.4.1 Descriptive statistics of empirical signal-to-noise ratios
Fig. 4.4.1A depicts the empirical cumulative distribution function (CDF) of a
total of 105; 141 HDPMa S=N ratios, with a mean of 1:062 and a standard
deviation of 0:165. Theminimum value is 0:2 and the maximum is 6:9. The CDF
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Figure 4.4.1: A: Empirical Cumulative Distribution function and B: emperical density for a total
of 105,141 HDPMa signal-to-noise ratios. The dotted red vertical lines are μ = 1:062 and the
two vertical black dotted lines are μ  1:96  σ , where σ = 0:165. The plot clearly illustrate
how the bulk of the data is centred around a signal-to-noise-ratio of 1.
clearly illustrates how the majority of the signals are centred around S=N = 1.
The precision of the read signals are only to the first decimal, the set of S=N ratios
therefore resembles a discrete dataset. However as the semi-discrete nature of the
data is merely a question of precision, we will treat it as continuos data. It should
however be noted that the data is highly tied, e.g. nS=N=1:0 = 60; 168, as fig.
4.4.1B clearly illustrates.
4.4.2 Direct signal mapping with standard score normalisation
The initial approach used the entire set of 105; 141 and was set up as a web server
called ’PepChipper-1.0’. Figure 4.4.2 and table 4.4.1 gives examples of output
from PepChipper-1.0 for VAR2CSA FCR3 sector 5. Full output is available in
Protein Sector Start End Avg Z Max Z Sequence
myprot_FCR3 5 1008 1025 10.212 13.349 CGSARTMKRGYKNDNYEL
myprot_FCR3 5 2676 2686 5.287 6.09 LEGKPIPNPLL
Table 4.4.1: Example of PepChipper-1.0 output for VAR2CSA FCR3 sector 5.
101
0 500 1000 1500 2000 2500
0
5
10
15
myprot FCR3 Sector 5
Sequence Position
Z−
Sc
or
e 
No
rm
ali
se
d 
av
g 
S/
N 
ra
tio
p = 0.05 (Bonferroni)1008−CGSARTMKRGYKNDNYEL−1025
2676−LEGKPIPNPLL−2686
0 500 1000 1500 2000 2500
0
5
10
15
myprot FCR3 Sector 6
Sequence Position
Z−
Sc
or
e 
No
rm
ali
se
d 
av
g 
S/
N 
ra
tio
p = 0.05 (Bonferroni)
1010−SARTMKRGYKN−1020
Figure 4.4.2: Plot of scan for linear b-cell epitopes in VAR2CSA FCR3, sector 5. On the x-axis
is the VAR2CSA sequence position and on the y-axis the z-score normalised average S/N ratio.
Signiﬁcant linear epitopes ɴɱɱɻ-CGSARTMKRGYKNDNYEL-ɴɱɵɸ and ɵɹɺɹ-LEGKPIPNPLL-ɵɹɻɹ
are identiﬁed. The red line signiﬁes Bonferroni-adjusted z-score threshold for signiﬁcance.
supplementary materials.
4.4.3 Identificationofepitopelineardeterminantusingak-merbased
non-parametric approach
Sector 5 contain 1,087 unique FCR3 15-mers. A total of 11,957 k-mers can be
generated of which 2,386 are unique. A z-score is computed for each of the 2,386
unique 5-mers. A total of 2,414 5-mers can be positionally mapped to FCR3.
Counting each unique 5-mer as a test and setting α = 0:05 corresponding to
z1 α = 1:64, yields an adjusted z-score thr shold of z1 α=2;386 = 4:10. It should be
noted that some of the 5-mers are mapped to more than one position. This is
important as the consequence of this is that a given 5-mer may produce a false
positive in an irrelevant part of the protein, simply as an artefact of it being
present in a true positive in a diﬀerent part of the analysed protein. Given this
frame-work, fig. 4.4.3 depict the mapping of the HDMPa sector 5, 5-mer
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Figure 4.4.3: Plot of results from the analysis of VAR2CSA FCR3 epitope scan data from sector
5 of the high density peptide microarray (HDPMa) chip using the k-mer method with k = 5.
The 5-mers mapped was generated from 1,087 unique FCR3 15-mers on the HDPMa chip, for
which S=N > 1:0. A total of 11,957 5-mers were generated, of which 2,386 were unique. For
each VAR2CSA FCR3 position pi, zpi = z(5merpi:::pi+4)jz > 0, i.e. the z-score assigned to
each position corresponds to the z-score of the 5-mer starting at that position, mapping only
k-mers for which the z-score is larger than 0. Here we apply a one-sided test, since we are only
interested in 5-mers with a positive z-score. The red line signiﬁes Bonferroni-adjusted z-score
threshold for signiﬁcance. The adjusted z-score threshold was obtained by counting each
unique 5-mer as a test and then calculating zadj = z1 α=ntests , where α = 0:05. Continuous
stretches of amino acid residues, containing 5-mers for which z > zadj are stated above the
respective peak along with the starting position.
population onto FCR3. Table 4.4.2 summarises the identified epitopes.
4.4.4 Evaluation of validity of normal assumption
Fig. 4.4.4 depict quantile-quantile normal plots for the distributions of A:The
raw signals from all of the 105,141 (3,748 unique) 15-mers and B:The z-scores
derived from analysing 1,156,551 5-mers (3,929 unique).
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Protein Sec zmax k-mermax Start End Sequence
FCR3 5 7.080 KRGYK 1010 1024 SARTMKRGYKNDNYE
FCR3 5 6.920 GKPIP 2671 2689 SGRGELEGKPIPNPLLGLD
FCR3 5 5.803 KDFFE 389 400 DYVKDFFEKLEA
FCR3 5 5.532 EDAKR 866 877 HIEDAKRNRKAG
FCR3 5 4.887 RGWRT 259 267 KRGWRTSGK
FCR3 5 4.389 IHDRM 2358 2363 IHDRMK
FCR3 5 4.233 LKKRY 649 653 LKKRY
Table 4.4.2: FCR3 mapping of 5-mer population. The 5-mers mapped was generated from
1,087 unique FCR3 15-mers from sector 5 on the HDPMa chip. A total of 11,957 5-mers were
generated, of which 2,386 are unique.
A
ll
l
l
l
ll
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l l
l
l l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l l
l
ll l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l ll ll
−4 −2 0 2 4
0
1
2
3
4
5
6
7
Theoretical Quantiles
Sa
m
pl
e 
Qu
an
tile
s
PCC = 0.66
B
l
l
ll
l
lll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
−2 0 2
−
20
−
10
0
10
20
30
Theoretical Quantiles
Sa
m
pl
e 
Qu
an
tile
s
PCC = 0.968
Figure 4.4.4: Quantile-quantile normal plot of A: raw signal distribution and B: k-mer based
z-score distribution.
4.5 Discussion
The peptide SCGSARTMKRGYKNDNYELCKYC or parts of it, was identified in FCR3
sectors 1,3,4,5,6,7,22,23 and 3D7 sectors 1,3,4,5,6,7,16,18,22,23. As the peptide
was observed to elicit a strong response across sectors, it was chosen to as test
peptide and used for immunisation and subsequent quantification of
immunogenicity and blocking capabilities. These studies were performed by our
experimental collaborator at CMP/KU.The peptide was found to be highly
immunogenic, but not blocking the VAR2CSA:receptor binding.
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Immunodominant epitopes acting as an immunological smoke-screen,
diverting response towards non-inhibiting epitopes.
As previously described, epitopes contain a linear determinant ranging from 4
to 7 consecutive amino acid residues. Therefore given a 15-mer with a high
signal, it is likely that the signal originates from e.g. 5 consecutive residues, but
exactly which 5 residues are responsible for the signal, remains diﬃcult to elude.
The second method described attempts to address this by subdividing each
15-mer into k-mers and then assigning the 15-mer signal to each k-mer. This way
if a given k-mer is consistently associated with a high signal, thusly constituting a
’driver-motif ’, it should be identifiable on the other hand if a given k-mer is found
only as a ’passenger-motif ’, it should also be found in 15-mers with low signal
reducing the final rank placement.
The initial method of direct mapping does not take this driver/passenger-motif
concept into account, furthermore the risk of quenching information is present.
The risk of information quenching arises, because we initially to any non-unique
15-mers assign the mean of the recorded S/N and subsequently each pi in the
reference sequence is assigned the mean of the observed signals. Lastly the
normal assumption is not a good fit as fig. 4.4.4A clearly illustrates.
The decision of excluding all 15-mers for which S=n  1:0 is substantiated by
the fact that zmax for the V5 tag GKPIPNPLLGLDST is lowered from
z(ɵɹɺɴ-SGRGELEGKPIPNPLLGLD-ɵɹɻɼ) = 6:920 to
z(ɵɹɺɷ-GELEGKPIPNPLLGLDST-ɵɹɼɴ) = 6:341 if all 15-mers are included in the
evaluation. The 5-mer with the highest z-score (underlined) does not change.
zmax for the top-ranking peptide, i.e. the one used for experimental immunisation,
is likewise lowered from z(ɴɱɴɱ-SARTMKRGYKNDNYE-ɴɱɵɷ) = 7:080 to
z(ɴɱɱɻ-CGSARTMKRGYKNDN-ɴɱɵɵ) = 6:399. Also here the core motif remains
constant.
The concept of driver-passenger motifs in quantitative peptide data is
illustrated in fig. 4.5.1.
The 3 peptides in fig. 4.5.1 overlaps, such that the C-terminus of peptide 1
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Figure 4.5.1: Driver-passenger motif. The C-terminus of peptide 1 overlaps the N-terminus of
peptide 2 and the C-terminus of peptide 2 overlaps the N-terminus of peptide 3 all overlaps
are by 5 residues. The driver-motif is highlighted in red and the passenger-motif is highlighted
in blue. Peptides 1 and 2 have a high signal because of the driver-motif, despite peptide 2
containing the passenger-motif. Peptide 3 has a low signal, containing only the passenger-
motif.
overlaps the N-terminus of peptide 2 and the C-terminus of peptide 2 overlaps
the N-terminus of peptide 3, where all overlaps are by 5 residues. The
driver-motif is highlighted in red and the passenger motif is highlighted in blue.
Peptides 1 and 2 have a high signal because of the driver-motif, despite peptide 2
containing the passenger-motif. Peptide 3 has a low signal, containing only the
passenger-motif. The idea of the k-mer approach is that dividing the 15-mers into
k-mers, we are able to separate the driver-motif from the passenger-motif and
thereby the driver-motif will rank better and the passenger-motif worse, within
the final test framework.
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Part V
Thesis Recapitulation
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The oﬀset of the work presented in this thesis was to aid traditional wet-lab
experiments, with in silico tools for sequence analysis aiming at elucidating the
surface variation of VAR2CSA. Moreover: ”The development and application of
computational tools aiming at obtaining a better understanding of how VAR2CSA
sequence variation aﬀects immunogenicity and capability to induce parasite adhesion
blocking antibodies. The ultimate goal being able to produce a vaccine, which can be
used to protect pregnant women against Placental Malaria.”
The results presented in this thesis demonstrate how computational
approaches can be applied for linear b-cell epitope discovery and how VAR2CSA
phenotypes can be correlated with specific immunogenic sequence motifs.
Furthermore use-ready in silico tools, which hopefully in the future, can bring us
closer to a PM vaccine, are described.
Part IIa: By algebraic analysis of the intrinsic properties of the SigniSite
framework, we have demonstrated how it is possible to reduce the total number
of tests performed in a system prior to analysis. The impact of this on the
sensitivity of the SigniSite framework, i.e. the ability to detect subtle association
was however limited. The reason for this is suggested to be due to the
non-linearity of the correcting for multiple testing, by dividing the level of
significance with the number of tests performed, the function become of type
f(x) = ax , which asymptotically approach zero as x increases. Therefore once
above a certain number of tests, there is not much diﬀerence in the adjusted
threshold, e.g. going from 1 to 10 tests, the increase in threshold i of a factor 1:78,
whereas going from 10 tests to 1,000 tests, the increase is of a factor 1:16.
Part IIb:We analysed 415MSAs containing from 20 to 43 HLA-A/B
sequences, each with an associated binding aﬃnity to the same peptide within
eachMSA and compared the prediction values from the Shannon entropy and
the absolute sum of the positional SigniSite z-scores across all 415MSAs, thereby
conducting a meta analysis. In doing so, we found that the two scoring methods
were in agreement regarding the ranks of which positions were important in
relation toMHC:peptide binding SCC = 0:996. We further noted that positions
in the pseudo-sequence, were distributed throughout the ranks and thusly
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surpassed in rank by positions not in the pseudo-sequence. Visual analysis of
top-ranking positions mapped onto HLA-A*02:01 furthermore revealed that the
top-ranking positions contained amino acid residues, with side-chains
protruding into theMHC-I binding groove. Based on these finding, it is
proposed to take a closer look at theMHCI pseudo-sequence to see if prediction
performance of existingMHCI:peptide predictors can be improved using these
top-ranked positions.
Part III: Applying SigniSite for the analysis of 70 VAR2CSA-DBL5ε sequences,
we found the motif ’TFKNI’ to be significantly associated with the birth weight of
the newborn. The increased birth weight can be linked to the acquired immunity,
as the initial response, will be directed against the VAR2CSAmotif, with the
greatest capability of inducing a response. Upon following infections, this motif
will be recognised and the IE prevented from cyto-adherence. This will give rise
to less immunogenic motifs. It has been proposed that the parasite is able of
antigenic switching and thusly express not-recognisable motifs. Obtaining a
deeper understanding of these mechanisms is crucial in the continuing search for
a PM vaccine.
Part IV:Using the HDPMa chip technology for scanning VAR2CSA for linear
b-cell epitopes revealed the peptide SCGSARTMKRGYKNDNYELCKYC or parts of it as
eliciting a significant signal. Based on this, the peptide was used for
immunisation and subsequent quantification of immunigenicity. The peptide was
found to be highly immunogenic, but unfortunately the antibodies it induced
were not capable of blocking the VAR2CSA:receptor interaktion. This is however
not surprising, as it is well known that VAR2CSA contain immunodominant
epitopes, against which the humane immune response is diverted, the so called
immunological ’smoke-screen’. This ensures that the parasite inside the IE retains
the cyte-adherence capabilities. In analysing the HDPMa chip data, twomethods
were applied. Both methods were in agreement with the findings regarding the
before mentioned peptide. However inspecting and comparing epitope plots
(see supplementary materials) it seems that the k-mer approach is capable of
finding epitopes with a more subtle signal. Based on this and the fact that the
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HDPMa chip technology has progressed since this study was conducted, it is
proposed to run a new chip and apply the k-mermethod and then subsequently
look for epitopes inducing VAR2CSA:receptor blocking antibodies. The fact that
immunity toward PM is gradually acquired demonstrate that such epitopes does
exist. The question regarding this however remains if the linear determinant of
the epitope is adequate in inducing antibodies or if the contact-points somehow
need to be seen in order to generate a broadly blocking response.
As concluding remark, I would like to stress the importance of continuing the
development of methods capable of making genotype-phenotype correlations.
Especially in the light of the development of sequencing methods. A sequence
without a phenotype really is not that interesting, it is not until we get the
phenotype that we are really able to decode the system. However the vast
amounts of data being generated poses a challenge in that, as previously
mentioned, given enough data, any diﬀerence can be significant, no matter how
small it may be. Given the increase in the amount of data, we are going from,
what has been referred to as ’p-value hacking’ because of small data sets, to a
situation, where experimentally based research institutions generate much more
data, than they are capable of analysing and the challenge become how to
distinguish the ’true’ findings from the findings, which arises as a function of the
data size, rather than actual biological significance.
Leon Eyrich Jessen
April 2014
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THE SIGNISITE METHOD
The initial step of SigniSite is to check if the submitted set
of sequences is aligned. This is done by checking the length
of each sequence. If not all sequences are of the same length,
i.e. not aligned, a multiple sequence alignment (MSA) will
be created using MAFFT with accurate options (’mafft-einsi’)
(1).
To perform the SigniSite analysis, each sequence must have
an associated real number, quantifying the phenotype of the
dataset. The sequence associated real number must be placed,
white-space separated, at the end of each FASTA header in
the MSA. If this is not the case, SigniSite will assume that
the submitted sequences are pre-sorted with respect to some
desired phenotype (The web-server will alert the user if pre-
sorting is assumed). The values can be sorted either ascending
or descending (default). If using ascending sorting, the lowest
value(s), is considered the strongest, e.g. binding affinity. If
using descending sorting, the highest value(s), is considered
the strongest, e.g. fluorescent label intensity. SigniSite utilises
a non-parametric approach for the analysis, in that SigniSite
will perform the analysis based on the ranks of the sequence
associated real numbers, rather than the values of these. In
the following the details of the SigniSite method will be
elaborated.
Rank matrix generation
The first step of the SigniSite method is to sort the submitted
MSA with respect to the sequence-associated real values.
Let N , (N≥2) be the number of sequences in the MSA
and np,a,
(
1≤np,a<N
)
be the number of a specific amino
acid type a observed at a specific position p in the MSA.
Henceforth subscript ’p,a’ will denote amino acid residue type
a at position p in the MSA. Initially the sequences in the MSA
are sorted descending on their associated real numbers. We
can now assign a rank value to each sequence, so that the
first sequence gets a rank of one, the second a rank of two,
etc. In case two or more sequences share the same annotated
real number value, the sequences are assigned the mean of
the ranks they occupy. Each type of amino acid residue a
observed at position p is subsequently assigned the rank of
the sequence they appear in. Given these rank values, we can
for each position p in the MSA and for each type of amino
acid residue a observed at p calculate an observed mean rank
value as:
xobsp,a=
1
np,a
N∑
i=1
rankp,bi ·δ(bi,a) (1)
where the sum is over all sequences in the MSA and bi
is the amino acid at position p in the i′th sequence in
the MSA, such that δ(bi,a)=1 if bi=a and bi,a=0 if
bi 6=a. The result of this is a mxnaa rank matrix, R, where
the number of rows, m, is the number of positions in the
MSA and the number of columns, naa=20, corresponds
to the 20 proteogenic amino acids, sorted according to
’A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V’.
Each position in R, ri,j , 1≤ i≤m, 1≤j≤naa hold the mean
of the assigned ranks for amino acid residue a at position p.
Please note that since each sequence as prerequisite has one
sequence associated value, each sequence, and subsequently
each amino acid at each position, has an assigned rank. The
number of sequences, sequence associated values and ranks
are thus all equal to N .
The statistical framework of SigniSite, z-score calculation
The statistical framework of SigniSite, is such that the
null-hypothesis for the non-parametric statistical test that is
performed by SigniSite is: H0: Amino acid residue a at
position p has no preference for ’strong’ or ’weak’ phenotypic
values and the alternative hypothesis is: H1: Amino acid
residue a at position p has a significant preference for either
’strong’ or ’weak’ phenotypic values, (two-tailed test) i.e.:
H0 : µ
exp
p,a =x
obs
p,a H1 : µ
exp
p,a 6=xobsp,a (2)
Where µexpp,a is the expected mean of the ranks and xobsp,a is
the observed mean rank. Under the null-hypothesis, we can
then compute a standard score zp,a quantifying the probability
of observing xobsp,a :
zp,a=
µ
exp
p,a −xobsp,a
σ
exp
p,a
(3)
where σexpp,a , σ
exp
p,a >0 is the standard deviation of the mean
expected rank given the composition of amino acid residues
c© 2013 The Author(s)
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at the position in question. Based on the magnitude of the
zp,a, we can then compare with the level of significance and
subsequently either reject or accept the null-hypothesis.
µ
exp
p,a and σ
exp
p,a could be computed by reshuffling
(permuting) the residues present at a given position p a large
number of times. For larger data sets, this approach however
becomes computationally unfeasible. The values are therefore
more efficiently estimated using an analytical approximation.
The statistical evaluation performed by SigniSite is similar
to the Wilcoxon rank statistic (2), and we can therefore
analytically derive approximations for µexpp,a and σ
exp
p,a . For
µexpp,a this yields:
µexpp,a =
N+1
2
(4)
recall that N is the number of sequences in the MSA. For
σexpp,a we get:
σexpp,a =
√
(N−np,a)(N+1) ·tc
12 ·np,a (5)
recall that np,a is the number of occurrences of residue
a at position p. If a given position in the MSA is fully
conserved, i.e. np,a=N⇒σexpp,a =0. In this case, the amino
acid a at position p is assigned zp,a=0. tc, 0<tc≤1, is the
tie-correction factor. tc=1⇒ no tied values, tc=0⇒ only
tied values (not allowed, since tc=0⇒σexpp,a =0, for which
zp,a is not defined). The tie-correction factor adjusts for tied
observations and is computed by defining a tie-vector, T,
where each element t1,t2,...,th (h being the number of unique
sequence-associated values) is the count of occurrences of a
given value vi (2). The tie-correction factor tc is defined as:
tc=1− 1
N3−N ·
h∑
i=1
(t3i −ti) (6)
Given a random set of amino acid sequences and
associated numerical values, the distribution of assigned z-
scores at a position Zp can be approximated by the normal
distribution Zp∼N (µ=0,σ2=1), thus allowing straight-
forward assignment of p-values to each of the observations.
The final result is a z-score matrix, with the same
dimensions as the rank matrix.
Correction for Multiple Comparisons
SigniSite will perform one test per residue per position in the
MSA. Clearly, this raises a multiple testing scenario, as the
more hypotheses we test, the higher the chance that we obtain
at least one false positive result. Based on the assigned p-
value, the user can address the multiple testing problem by
two different methods: Bonferroni’s single-step and Holm’s
step-down procedure (3). Bonferroni correction is more
conservative than Holm correction. A detailed elaboration of
these procedures is beyond the scope of this study and the
reader is referred to Dudoit et al., 2002 for details on these
procedures.
Example of calculations
The following is a simple fictive example for illustrating
how to perform an evaluation. In an alignment, at p13, we
observe ’R’ in 5 of 20 sequences. After descending sorting,
’R’ occupies ranks 1,2,5,6,7. We now know the ranks, that
n13,R=5 and that N=20, therefore:
xmean13,R =
1
5
20∑
i=1
rank13,bi ·δ(bi,R)=
1
5
·(1+2+5+6+7)=4.2
σexp13,R=
√
(20−5)(20+1)·1
12 ·5 =2.3
µexp13,R=
20+1
2
=10.5
zp,a=
10.5−4.2
2.3
=2.75
The final z13,R=2.75 corresponds to an uncorrected p-value
of p13,R=0.006. At first this may seem highly signficant, but
if e.g. a total of 50 tests are performed when analysing the
alignment, the Bonferroni corrected p-value becomes:
pBonf.adj =min(1,p·ntests)=min(1,0.006·50)=0.3
Corresponding to zadj=1.04.
BENCHMARK DATASETS
Stanford University HIVdb Genotype-Phenotype Datasets
Human immunodeficiency virus type 1 (HIV-1) Protease
Genotype-Phenotype Datasets (GPDs) (Version 5.0, March,
2012) were downloaded from the Stanford University HIV
Drug Resistance Database (HIVdb) (4, 5), available at
[http://HIVdb.stanford.edu/cgi-bin/GenoPhenoDS.cgi]. The
GPDs consist of sequenced variants of the HIV-1 protease,
where the fold-change in resistance of each variant (compared
to wild-type) against 8 different Protease Inhibitors (PIs),
namely APV, ATV, IDV, LPV, NFV, RTV, SQV, TPV (See
section ”Overview of HIV-1 PIs” for details) has been
measured using 3 different assays (’Antivirogram’ (VircoTM),
’PhenoSense’ (ViroLogicTM) and ’All Others’).
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Compilation of HIVdb multiple sequence alignments
Multiple sequence alignments (MSAs) were compiled from
the GPDs. Each MSA contains the sequences of a set of
HIV-1 protease variants, each with measured fold change
in resistance (compared to wild-type) towards the same
PI, measured using the same assay. The sequences were
filtered such that any sequences containing: ’no sequence’ (.),
’insertions’ (#), ’deletions’ (∼), ’stop codon’ (*) or ’unknown
amino acid residue’ (X) (according to HIVdb nomenclature)
were excluded. We noted that these exclusions reduced the
size of the data, we however deemed high-confidence data to
be the more important parameter. At positions where HIVdb
states that two or more residues were observed (i.e. a mixture)
a random of the observed residues was selected, such that
only one sequence per sequence id was constructed (see
section: ”The impact of chosen seed for random number
generation” for details). It should be noted that the choice
only to construct one sequence per sequence id, was deliberate
due to combinatorics. The HIV-1 protease consists of 99
residues, if just 5 positions held a mixture of 3 residues
the outcome of all combinations would be 243 sequences,
thus greatly skewing the MSA towards this/these variants.
The assayed PIs listed in the GPDs were cross-referenced
with those in the information in table of Resistance Mutation
Scores (RMS), and the intersection of PIs available for
analysis and comparison was: ATV, IDV, LPV, NFV, SQV and
TPV each of which was measured using the ’Antivirogram’
(VircoTM), ’PhenoSense’ (ViroLogicTM) and ’All Others’
types of assays. A total of 12,714 sequence distributed on
18 multiple sequence alignments (MSAs) were compiled this
way (6 PIs times 3 assays) (see Table 1).
Observed discrepancies in the HIVdb
We noted that in the GPD ’Antivirogram’, the sequence id
’159250’ contained a lowercase ’i’ in the ’P32’ column and
in the GPD ’PhenoSense’ the sequence id ’45124’ contained a
’,’ in the ’IsolateName’ column.
RMS: HIVdb Resistance Mutation Scores
The RMS table was downloaded from
the HIVdb PI Resistance Notes (4, 5),
Table 1. Summary of the number of sequences in each of the 18 multiple
sequence alignments (MSAs) used in the benchmark of SigniSite. One MSA
was compiled for each set of HIV-1 protease sequences with a fold change in
resistance (compared to wild-type) against the same Protease Inhibitor (PI),
measured using the same assay.
Assay PhenoSense Antivirogram All Others
PI ViroLogicTM VircoTM
ATV 812 670 37
IDV 1,322 1,072 235
LPV 1,097 962 15
NFV 1,374 1,104 125
SQV 1,339 1,104 242
TPV 559 632 13
Total 6,503 5,544 667
A total of 12,714 sequences were constructed. The length of each of the HIV-1 protease
variants is 99 amino acid residues.
available at [http://HIVdb.stanford.edu/DR/cgi-
bin/rules scores HIVdb.cgi?class=PI]. The RMS table
contains information about positions with known resistance
mutations and their individual impact on the resistance
towards 8 different PIs compared to wild-type. The scores
range from −10 to 60, where a positive score indicates
that this particular mutation away from wild-type increases
the resistance towards a given PI. A negative score in turn
indicates that there is an increase in susceptibility towards the
PI (i.e. decreased resistance). At each position in the table of
RMS harbouring a resistance mutation, the consensus residue
was assigned a RMS of 0.
IAS: International Antiviral Society-USA - Update of the
Drug Resistance Mutations in HIV-1: March 2013
From the International Antiviral Society-USAs (IAS) Update
of the Drug Resistance Mutations in HIV-1: March 2013 (6),
available at [https://www.iasusa.org/sites/default/files/tam/21-
1-6.pdf] protease mutations known to impact PI resistance
were retrieved. The annotations are given in the table:
”Mutations in the protease gene associated with resistance
to protease inhibitors”. We assigned scores such that the
residue at a given position, annotated as a resistance mutation
compared to wild-type was assigned an IAS score of ’1’. As
with the RMS, the consensus residue at annotated resistance
positions was assigned an IAS score of 0. It should be noted
that the IAS scores, unlike the fold-values of the RMS, are
binary.
RMS and IAS tables versions used in the benchmarking
RMSbin: Creating the binary RMS table. The RMS
downloaded from the HIVdb contained real number scores.
In order to transform this table to a binary table (RMSbin)
containing actual positives (APs) and actual negatives (ANs),
table scores were assigned as follows: AP :Srms>0⇒
Srmsbin=1 and AN :Srms≤0⇒Srmsbin=0.
(RMS+IAS)mut: Enriching the binary RMS table with
the IAS table. In order to create the enriched consensus
table of RMSbin and IAS. Scores were assigned as
follows: AP :Srmsbin>0 or Sias>0⇒S(rms+ias)mut=1.
Otherwise AN :S(rms+ias)mut=0.
(RMS+IAS)pos: Positional targets for SigniSite and
SPEER comparison. Positional targets were created by
looking at each position annotated in the (RMS+IAS)mut
and then assigning AP :S(rms+ias)pos=1 if at least
one score S(rms+ias)mut=1 was found. Otherwise
AN :S(rms+ias)pos=0.
The SPEER program and SDP benchmark data
The SPEER program (Specificity Prediction using amino
acids’ properties, Entropy and Evolution Rate) (7, 8)
was downloaded along with MSAs and corresponding
experimentally annotated specificity determining
sites SDS) from the SPEER repository available at:
[ftp://ftp.ncbi.nih.gov/pub/SPEER/]. We downloaded the
latest curated version of the data as described by Chakrabarti
and Panchenko (9) (See (9) for detailed description of the
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alignments). A total of 20 MSAs were downloaded, 13 of
which contained only subgroup ’1’ and ’2’ assignment.
BENCHMARK STRATEGY
The strategy for benchmarking SigniSite followed three steps:
i. Threshold dependent performance evaluation, ii. Threshold
independent performance evaluation and iii. Comparison with
existing methods.
i. Threshold dependent benchmarking
SCC
(
zp,a∼RMS
)
: The initial step in the benchmarking of
SigniSite was to use Spearman’s rank correlation (SCC) to
quantify the correlation between the SigniSite z-scores (i.e.
the zp,a’s) obtained from the analysis of the 18 HIV-1
MSAs and the known real-number quantified fold-resistance-
increase scores per mutation, as given in the RMS. If
the SigniSite z-scores correlated with the RMS, this was
an indication that SigniSite was able to identify resistance
(phenotype) impacting mutations (genotype), i.e. perform
Genotype-Phenotype correlation. The SCC was calculated at
three different thresholds for including a given zp,a: i. |zp,a|≥
0∼p-values≤1, ii. |zp,a|≥1.96∼p-values≤0.05 and lastly
iii. |zp,a|≥1.96∼p-values≤0.05 after correction for multiple
comparisons using the Bonferroni Single-Step approach, i.e.
padj=min[1,p·ntests].
[MCC, SENS, SPEC]
(
zp,a∼(RMS+IAS)mut
)
: Next we
calculated the standard performance measures of Sensitivity
(SENS), Specificity (SPEC) and Matthew’s Correlation
Coefficient (MCC) letting the (RMS+IAS)mut define APs
and ANs. These measures were calculated at three different
threshold for assigning significance (Predicted Positives) to
zp,a: i. |zp,a|≥0∼p-values≤1, ii. |zp,a|≥1.96∼p-values≤
0.05 and lastly iii. |zp,a|≥1.96∼p-values≤0.05 after
correction for multiple comparisons using the Bonferroni
Single-Step approach, i.e. padj=min[1,p·ntests].
ii. Threshold independent benchmarking
AUC
(
zp,a∼(RMS+IAS)mut
)
: Having evaluated the
performance of SigniSite using the conventional threshold
dependent approaches of SCC, MCC, SENS and SPEC, we
turned to the threshold independent measure of area under the
receiever operator characteristics (ROC) curve (AUC). Using
the SigniSite z-scores as prediction values and subsequently
calculating the AUC
(
zp,a∼(RMS+IAS)mut
)
.
iii. Comparing SigniSite to existing methods
Having evaluated SigniSite extensively on the HIVdb data
sets, we turned to comparing SigniSite with a state-of-
the-art SDP method. In a 2009 SDP benchmark review
(9) the SPEER method (7, 8) was identified as the best
performing method. We therefore chose to benchmark
SigniSite against SPEER on both the HIVdb data sets
and SPEER’s native benchmark dataset (SDP), available at
[ftp://ftp.ncbi.nih.gov/pub/SPEER].
Positional versus residue level evaluations. As SPEER makes
only positional predictions, the challenge was to setup the
benchmark in a fair manor, not letting any of the two
methods have an advantage. As SigniSite makes a prediction
per present residue per position, we had to transform this
to a positional score. This transformation was done by
assigning the maximum of the absolute z-scores computed per
position, i.e. zp=max
(|zp,A|,|zp,R|,...,|zp,Y |,|zp,V |). The
(RMS+IAS)pos was used for defining APs and ANs. It should
be noted that SigniSite assigns significance to a site by
evaluating ifmax
(|zp,A|,|zp,R|,...,|zp,Y |,|zp,V |)≥1.96 after
CMT. As this is already build into the method we perceive the
above transformation to be valid.
Scoring all positions versus excluding the unlikely. SigniSite
makes at least one prediction for each position, regardless
of composition, whereas SPEER will skip fully conserved
positions and positons with a gap-frequency larger than
20%. We therefore assigned −100 as SPEER-score to these
positions, as this was a lower score than any of the observed
SPEER-scores.
SPEER requires a pre-classification of subgroups in the MSA.
To make the HIVdb data sets compatible with SPEER, in
that they contain only real-valued sequence-associated values,
we chose to sort the HIVdb sequences descending on their
associated values and subsequently split the sequences into
subgroups ’1’ and ’2’ on the median of these values. If this
yielded a spare sequence (uneven number of values), subgroup
’1’ was assigned to the spare sequence.
SigniSite requires a sequence associated real number. To
make the SDP data sets compatible with SigniSite we chose
only to include 13 of the 20 available MSAs as they included
only subgroups ’1’ and ’2’ assignments. We subsequently
simply assigned the subgroup number as ’real’ value to each
of the sequences.
SigniSite vs. SPEER: Final performance comparison Using
the above framework, we computed the mean(AUC) and
standard error of the mean for two sets of comparisons: i.
SigniSite versus SPEER on the HIVdb data sets (18 MSAs)
and ii. SigniSite versus SPEER on the SDP datasets (13
MSAs).
THE IMPACT OF CHOSEN SEED FOR RANDOM
NUMBER GENERATION
At the download page for the Genotype-Phenotype Datasets
from the HIVdb, it is stated that: ”p1...pn: Two and more
amino acid codes indicates a mixture”. At such positions,
we chose to select a random of the observed amino acid
residues. In doing so, we observed that the seed used to
initialise the pseudo random number generator for making a
random choice of amino acids impacted the performance. In
order not to artificially increase the performance by selecting
the seed, which yielded the best performance, we instead
decided to evaluate the extent of this impact. We constructed
a seed-vector with n=1,000 random integer elements γ∈[−510,510] using perl (v5.12.2) and a seed of -1. Each
element γ1,γ2,...,γn was then used as seed when constructing
the MSA, and the mean(SCC) were recorded as a function
of the random generated seeds. We then identified the seed
4601882967 as yielding a mean(SCC)-performance equal
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to the mean of the different mean(SCC)-performances as
a function of the 1,000 random seeds. Table 2 summarises the
findings.
As seen in Table 2C using a seed of 4601882967 does not
produce results, which are significantly different from the ’true
mean’ as estimated by generating the 1,000 random seeds.
OVERVIEW OF HIV-1 PROTEASE INHIBITORS
Table 3 gives and overview of the protease inhibitors (PIs)
mentioned in the SigniSite paper.
ABBREVIATIONS
Table 4 gives an overview of the abbreviations used in the
SigniSite paper.
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Table 4. Abbriviations used in this paper.
Abbr. Meaning
AA Amino Acid
AN Actual Negative
AP Actual Positive
APV Amprenavir
ATV Atazanavir
AUC Area Under the ROC Curve
CMT Correction for Multiple Testing
DRV Darunavir
FPV Fosamprenavir
GPD Genotype-Phenotype Dataset
HIV Human Immunodeficiency Virus
HIVdb HIV Drug Resistance Database - Stanford University
IAS International Antiviral Society United States of America
IDV Indinavir
LPV Lopinavir
MCC Matthew’s Correlation Coefficient
MSA Multiple Sequence Alignment
NA (data) Not Available
NFV Nelfinavir
PI Protease Inhibitor
ROC Reciever Operator Characteristics
RMS Resistance Mutation Scores
RTV Ritonavir
SENS Sensitivity
SCC Spearman’s rank correlation
SPEC Specificity
SDS Specificity Determining Site
SDP Specificity Determining Prediction
SE Standard Error
SPEER Specificity Prediction using AA properties, Entropy and Evolution Rate
SQV Saquinavir
THR Threshold
TPV Tipranavir
WT Wild-type
5.2 Part III - Paper II: Insight into Antigenic Diversity of
VAR2CSA-DBL5εDomainfromMultiplePlasmodiumfal-
ciparum Placental Isolates
Figure of multiple alignment of parasite isolates VAR2CSADBL5ε sequences.
cDNA from 40 placental parasites isolates (39 placental isolates from Senegal and
one from Tanzania) were amplified, cloned, and sequenced. Sequence ids are
given at the far left. The Tanzanian isolate was isolate 748 (sequences 748_1/2a
and 748_1/2b) corresponding to the DBL5? domain amplified in this isolate.
The remaining sequences correspond to those obtained in isolates from Senegal.
The remaining CYK are Senegalese isolates. The CYK suﬃx corresponds to the
placenta id from which the isolate was extracted. The DBL5ε and ID5 highly
conserved (blue, Shannon entropy 0  H  1), conserved (green,
1 < H < 1:5), and relatively variable (red, 1:5  H  2) blocks, are indicated.
The 15%most variable positions were selected and marked with ’x’.
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5.3 Part IV - Development andApplication of Bioinformat-
icstoolforSignalDetectioninHighThroughput,High
Density PeptideMicroarray
147
5.3.1 Complete Output from the PepChipper-1.0 Server
Plots of VAR2CSA FCR3 epitopes identified using the direct signal
mapping approach
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HeatmapofVAR2CSAFCR3epitopes identifiedusingthedirect signal
mapping approach for pan-sector signal identification
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PlotsofVAR2CSA3D7epitopes identifiedusingthedirect signalmap-
ping approach
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Heatmap of VAR2CSA 3D7 epitopes identified using the direct signal
mapping approach for pan-sector signal identification
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TablesofVAR2CSA3D7epitopes identifiedusingthedirectsignalmap-
ping approach
Protein Sector Start End Avg Z Max Z Sequence
myprot_3D7 1 378 393 9.994 12.425 SRYDDYVKDFFKKLEA
myprot_3D7 1 997 1005 4.99 5.363 RTMKRGYKN
myprot_3D7 2 2263 2276 6.401 8.491 GMDEFKNTFKNIKE
myprot_3D7 3 420 431 6.625 7.873 NSSDANNPSEKI
myprot_3D7 3 995 1004 5.035 5.513 SARTMKRGYK
myprot_3D7 3 2266 2266 4.283 4.283 E
myprot_3D7 3 2268 2268 4.283 4.283 K
myprot_3D7 4 994 1011 9.21 12.464 GSARTMKRGYKNDNYELC
myprot_3D7 4 1038 1044 5.17 5.815 FNLFEQW
myprot_3D7 5 993 1011 10.772 14.521 CGSARTMKRGYKNDNYELC
myprot_3D7 6 862 864 4.416 4.473 NRK
myprot_3D7 6 995 1004 4.927 5.396 SARTMKRGYK
myprot_3D7 6 1286 1295 5.456 6.323 KRYGGRSNIK
myprot_3D7 6 2268 2268 4.732 4.732 K
myprot_3D7 6 2270 2270 4.732 4.732 T
myprot_3D7 7 994 1008 8.419 10.082 GSARTMKRGYKNDNY
myprot_3D7 9 862 866 4.962 5.527 NRKAG
myprot_3D7 9 2668 2669 4.326 4.326 AG
myprot_3D7 10 1597 1611 7.906 9.651 GNDRTWSKKYIKKLE
myprot_3D7 11 1579 1591 5.422 5.977 YEYNNAEKKNNKS
myprot_3D7 12 1573 1587 10.34 14.072 CEQVKYYEYNNAEKK
Table 5.3.1: PepChipper-1.0 epitope list for VAR2CSA 3D7, sectors 1-12
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Protein Sector Start End Avg Z Max Z Sequence
myprot_3D7 14 1689 1703 8.976 11.159 RGSFYDLEDIIKGND
myprot_3D7 14 1734 1734 4.739 4.739 A
myprot_3D7 14 1736 1740 4.83 5.448 TDWWE
myprot_3D7 14 1742 1742 4.654 4.654 E
myprot_3D7 15 863 866 4.729 5.279 RKAG
myprot_3D7 15 2668 2669 5.901 5.901 AG
myprot_3D7 16 998 1003 4.622 4.836 TMKRGY
myprot_3D7 16 1925 1942 8.88 13.341 NSTSGTVNKKLQKKETQC
myprot_3D7 17 860 866 4.683 5.151 KRNRKAG
myprot_3D7 18 853 858 4.441 4.585 SKYIED
myprot_3D7 18 860 866 4.617 5.007 KRNRKAG
myprot_3D7 18 994 1001 4.726 4.958 GSARTMKR
myprot_3D7 19 863 867 5.173 5.488 RKAGT
myprot_3D7 20 385 392 5.947 7.279 KDFFKKLE
myprot_3D7 20 695 709 7.893 11.475 GKLFRKYIKKNNTAE
myprot_3D7 21 862 866 5.212 6.145 NRKAG
myprot_3D7 21 2046 2046 4.289 4.289 V
myprot_3D7 21 2048 2052 4.604 4.883 IPPRR
myprot_3D7 21 2668 2669 4.929 4.929 AG
myprot_3D7 22 998 1005 4.968 5.263 TMKRGYKN
myprot_3D7 22 1034 1051 8.763 12.269 DVTFFNLFEQWNKEIQYQ
myprot_3D7 23 993 1008 8.453 10.325 CGSARTMKRGYKNDNY
myprot_3D7 23 1037 1048 5.55 6.653 FFNLFEQWNKEI
myprot_3D7 24 860 862 4.469 4.619 KRN
myprot_3D7 24 864 864 4.282 4.282 K
myprot_3D7 24 2048 2053 4.672 4.93 IPPRRR
myprot_3D7 24 2057 2060 4.327 4.394 FSRI
Table 5.3.2: PepChipper-1.0 epitope list for VAR2CSA 3D7, sectors 13-24
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Tables of VAR2CSA FCR3 epitopes identified using the direct signal
mapping approach
180
Protein Sector Start End Avg Z Max Z Sequence
myprot_FCR3 1 386 402 9.822 12.158 RYDDYVKDFFEKLEANY
myprot_FCR3 1 1013 1018 4.686 4.805 TMKRGY
myprot_FCR3 3 1010 1020 5.121 5.694 SARTMKRGYKN
myprot_FCR3 3 2680 2692 6.252 6.952 PIPNPLLGLDSTR
myprot_FCR3 4 1009 1026 9.182 12.45 GSARTMKRGYKNDNYELC
myprot_FCR3 5 1008 1025 10.212 13.349 CGSARTMKRGYKNDNYEL
myprot_FCR3 5 2676 2686 5.287 6.09 LEGKPIPNPLL
myprot_FCR3 6 1010 1020 5.115 5.683 SARTMKRGYKN
myprot_FCR3 7 1009 1023 7.747 9.287 GSARTMKRGYKNDNY
myprot_FCR3 7 2680 2692 5.798 6.383 PIPNPLLGLDSTR
myprot_FCR3 8 268 273 5.017 5.373 SDRKKN
myprot_FCR3 10 2680 2694 8.064 9.476 PIPNPLLGLDSTRTG
myprot_FCR3 11 1954 1973 9.872 14.446 CEEEKGPLDLMNEVLNKMDK
myprot_FCR3 13 1953 1967 11.162 13.205 ECEEEKGPLDLMNEV
myprot_FCR3 14 1715 1726 5.381 5.88 SFYDLEDIIKGN
myprot_FCR3 14 1787 1802 9.273 10.774 SGVRYAVEEKNENFPL
myprot_FCR3 15 1691 1706 9.285 10.534 WKQYNPTGKGIDDANK
myprot_FCR3 16 1938 1954 9.931 11.824 TTSGTVNKKLQKKETEC
myprot_FCR3 17 1954 1968 6.845 7.925 CEEEKGPLDLMNEVL
myprot_FCR3 18 651 664 6.313 7.618 KRYPQNKNSGNKEN
myprot_FCR3 18 1958 1970 7.09 7.842 KGPLDLMNEVLNK
myprot_FCR3 19 2681 2681 4.453 4.453 I
myprot_FCR3 19 2684 2688 4.445 4.531 PLLGL
myprot_FCR3 20 388 403 10.39 13.021 DDYVKDFFEKLEANYS
myprot_FCR3 21 1957 1970 7.198 8.29 EKGPLDLMNEVLNK
myprot_FCR3 21 2681 2689 4.455 4.682 IPNPLLGLD
myprot_FCR3 22 388 402 6.775 8.41 DDYVKDFFEKLEANY
myprot_FCR3 22 1014 1017 4.399 4.432 MKRG
myprot_FCR3 22 1051 1064 7.075 8.33 TFFNLFEQWNKEIQ
myprot_FCR3 23 261 272 6.254 7.303 GWRTSGKSDRKK
myprot_FCR3 23 1009 1023 7.329 8.704 GSARTMKRGYKNDNY
myprot_FCR3 23 1054 1060 4.601 4.656 NLFEQWN
myprot_FCR3 24 2061 2065 4.488 4.613 PPRRR
Table 5.3.3: PepChipper-1.0 epitope list for VAR2CSA FCR3
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5.3.2 K-mer plots for FCR3 and 3D7
Plots of VAR2CSA FCR3 epitopes identified using the k-mer approach
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Plots of VAR2CSA 3D7 epitopes identified using the k-mer approach
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Tables ofVAR2CSAFCR3 epitopes identifiedusing thek-merapproach
Sector max(z) max(k-mer) Start End Epitope
1 7.819 VKDFF 386 400 RYDDYVKDFFEKLEA
1 6.909 TMKRG 1008 1024 CGSARTMKRGYKNDNYE
2 5.100 GKSDR 265 271 SGKSDRK
2 4.719 KNLKK 645 653 EGKNLKKRY
2 4.470 EDAKR 868 874 EDAKRNR
2 4.389 YKNIH 2355 2362 YKNIHDRM
2 4.331 RGWRT 260 265 RGWRTS
3 6.142 GWRTS 257 270 LIKRGWRTSGKSDR
3 5.991 MKRGY 1009 1020 GSARTMKRGYKN
3 5.486 LIPPR 2384 2391 GVLIPPRR
3 5.486 LIPPR 2057 2065 GVLIPPRRR
3 5.250 TISKR 2262 2270 QWETISKRY
3 4.876 PNPLL 2681 2689 IPNPLLGLD
3 4.774 EDAKR 867 875 IEDAKRNRK
3 4.383 LKKRY 649 653 LKKRY
3 4.334 IHDRM 2358 2364 IHDRMKK
3 4.160 NYNKF 1138 1143 NYNKFR
3 4.150 SKRWD 853 857 SKRWD
4 7.417 KRGYK 1010 1025 SARTMKRGYKNDNYEL
4 4.951 IGGVG 1411 1420 KIGGVGSSTE
4 4.664 NLFEQ 1054 1061 NLFEQWNK
4 4.607 RTSGK 261 268 GWRTSGKS
4 4.361 GVLIP 2384 2389 GVLIPP
4 4.361 GVLIP 2057 2062 GVLIPP
5 7.080 KRGYK 1010 1024 SARTMKRGYKNDNYE
5 6.920 GKPIP 2671 2689 SGRGELEGKPIPNPLLGLD
5 5.803 KDFFE 389 400 DYVKDFFEKLEA
5 5.532 EDAKR 866 877 HIEDAKRNRKAG
5 4.887 RGWRT 259 267 KRGWRTSGK
5 4.389 IHDRM 2358 2363 IHDRMK
5 4.233 LKKRY 649 653 LKKRY
Table 5.3.4: K-mer mapping of VAR2CSA FCR3 epitopes identiﬁed using the HDPMa chip.
Sectors 1-5. Absent sectors imply no epitopes were found.
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Tables of VAR2CSA 3D7 epitopes identified using the k-mer approach
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Sector max(z) max(k-mer) Start End Epitope
6 5.538 MKRGY 1011 1020 ARTMKRGYKN
6 4.797 LIPPR 2384 2391 GVLIPPRR
6 4.797 LIPPR 2057 2067 GVLIPPRRRQL
6 4.660 EDAKR 867 876 IEDAKRNRKA
6 4.508 GWRTS 260 266 RGWRTSG
6 4.218 TISKR 2265 2269 TISKR
7 7.260 TMKRG 1008 1024 CGSARTMKRGYKNDNYE
7 6.227 PNPLL 2679 2690 KPIPNPLLGLDS
7 4.255 LIPPR 2386 2390 LIPPR
7 4.255 LIPPR 2059 2063 LIPPR
7 4.168 SGQGD 1512 1516 SGQGD
8 5.573 LIPPR 2384 2391 GVLIPPRR
8 5.573 LIPPR 2053 2073 NKHKGVLIPPRRRQLCFSRIV
8 5.085 KAYGG 2429 2435 KKAYGGA
8 4.735 KRSIQ 2254 2266 EWSRKRSIQWETI
8 4.301 GSART 1009 1015 GSARTMK
8 4.198 TSGKS 264 268 TSGKS
8 4.163 EDAKR 868 873 EDAKRN
9 4.807 KFRSK 1139 1145 YNKFRSK
9 4.725 RTSGK 262 270 WRTSGKSDR
9 4.577 SIQWE 2260 2267 SIQWETIS
9 4.386 VLIPP 2385 2391 VLIPPRR
9 4.386 VLIPP 2058 2064 VLIPPRR
9 4.195 KNLKK 647 651 KNLKK
10 5.997 PLLGL 2680 2692 PIPNPLLGLDSTR
10 5.424 PPRRR 2056 2071 KGVLIPPRRRQLCFSR
10 5.287 RGWRT 258 271 IKRGWRTSGKSDRK
10 5.287 ARTMK 1010 1018 SARTMKRGY
10 5.022 GVLIP 2384 2391 GVLIPPRR
10 4.637 NIHDR 2357 2361 NIHDR
10 4.512 NLKKR 647 652 KNLKKR
10 4.351 EDAKR 868 873 EDAKRN
10 4.139 GARAK 2434 2438 GARAK
10 4.117 KSNKE 1890 1895 KSNKES
Table 5.3.5: K-mer mapping of VAR2CSA FCR3 epitopes identiﬁed using the HDPMa chip.
Sectors 6-10. Absent sectors imply no epitopes were found.
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Sector max(z) max(k-mer) Start End Epitope
11 6.275 DLMNE 1955 1969 EEEKGPLDLMNEVLN
11 5.254 YNNAE 1604 1612 KYNNAEKKN
11 4.407 GWRTS 261 266 GWRTSG
11 4.260 KNIHD 2356 2362 KNIHDRM
11 4.257 NAEKK 1218 1222 NAEKK
11 4.256 IPPRR 2060 2064 IPPRR
11 4.182 GVLIP 2384 2388 GVLIP
11 4.182 GVLIP 2057 2061 GVLIP
12 5.132 GSART 1008 1019 CGSARTMKRGYK
12 5.121 PLLGL 2680 2689 PIPNPLLGLD
12 4.693 TISKR 2264 2271 ETISKRYK
12 4.479 NIHDR 2357 2361 NIHDR
12 4.270 GWRTS 261 268 GWRTSGKS
12 4.218 NLKKR 648 652 NLKKR
12 4.180 EDAKR 868 872 EDAKR
13 7.491 LDLMN 1952 1971 TECEEEKGPLDLMNEVLNKM
13 4.346 GWRTS 261 265 GWRTS
13 4.182 TSGKS 264 268 TSGKS
14 5.616 YAVEE 1789 1800 VRYAVEEKNENF
14 5.494 DLMNE 1959 1968 GPLDLMNEVL
14 5.412 RTDWW 1758 1768 ARTDWWENETI
14 5.264 FYDLE 1715 1724 SFYDLEDIIK
14 4.986 DANKK 1701 1707 IDDANKK
14 4.504 GWRTS 261 265 GWRTS
14 4.230 YVPPR 1644 1648 YVPPR
15 5.563 TGKGI 1693 1703 QYNPTGKGIDD
16 6.192 TMKRG 1008 1022 CGSARTMKRGYKNDN
16 5.514 KKLQK 1941 1952 GTVNKKLQKKET
16 4.875 NIHDR 2356 2362 KNIHDRM
16 4.795 GWRTS 261 267 GWRTSGK
16 4.589 GVLIP 2384 2389 GVLIPP
16 4.589 GVLIP 2057 2062 GVLIPP
16 4.223 PLDLM 1960 1964 PLDLM
16 4.223 EEKGP 1956 1960 EEKGP
Table 5.3.6: K-mer mapping of VAR2CSA FCR3 epitopes identiﬁed using the HDPMa chip.
Sectors 11-16. Absent sectors imply no epitopes were found.
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Sector max(z) max(k-mer) Start End Epitope
17 5.641 GPLDL 1956 1969 EEKGPLDLMNEVLN
17 4.883 RTMKR 1011 1017 ARTMKRG
17 4.536 GWRTS 261 266 GWRTSG
17 4.507 EDIIK 2125 2130 EDIIKG
17 4.507 EDIIK 1720 1725 EDIIKG
18 5.936 PQNKN 649 664 LKKRYPQNKNSGNKEN
18 5.580 LDLMN 1957 1970 EKGPLDLMNEVLNK
18 5.017 RGWRT 257 269 LIKRGWRTSGKSD
20 8.627 FEKLE 388 404 DDYVKDFFEKLEANYSS
20 5.428 NLKFD 128 139 TYNLENLKFDKI
21 6.154 PLDLM 1955 1968 EEEKGPLDLMNEVL
21 4.633 NLKKR 647 652 KNLKKR
21 4.349 PNPLL 2681 2686 IPNPLL
21 4.193 PPRRR 2061 2065 PPRRR
22 6.038 KDFFE 389 400 DYVKDFFEKLEA
22 5.770 NLFEQ 1049 1063 DVTFFNLFEQWNKEI
22 5.162 KYKDL 366 374 NKYKDLYEQ
22 5.002 YYKYN 1600 1608 VKYYKYNNA
22 4.650 MKRGY 1011 1019 ARTMKRGYK
23 6.589 MKRGY 1008 1023 CGSARTMKRGYKNDNY
23 6.044 SGKSD 261 273 GWRTSGKSDRKKN
23 5.697 NLFEQ 1051 1062 TFFNLFEQWNKE
23 5.425 YEQNK 368 379 YKDLYEQNKNKT
23 4.945 KPIPN 2678 2684 GKPIPNP
23 4.625 DDYVK 388 395 DDYVKDFF
23 4.372 KKRYP 650 654 KKRYP
Table 5.3.7: K-mer mapping of VAR2CSA FCR3 epitopes identiﬁed using the HDPMa chip.
Sectors 17-23. Absent sectors imply no epitopes were found.
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Sector max(z) max(k-mer) Start End Epitope
24 6.048 IPPRR 2384 2391 GVLIPPRR
24 6.048 IPPRR 2056 2076 KGVLIPPRRRQLCFSRIVRGP
24 5.305 ARTMK 1009 1018 GSARTMKRGY
24 5.288 KRNRK 867 878 IEDAKRNRKAGT
24 4.962 RGWRT 257 271 LIKRGWRTSGKSDRK
24 4.889 YNKFR 1137 1147 DNYNKFRSKQI
24 4.850 NLKKR 647 655 KNLKKRYPQ
24 4.843 RYKKY 2263 2275 WETISKRYKKYKR
24 4.692 HDRMK 2358 2364 IHDRMKK
24 4.655 GACKR 1519 1528 QGACKRKCEK
24 4.436 GGARA 2428 2438 LKKAYGGARAK
Table 5.3.8: K-mer mapping of VAR2CSA FCR3 epitopes identiﬁed using the HDPMa chip.
Sector 24. Absent sectors imply no epitopes were found.
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Sector max(z) max(k-mer) Start End Epitope
1 6.066 DDYVK 378 391 SRYDDYVKDFFKKL
1 4.140 GYKND 1002 1007 GYKNDN
2 5.040 EDAKR 853 863 SKYIEDAKRNR
2 4.657 RGWRT 252 261 KRGWRTSGKS
2 4.139 KNTFK 2268 2273 KNTFKN
2 4.139 EFKNT 2266 2270 EFKNT
2 4.062 FQRKQ 1127 1131 FQRKQ
3 4.341 GVLIP 2045 2049 GVLIP
3 4.240 ARTMK 996 1000 ARTMK
3 4.128 LIPPR 2047 2051 LIPPR
4 5.435 MKRGY 997 1005 RTMKRGYKN
4 4.967 NLFEQ 1037 1045 FFNLFEQWN
5 5.426 MKRGY 994 1005 GSARTMKRGYKN
5 4.419 DDYVK 381 386 DDYVKD
5 4.189 KRNRK 860 864 KRNRK
6 4.239 MKRGY 999 1005 MKRGYKN
7 5.590 MKRGY 995 1009 SARTMKRGYKNDNYE
7 4.728 IKRGW 249 259 LLIKRGWRTSG
8 4.415 LIPPR 2046 2053 VLIPPRRR
8 4.319 NKFQR 1124 1130 YNKFQRK
9 4.513 GAGAG 7 12 GAGAGA
9 4.513 GAGAG 2663 2668 GAGAGA
9 4.513 GAGAG 2657 2662 GAGAGA
9 4.513 GAGAG 1 6 GAGAGA
12 4.684 RNRKA 859 867 AKRNRKAGT
13 6.157 AGAGA 7 12 GAGAGA
13 6.157 AGAGA 2663 2668 GAGAGA
13 6.157 AGAGA 2657 2662 GAGAGA
13 6.157 AGAGA 1 6 GAGAGA
13 4.611 NHSDS 71 75 NHSDS
16 4.305 LIPPR 2047 2051 LIPPR
16 4.305 GVLIP 2045 2049 GVLIP
16 4.074 MKRGY 999 1003 MKRGY
17 4.367 EDAKR 855 865 YIEDAKRNRKA
18 4.202 SARTM 995 1001 SARTMKR
18 4.138 EDAKR 857 861 EDAKR
Table 5.3.9: K-mer mapping of VAR2CSA 3D7 epitopes identiﬁed using the HDPMa chip.
Sectors 1-18. Absent sectors imply no epitopes were found.
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Sector max(z) max(k-mer) Start End Epitope
20 6.462 KDFFK 381 395 DDYVKDFFKKLEANY
20 5.028 KANKK 470 477 KANKKKVC
20 5.028 GPANL 2063 2071 GPANLRNLK
21 4.684 LIPPR 2046 2056 VLIPPRRRQLC
21 4.356 SARTM 995 1000 SARTMK
21 4.356 CGSAR 993 997 CGSAR
21 4.094 RKAGT 863 867 RKAGT
22 5.075 MKRGY 998 1005 TMKRGYKN
22 4.775 NLFEQ 1037 1047 FFNLFEQWNKE
22 4.637 LQDKY 209 216 KVLQDKYP
23 5.204 MKRGY 996 1005 ARTMKRGYKN
23 4.795 NLFEQ 1037 1047 FFNLFEQWNKE
23 4.086 RKAGT 863 867 RKAGT
Table 5.3.10: K-mer mapping of VAR2CSA 3D7 epitopes identiﬁed using the HDPMa chip.
Sectors 20-23. Absent sectors imply no epitopes were found.
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5.3.3 FCR3 and 3D7 sequences
>VARɵCSA_FCRɶ ɵɺɴɸ residues
GAGAGAGAGAGAGAGGYLLEFMDSTSTIANKIEEYLGAKSDDSKIDELLKADPSEVEYYRSGGDGDYLKNNICKITVNHS
DSGKYDPCEKKLPPYDDNDQWKCQQNSSDGSGKPENICVPPRRERLCTYNLENLKFDKIRDNNAFLADVLLTARNEGEKI
VQNHPDTNSSNVCNALERSFADLADIIRGTDQWKGTNSNLEKNLKQMFAKIRENDKVLQDKYPKDQKYTKLREAWWNANR
QKVWEVITCGARSNDLLIKRGWRTSGKSDRKKNFELCRKCGHYEKEVPTKLDYVPQFLRWLTEWIEDFYREKQNLIDDME
RHREECTREDHKSKEGTSYCSTCKDKCKKYCECVKKWKTEWENQENKYKDLYEQNKNKTSQKNTSRYDDYVKDFFEKLEA
NYSSLENYIKGDPYFAEYATKLSFILNPSDANNPSGETANHNDEACNCNESGISSVGQAQTSGPSSNKTCITHSSIKTNK
KKECKDVKLGVRENDKDLKICVIEDTSLSGVDNCCCQDLLGILQENCSDNKRGSSSNDSCDNKNQDECQKKLEKVFASLT
NGYKCDKCKSGTSRSKKKWIWKKSSGNEEGLQEEYANTIGLPPRTQSLYLGNLPKLENVCEDVKDINFDTKEKFLAGCLI
VSFHEGKNLKKRYPQNKNSGNKENLCKALEYSFADYGDLIKGTSIWDNEYTKDLELNLQNNFGKLFGKYIKKNNTAEQDT
SYSSLDELRESWWNTNKKYIWTAMKHGAEMNITTCNADGSVTGSGSSCDDIPTIDLIPQYLRFLQEWVENFCEQRQAKVK
DVITNCKSCKESGNKCKTECKTKCKDECEKYKKFIEACGTAGGGIGTAGSPWSKRWDQIYKRYSKHIEDAKRNRKAGTKN
CGTSSTTNAAASTDENKCVQSDIDSFFKHLIDIGLTTPSSYLSNVLDDNICGADKAPWTTYTTYTTTEKCNKERDKSKSQ
SSDTLVVVNVPSPLGNTPYRYKYACQCKIPTNEETCDDRKEYMNQWSCGSARTMKRGYKNDNYELCKYNGVDVKPTTVRS
NSSKLDGNDVTFFNLFEQWNKEIQYQIEQYMTNANISCIDEKEVLDSVSDEGTPKVRGGYEDGRNNNTDQGTNCKEKCKC
YKLWIEKINDQWGKQKDNYNKFRSKQIYDANKGSQNKKVVSLSNFLFFSCWEEYIQKYFNGDWSKIKNIGSDTFEFLIKK
CGNNSAHGEEIFSEKLKNAEKKCKENESTDTNINKSETSCDLNATNYIRGCQSKTYDGKIFPGKGGEKQWICKDTIIHGD
TNGACIPPRTQNLCVGELWDKSYGGRSNIKNDTKELLKEKIKNAIHKETELLYEYHDTGTAIISKNDKKGQKGKNDPNGL
PKGFCHAVQRSFIDYKNMILGTSVNIYEHIGKLQEDIKKIIEKGTPQQKDKIGGVGSSTENVNAWWKGIEREMWDAVRCA
ITKINKKNNNSIFNGDECGVSPPTGNDEDQSVSWFKEWGEQFCIERLRYEQNIREACTINGKNEKKCINSKSGQGDKIQG
ACKRKCEKYKKYISEKKQEWDKQKTKYENKYVGKSASDLLKENYPECISANFDFIFNDNIEYKTYYPYGDYSSICSCEQV
KYYKYNNAEKKNNKSLCYEKDNDMTWSKKYIKKLENGRSLEGVYVPPRRQQLCLYELFPIIIKNEEGMEKAKEELLETLQ
IVAEREAYYLWKQYNPTGKGIDDANKKACCAIRGSFYDLEDIIKGNDLVHDEYTKYIDSKLNEIFGSSNTNDIDTKRART
DWWENETITNGTDRKTIRQLVWDAMQSGVRYAVEEKNENFPLCMGVEHIGIAKPQFIRWLEEWTNEFCEKYTKYFEDMKS
KCDPPKRADTCGDNSNIECKKACANYTNWLNPKRIEWNGMSNYYNKIYRKSNKESEDGKDYSMIMAPTVIDYLNKRCHGE
INGNYICCSCKNIGAYNTTSGTVNKKLQKKETECEEEKGPLDLMNEVLNKMDKKYSAHKMKCTEVYLEHVEEQLNEIDNA
IKDYKLYPLDRCFDDQTKMKVCDLIADAIGCKDKTKLDELDEWNDMDLRGTYNKHKGVLIPPRRRQLCFSRIVRGPANLR
SLNEFKEEILKGAQSEGKFLGNYYKEHKDKEKALEAMKNSFYDYEDIIKGTDMLTNIEFKDIKIKLDRLLEKETNNTKKA
EDWWKTNKKSIWNAMLCGYKKSGNKIIDPSWCTIPTTETPPQFLRWIKEWGTNVCIQKQEHKEYVKSKCSNVTNLGAQAS
ESNNCTSEIKKYQEWSRKRSIQWETISKRYKKYKRMDILKDVKEPDANTYLREHCSKCPCGFNDMEEMNNNEDNEKEAFK
QIKEQVKIPAELEDVIYRIKHHEYDKGNDYICNKYKNIHDRMKKNNGNFVTDNFVKKSWEISNGVLIPPRRKNLFLYIDP
SKICEYKKDPKLFKDFIYWSAFTEVERLKKAYGGARAKVVHAMKYSFTDIGSIIKGDDMMEKNSSDKIGKILGDTDGQNE
KRKKWWDMNKYHIWESMLCGYREAEGDTETNENCRFPDIESVPQFLRWFQEWSENFCDRRQKLYDKLNSECISAECTNGS
VDNSKCTHACVNYKNYILTKKTEYEIQTNKYDNEFKNKNSNDKDAPDYLKEKCNDNKCECLNKHIDDKNKTWKNPYETLE
DTFKSKCDCPKPLPSPIKPDDLPPQADEPFSGRGELEGKPIPNPLLGLDSTRTGHHHHHHGAGAGAGAGAGAGAG
>VARɵCSA_ɶDɺ ɵɹɺɴ residues
GAGAGAGAGAGAGAGMDKSSIANKIEAYLGAKSDDSKIDQSLKADPSEVQYYGSGGDGYYLRKNICKITVNHSDSGTNDP
CDRIPPPYGDNDQWKCAIILSKVSEKPENVFVPPRRQRMCINNLEKLNVDKIRDKHAFLADVLLTARNEGERIVQNHPDT
NSSNVCNALERSFADIADIIRGTDLWKGTNSNLEQNLKQMFAKIRENDKVLQDKYPKDQNYRKLREDWWNANRQKVWEVI
TCGARSNDLLIKRGWRTSGKSNGDNKLELCRKCGHYEEKVPTKLDYVPQFLRWLTEWIEDFYREKQNLIDDMERHREECT
SEDHKSKEGTSYCSTCKDKCKKYCECVKKWKSEWENQKNKYTELYQQNKNETSQKNTSRYDDYVKDFFKKLEANYSSLEN
YIKGDPYFAEYATKLSFILNSSDANNPSEKIQKNNDEVCNCNESGIASVEQEQISDPSSNKTCITHSSIKANKKKVCKHV
KLGVRENDKDLRVCVIEHTSLSGVENCCCQDFLRILQENCSDNKSGSSSNGSCNNKNQEACEKNLEKVLASLTNCYKCDK
CKSEQSKKNNKNWIWKKSSGKEGGLQKEYANTIGLPPRTQSLCLVVCLDEKGKKTQELKNIRTNSELLKEWIIAAFHEGK
NLKPSHEKKNDDNGKKLCKALEYSFADYGDLIKGTSIWDNEYTKDLELNLQKIFGKLFRKYIKKNNTAEQDTSYSSLDEL
RESWWNTNKKYIWLAMKHGAGMNSTTCCGDGSVTGSGSSCDDIPTIDLIPQYLRFLQEWVEHFCKQRQEKVKPVIENCKS
CKESGGTCNGECKTECKNKCEVYKKFIEDCKGGDGTAGSSWVKRWDQIYKRYSKYIEDAKRNRKAGTKNCGPSSTTNAAE
NKCVQSDIDSFFKHLIDIGLTTPSSYLSIVLDDNICGADKAPWTTYTTYTTTEKCNKETDKSKLQQCNTAVVVNVPSPLG
NTPHGYKYACQCKIPTNEETCDDRKEYMNQWSCGSARTMKRGYKNDNYELCKYNGVDVKPTTVRSNSSKLDDKDVTFFNL
FEQWNKEIQYQIEQYMTNTKISCNNEKNVLSRVSDEAAQPKFSDNERDRNSITHEDKNCKEKCKCYSLWIEKINDQWDKQ
KDNYNKFQRKQIYDANKGSQNKKVVSLSNFLFFSCWEEYIQKYFNGDWSKIKNIGSDTFEFLIKKCGNDSGDGETIFSEK
LNNAEKKCKENESTNNKMKSSETSCDCSEPIYIRGCQPKIYDGKIFPGKGGEKQWICKDTIIHGDTNGACIPPRTQNLCV
GELWDKRYGGRSNIKNDTKESLKQKIKNAIQKETELLYEYHDKGTAIISRNPMKGQKEKEEKNNDSNGLPKGFCHAVQRS
FIDYKNMILGTSVNIYEYIGKLQEDIKKIIEKGTTKQNGKTVGSGAENVNAWWKGIEGEMWDAVRCAITKINKKQKKNGT
FSIDECGIFPPTGNDEDQSVSWFKEWSEQFCIERLQYEKNIRDACTNNGQGDKIQGDCKRKCEEYKKYISEKKQEWDKQK
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TKYENKYVGKSASDLLKENYPECISANFDFIFNDNIEYKTYYPYGDYSSICSCEQVKYYEYNNAEKKNNKSLCHEKGNDR
TWSKKYIKKLENGRTLEGVYVPPRRQQLCLYELFPIIIKNKNDITNAKKELLETLQIVAEREAYYLWKQYHAHNDTTYLA
HKKACCAIRGSFYDLEDIIKGNDLVHDEYTKYIDSKLNEIFDSSNKNDIETKRARTDWWENEAIAVPNITGANKSDPKTI
RQLVWDAMQSGVRKAIDEEKEKKKPNENFPPCMGVQHIGIAKPQFIRWLEEWTNEFCEKYTKYFEDMKSNCNLRKGADDC
DDNSNIECKKACANYTNWLNPKRIEWNGMSNYYNKIYRKSNKESEDGKDYSMIMEPTVIDYLNKRCNGEINGNYICCSCK
NIGENSTSGTVNKKLQKKETQCEDNKGPLDLMNKVLNKMDPKYSEHKMKCTEVYLEHVEEQLKEIDNAIKDYKLYPLDRC
FDDKSKMKVCDLIGDAIGCKHKTKLDELDEWNDVDMRDPYNKYKGVLIPPRRRQLCFSRIVRGPANLRNLKEFKEEILKG
AQSEGKFLGNYYNEDKDKEKALEAMKNSFYDYEYIIKGSDMLTNIQFKDIKRKLDRLLEKETNNTEKVDDWWETNKKSIW
NAMLCGYKKSGNKIIDPSWCTIPTTETPPQFLRWIKEWGTNVCIQKEEHKEYVKSKCSNVTNLGAQESESKNCTSEIKKY
QEWSRKRSIQWEAISEGYKKYKGMDEFKNTFKNIKEPDANEPNANEYLKKHCSKCPCGFNDMQEITKYTNIGNEAFKQIK
EQVDIPAELEDVIYRLKHHEYDKGNDYICNKYKNINVNMKKNNDDTWTDLVKNSSDINKGVLLPPRRKNLFLKIDESDIC
KYKRDPKLFKDFIYSSAISEVERLKKVYGEAKTKVVHAMKYSFADIGSIIKGDDMMENNSSDKIGKILGDGVGQNEKRKK
WWDMNKYHIWESMLCGYKHAYGNISENDRKMLDIPNNDDEHQFLRWFQEWTENFCTKRNELYENMVTACNSAKCNTSNGS
VDKKECTEACKNYSNFILIKKKEYQSLNSQYDMNYKETKAEKKESPEYFKDKCNGECSCLSEYFKDETRWKNPYETLDDT
EVKNNCMCKPPPPASNGAGAGAGAGAGAGAG
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